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Diabetic nephropathy, a progressive kidney disease due to longstanding diabetes, is 
the leading cause of end stage renal disease in the Western world (1). However, not 
all patients with diabetes-mediated hyperglycemia will develop this disease (2;3;4). It 
appears that both environmental and genetic factors play a role in the development of 
diabetic nephropathy, making diabetic nephropathy a complex disease. 
One of the aims of this thesis was to create a histopathological classification of 
diabetic nephropathy. Another goal was to create a systematic overview of genetic 
associations in diabetic nephropathy. Furthermore, we focused more on one of these 
genetic variants, the number of trinucleotide repeats coding for leucine in the CNDP1 
gene. Concerning this genetic variant, we examined the genotypic distribution in 3 
ethnic groups. Additionally, we investigated whether the association between this 
genetic variant and diabetic nephropathy was sex-specific. Furthermore, the association 
between the CNDP1 genotype and other progressive glomerular diseases was studied. 
Finally, as the CNDP1 gene encodes for the enzyme carnosinase and carnosinase breaks 
down carnosine, which is known to have many protective capacities, we searched for 
determinants of carnosine levels.
The outline of this introduction is as follows. First, an introduction on diabetes, the 
kidney and diabetic nephropathy (part I) will be given, followed by an introduction on 
genetics in diabetic nephropathy (part II). Continuing with the CNDP1 gene, the enzyme 
it codes for, carnosinase-1 and its substrate L-carnosine (part III). 
Part i – diabetes, the kidney and diabetic nePhroPathy
Diabetes
Diabetes mellitus is a metabolic disorder of multiple causes which is characterized by 
chronic hyperglycemia with disturbances of carbohydrate, fat, and protein metabolism. 
The word diabetes originates from two Greek words; ‘dia’ (=δια) means ‘through’ and 
‘bainein’ (=βαινειν) means ‘to pass’. The word mellitus comes from Latin, meaning 
‘honey sweet’. Therefore, diabetes mellitus could be translated as ‘honey sweet 
passage’. 
The two most common types of diabetes mellitus are type 1 and type 2 diabetes. 
Type 1 diabetes, accounting for 5-10% of cases of diabetes in populations of European 
origin, is associated with primary beta cell failure, mostly a result of autoimmune 
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destruction. Type 2 diabetes, the most common type in all populations, is characterized 
by high glucose in the context of insulin resistance and relative insulin deficiency. The 
number of type 2 diabetes patients has rapidly increased in the past few decades and is 
still rising further. In 2002, the number of diabetes patients worldwide was estimated at 
173 million and has been predicted to increase to 350 million in 2030 (1). 
Approximately 5% of the diabetes patients have maturity onset diabetes of the 
young (MODY). MODY is caused by a genetic defect leading to pancreatic beta cell 
dysfunction. One percent of the diabetes patients have mitochondrial diabetes, due to 
defects in the mitochondria. 
Long-term hyperglycemia can lead to severe complications later in life. These 
complications of diabetes are divided in macrovascular and microvascular complications. 
Macrovascular disease is mainly confined to cardiovascular disease. Microvascular 
complications occur mainly in the eyes, kidneys, peripheral lower limbs and nerves, 
resulting in diabetic retinopathy, diabetic nephropathy, diabetic foot and diabetic 
neuropathy respectively. In this thesis we will further focus on diabetic nephropathy 
due to type 1 and type 2 diabetes. 
The kidney
To understand the pathology of diabetic nephropathy we first briefly describe the 
anatomy and function of the human kidney. The kidneys are the main excretory organs 
of the human body. They regulate the extracellular volume, water and salt balance, and 
acid-base homeostasis. Furthermore, kidneys are endocrine organs, producing hormones 
with a role in erythropoiesis, calcium metabolism and blood pressure regulation.
Each kidney weighs approximately 150 grams in adults, and is located in the 
retroperitoneum. A kidney has three major components: the cortex, the medulla and 
the collecting system. The cortex, the outer layer of the kidney, consists mainly of 
glomeruli and convoluted tubuli. Situated more to the centre is the medulla consisting 
of pyramidal structures of parallel arranged tubular structures with apical papillae. 
The bases of the pyramids are at the corticomedullary junction and the apices extend 
into the collecting system. In the collecting system the pre-urine goes from the minor 
calyces, which receive pre-urine from a medullary papilla, to the major calyces, pelvis 
and finally it enters the ureter.   
The blood supply of each kidney is by a single renal artery originating from the 
abdominal aorta. The main renal artery branches form anterior and posterior divisions 
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at the hilus and divides further into the interlobar arteries which run between lobes. 
Interlobar arteries extend to the corticomedullary junction and give rise to arcuate 
arteries, which arch between cortex and medulla. Afferent arterioles branch off from 
the arcuate arteries, each directing to a single glomerulus. A glomerulus represents 
a spherical bag of capillary loops arranged in several lobules. The capillaries come 
together to exit the glomerulus through the efferent arteriole. In most nephrons, the 
efferent arterioles branch off to form another vascular bed, the peritubular capillaries, 
which surround the tubules. 
A nephron is a functional unit of the kidney and consists of a glomerulus with attached 
tubuli. Each kidney has approximately one million nephrons. The glomerulus consists 
of 4 types of cells: the mesangial cell, endothelial cell, visceral epithelial cell (podocyte), 
and parietal epithelial cell. The mesangial cells are responsible for the production of 
the mesangial extracellular matrix. Mesangial cells have numerous functions including 
contraction, production of extracellular matrix, secretion of inflammatory and other 
active mediators and phagocytosis. Mesangial cells and their mesangial matrix together 
form the mesangium.
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The blood from the capillary network of the glomerulus is filtered into the tubuli. The 
filtration barrier of the glomerulus consists of endothelial cells, glomerular basement 
membrane and podocytes. Endothelial cells of the glomerulus are thin and have multiple 
fenestrae with a glycocalyx, extracellular polymeric material at the apical site of the 
endothelial cell. The glomerular basement membrane is a 300-350 nm thick network 
that surrounds the glomerular capillaries. The outer aspects of the glomerular capillaries 
are covered with podocytes. Each podocyte has a large body with small finger-like 
processes that interdigitate with similar structures from adjacent cells. These structures 
cover the glomerular capillaries forming slit pores. Blood is filtered through these slits, 
known as a slit diaphragm. After passing through the glomerular filtration barrier and 
leaving large and negatively charged molecules in the capillaries, the filtrated blood 
enters the Bowman’s space which is aligned by parietal epithelial cells. The Bowman’s 
space is continuous with the tubular system. 
The remaining portion of the nephron consists of tubuli. First, the filtrated blood 
enters the proximal tubule, then enters the loop of Henle and finally the distal tubules. 
These structures concentrate the pre-urine and reabsorb essential molecules, but also 
secretion from blood to tubuli occurs. The tubuli are supported by the interstitium, 
which consists of thin connective tissue in peritubular and periarterial spaces. 
Diabetic nephropathy
The UK prospective diabetes study (UKPDS) and diabetes control and complications trial 
(DCCT) have established an initiating role for hyperglycemia in developing microvascular 
complications such as diabetic nephropathy (2;5). 
There are four main hypotheses about how hyperglycemia causes diabetic nephropathy:
1) increased polyol pathway flux, 
2) increased advanced glycation end product formation,
3) activation of the protein kinase C isoforms,
4) increased hexosamine pathway flux. 
Each of these hypotheses will be described in detail below:
1) Aldose reductase is the first enzyme in the polyol pathway and an oxidoreductase 
that catalyses the NADPH-dependent reduction of a wide variety of carbonyl compounds, 
such as glucose. Aldose reductase has a low affinity for glucose and in the normal 
situation the metabolism of glucose by this pathway is minimal. In a hyperglycemic 
environment, increased intracellular glucose results in its increased enzymatic conversion 
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to sorbitol, with concomitant decrease in NADPH. In the polyol pathway, sorbitol is 
oxidized to fructose by the enzyme sorbitol dehydrogenase with NAD+ being reduced 
to NADH. The most accepted theory how the polyol pathway is involved in causing 
diabetic nephropathy is as follows. Reduction of glucose to sorbitol consumes NADPH. 
As NADPH is required for generating glutathione, and glutathione protects cells from 
oxidative stress, this could induce intracellular oxidative stress (6;7). 
2) Advanced glycation end products (AGE) are irreversibly damaged proteins or lipids 
resulting from a chain of chemical reactions after an initial glycation reaction (8). AGE 
formation is increased in diabetes due to increased intracellular glucose. Intracellular 
and extracellular AGEs and its precursors damage cells by three mechanisms. First, 
intracellular proteins modified by AGEs have an altered function. Second, extracellular 
matrix components modified by AGE precursors interact abnormally with other matrix 
components and with the receptors for matrix proteins, such as integrins on cells. Third, 
plasma proteins modified by AGE precursors bind to AGE receptors on endothelial cells, 
mesangial cells and macrophages, inducing receptor-mediated production of reactive 
oxygen species. 
3) Intracellular increase of glucose augments the synthesis of a molecule called 
diacylglycerol (DAG), which is a critical activating cofactor for the classic isoforms of 
protein kinase C (PKC), β, δ and α. PKC has an effect on expression of a variety of genes. 
Its overactivation leads to blood flow abnormalities, vascular permeability, capillary and 
vascular occlusion, pro-inflammatory gene expression and oxidative stress (9-11).
4) In the hexosamine pathway, fructose-6-phosphate is diverted from glycolysis 
leading to an increase in uridine diphosphate-N-acetylglucosamine. Overmodification 
by this glucosamine of serine and threonine residues leads to pathological changes in 
gene expression and protein function. Although a role for this relatively newly identified 
pathway in diabetic nephropathy is evident (12;13), the exact pathogenic mechanisms 
still need to be established. 
Brownlee (14) hypothesized that these four pathways can be linked together by 
a common initiating factor: superoxide formation by the mitochondria. Increased 
hyperglycemia-derived electron donors from the tricarboxylic acid cycle (also known 
as the citric acid cycle), NADH and FADH2, generate a high mitochondrial membrane 
potential, by pumping protons across the mitochondrial inner membrane. This inhibits 
electron transport, increasing the half-life of free radical intermediates of co-enzyme 
O, which reduce O2 to superoxide. Hyperglycemic induced superoxide formation 
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by the mitochondria decreases GAPDH which converts glyceraldehyde-3-P into 
1,3-diphosphoglycerate in the tricarboxylic acid cycle. As a result glyceraldehyde-3-P, 
which is a precursor for AGE and PKC, increases. This initiates AGE formation and 
PKC activation. Due to the reduced conversion by GAPDH, the molecules upstream 
the tricarboxylic acid cycle will also increase. These are fructose-6-P, activating the 
hexosamine pathway, and glucose itself, increasing the polyol pathway activity. 
Early in the course of diabetes, abnormalities in blood flow and increased vascular 
permeability occur. In this stage, there is decreased activity of vasodilators, such as nitric 
oxide and increased activity of vasoconstrictors, such as angiotensin II and endothelin-1 
and elaboration of permeability factors such as vascular endothelial growth factor 
(VEGF). Later, abnormalities in the extracellular matrix contribute to an irreversible 
increase in vascular permeability. With time, microvascular cell loss occurs, in part as 
result of apoptosis, and there is progressive capillary occlusion due to both extracellular 
matrix overproduction induced by growth factors such as transforming growth factor 
β (TGF-β) and deposition of hyaline material. Together, these changes lead to oedema, 
high blood pressure in the glomerulus and ischemia, finally leading to glomerulosclerosis. 
The abovementioned mechanisms are not confined to diabetic nephropathy. They 
also play a role in macrovascular complications and other microvascular complications. 
Clinical features
Clinically, the natural history of diabetic nephropathy is described to consist of five 
stages (15). The first stage is characterized by hyperfiltration and hypertrophy of the 
glomerulus, leading to higher glomerular filtration rate and renal enlargement. This 
stage is still reversible but is associated with an increased risk of developing more 
advanced diabetic nephropathy (16). Stage 2 develops silently over many years and is 
characterized by morphologic lesions without signs of clinical disease. Then diabetic 
nephropathy progresses from microalbuminuria (incipient diabetic nephropathy, stage 
3) to macroalbuminuria (overt nephropathy, stage 4) and finally, end stage renal 
disease (advanced diabetic nephropathy). Microalbuminuria can still regress in contrast 
to the later stages. When high blood pressure in the stage 4 diabetic nephropathy 
(macroalbuminuria) is left untreated, renal function (GFR) declines, the mean fall 
rate being around 1 ml/min/month. Long-term antihypertensive treatment reduces 
the fall rate by about 60% and thus postpones end stage renal disease considerably 
(15). End stage renal disease refers a stage in which patients require dialysis or kidney 
transplantation, because the kidneys do not function anymore.
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There is still debate whether diabetic nephropathy due to type 1 and type 2 diabetes 
can be considered the same disease. Two early studies showed a similar course in 
clinical diabetic nephropathy in type 1 and type 2 diabetes (17;18). However, several 
differences have been described between diabetic nephropathy in type 1 and type 2 
diabetes. Diabetic nephropathy due to type 1 diabetes almost always coincides with 
diabetic retinopathy (19) in contrast to type 2 diabetes in which this parallel is less clear. 
However, the relationship between diabetic nephropathy and retinopathy in type 2 
diabetes varies depending on the diabetes regimen (20). In patients treated with insulin, 
the relationship between nephropathy and the severity of retinopathy is similar to that 
in type 1 diabetes (21). Furthermore, some claim that diabetic nephropathy develops 
more often in type 1 diabetes than in type 2 diabetes. The difficulty in type 2 diabetes 
is that many die due to cardiovascular disease before reaching the clinical stage of 
diabetic nephropathy. If we look at Pima Indians who have type 2 diabetes relatively 
early in life and are known for their relatively low cardiovascular mortality risk, 65% 
of the diabetes type 2 patients will develop ESRD (22), suggesting that cardiovascular 
disease in Caucasians might influence the incidence rate of diabetic nephropathy due 
to type 2 diabetes.
For pathologists, diabetic nephropathy due to type 1 and type 2 diabetes appears 
to be undistinguishable (23;24). However, on the genetic level, there seem to be 
differences in genetic susceptibility between diabetic nephropathy due to type 1 and 
type 2 diabetes (25-29). This is suggestive for different mechanisms in type 1 and type 2 
diabetes leading to similar histopathologic appearance of diabetic nephropathy. 
Histopathology 
Diabetic nephropathy causes pathological abnormalities in the glomerulus and 
tubulus extraglomerular vessels and interstitium. The first pathological sign of diabetic 
nephropathy is enlargement of the glomerulus which corresponds to the clinical stage of 
glomerular hyperfiltration (stage 1) (15). Additionally, glomerular basement thickening 
occurs in an early stage and is seen to be present after 2 years of diabetes duration (30). 
When the disease progresses the mesangium starts to expand, corresponding to the 
clinical stage of both micro- and macroalbuminuria. 
Two forms of diabetic nephropathy are described; diffuse versus nodular 
glomerulosclerosis (31). This designation is primarily of descriptive value, because the 
distinctions do not have clear-cut clinical significance, although nodular glomerulo-
sclerosis is more often described in severe cases (31;32). Diffuse diabetic glomerulo-
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sclerosis is less specific for diabetic glomerulosclerosis than nodular glomerulosclerosis. 
The nodular lesions of diabetic glomerulosclerosis are also known as Kimmelstiel-Wilson 
lesions. 
Glomerular hyalinosis is common in diabetic glomerulosclerosis. These hyaline lesions 
may result from insudation or exudation of plasma proteins from vessels followed by 
entrapment in the matrix. The hyalinosis can occur anywhere in the glomerular tufts, 
but there are two characteristic patterns: capsular drops and hyaline caps (also known 
as fibrin caps). Capsular drops are spherical accumulations of hyaline material adjacent 
to or within the Bowman’s capsule. The hyaline caps occupy the capillary lumen instead 
of being attached to Bowman’s capsule. 
Arteriolosclerosis and arteriosclerosis often accompany diabetic glomerulosclerosis. 
Arteriolar hyalinosis at the glomerular hilum is present in diabetic glomerulosclerosis 
and typically affects both the afferent and efferent arterioles. Hypertensive hyaline 
arteriolar sclerosis affects the afferent but not the efferent arteriole (33). 
The earliest tubular change is thickening of tubular basement membrane that is 
analogous to the glomerular basement membrane thickening. When the disease 
progresses, tubules become atrophic and, fibrosis and chronic inflammation are present 
in the interstitium. Mononuclear cells can also be found in the interstitium in diabetic 
nephropathy. Inflammatory infiltrates of the interstitium, predominantly by T lympho-
cytes and macrophages, have been described (34). These chronic tubulointerstitial 
changes are not specific to diabetic nephropathy. 
Pathological classification of diabetic nephropathy
Although for many kidney diseases pathological classification schemes exist (35-37), 
for diabetic nephropathy no uniform internationally accepted classification scheme 
has been developed yet. Classification schemes improve communication between 
and among renal pathologists and clinical nephrologists, provide logistical structure 
for prognostic and interventional studies and assist clinical management and efficiency 
(38).
In the past, several attempts have been made in classifying diabetic nephropathy. 
In 1959, Gellman et al. (39) proposed a systematic evaluation examining glomeruli, 
tubules, arterioles and the interstitium of kidney biopsies with diabetic nephropathy. 
The unique feature of this paper was that it presented for the first time associations 
between histopathological findings in renal biopsies with diabetic nephropathy and 
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severity of clinical parameters (39). Due to its extensive and elaborate nature, this 
evaluation system turned out to be unsuitable for practical usage. 
More recently, in 1993, Gambara et al. (40) suggested to distinguish three classes 
of type 2 diabetes related nephropathy: class 1, typical diabetic glomerulopathy; class 
2, aspecific glomerular and tubulointerstitial lesions, and class 3, different glomerular 
diseases superimposed on diabetic lesions. This system does not distinguish in severity 
of the lesions; it also contains a rather broad ‘aspecific’ category.
In 1996, Fioretto et al. (41) proposed another categorization of lesions for diabetic 
nephropathy in type 2 diabetes, also distinguishing between three classes: Class I, normal 
or near normal renal structure; Class II, typical diabetic nephropathy; Class III, atypical 
diabetic nephropathy. Although this system proved useful in evaluating renal biopsies 
for research purposes, it is not practical for clinical use. There are four drawbacks to 
this system: 
-	 it does not discriminate between damage from other causes (e.g. vascular 
damage) and diabetic nephropathy, 
-	 it does not distinguish in severity of the lesions, 
-	 it is only suitable for ‘proven’ diabetic nephropathy at the electron microscopy 
level, 
-	 the category ‘atypical’ is too broad to make a reliable evaluation of the biopsy.
In 2002, Mazzucci et al. (42) published an evaluation system for type 2 diabetic 
nephropathy that was based upon Gambara’s scheme from 1993 (40). Mazzucci et 
al. (42) revised the Gambara scheme by re-naming class 2 into a category mainly 
characterized by changes related to vascular damage. In addition to this revision, they 
split class 3 into two subtypes: 3a) glomerular diseases superimposed on diabetic 
glomerulosclerosis and 3b) glomerular disease as the only renal change. They concluded 
that a renal biopsy should play a central role in management of type 2 diabetic patients 
with proteinuria.  
None of these classification schemes were used in clinical practice. A standardized 
classification could encourage international uniformity in classifying diabetic 
nephropathy, facilitate experiments, be applied in multi-center clinical trials, and 
ultimately lead to improvement in the care of diabetic nephropathy. A proposal for such 
a classification scheme, based on severity of diabetic nephropathy, is made in chapter 
2 by a group of experts. 
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Part ii – Genetics in diabetic nePhroPathy
Francis Harry Compton Crick, James Dewey Watson and Maurice Hugh Frederick Wilkins 
received the Nobel Prize in Medicine for their discoveries in the molecular structure of DNA 
in 1962. Since then, many techniques have been developed to investigate variations in 
this DNA molecule in relation to disease. Several distinctions in genetic variation between 
individuals can be made based on variation in the DNA sequence and allele frequency. 
At the DNA level, there are insertion/deletions, copy number variations, microsatellites, 
and single nucleotide polymorphisms (SNP). Insertion/deletion are insertions or deletion 
in a certain part of the DNA sequence. Copy number variation is the same but larger, 
also referred to as duplications and insertions. Microsatellites are repeated sequences of 
which the CA repeat is the most common one. A single nucleotide polymorphism is a 
variant in a single nucleotide. Furthermore, based on allele frequency, the distinction is 
made between a polymorphism (minor allele frequency greater or similar to 1%) and a 
mutation, which is more rare (minor allele frequency <1%). 
In the beginning, genetic mapping was used to search for causal mutations of 
diseases that run in families and are inherited by the principles of Mendel. These 
Mendelian diseases, also called monogenetic disorders, are caused by a mutation in 
a single gene. Duchenne muscular dystrophy is an example of a Mendelian disease. 
The disorder is caused by a mutation in the gene DMD, which encodes for the protein 
dystrophin, an important structural component within muscle tissue. Due to a single 
gene mutation the protein is not produced adequately, leading to the severely disabling 
phenotype of Duchenne. In contrast to Mendelian diseases, complex diseases are 
disorders in which the cause is considered to be a combination of several genetic effects 
and environmental influences. For example, type 1 and 2 diabetes, diabetic nephropathy 
and cardiovascular disease are such complex diseases. 
Genetic mapping 
Genetic mapping in the last century has resulted in a rapid increase in the understanding 
of disease pathology in many Mendelian diseases. These were found by a family-
based approach based on the principle of linkage. Linkage is the tendency of certain 
loci or alleles to be inherited together. In family based linkage studies, it has been 
investigated which DNA markers (microsatellites) are more often inherited in affected 
family members compared to unaffected family members. When a genetic marker is 
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tightly linked (i.e. often inherited) with the disease, additional DNA markers near this 
marker are sought and studied. This process is often referred to as positional cloning 
and finally leads to the gene involved in the disease. This is a most useful approach in 
Mendelian disease, but in complex disease one gene does not ultimately lead to the 
disease. Therefore some relatives might be affected without the risk allele of the genetic 
variant and unaffected relatives might have this risk allele. Especially when a risk allele 
and disease are common (> 5% allele frequency), the inheritance pattern of the risk 
allele might not be so informative. An impractically large number of families would be 
needed to study a complex disease to find a small enough region to ultimately lead to 
one gene. 
A candidate gene is a gene which is suspected to be involved in diabetic nephropathy 
based on the literature. To investigate a candidate gene association studies are used. 
Association studies investigate whether a risk allele occurs more frequently in subjects 
with the disease than in individuals without the disease. In contrast to familial studies, 
in association studies a problem called population stratification can occur. Population 
stratification refers to the problem that results in genetic association studies are due to 
ancestral differences in cases versus controls instead of related to the disease. Population 
stratification can only occur when either allele frequency or the disease risk differs 
between ancestral backgrounds. Another problem is that a clear biological explanation 
beforehand is needed to choose such a candidate gene and from Mendelian diseases 
we have learned that most genes found, were completely unexpected. 
A new approach, developed to investigate complex disease, is the genome wide 
association scan (GWAS). This is an association study of the genome with common SNPs 
used as genetic markers. Since many SNPs are present in the human genome, this gives 
a good coverage of the human genome. A great advantage of the GWAS is that it does 
not need a biological explanation beforehand. It maps the genome with common SNPs 
either directly involved in disease pathology or indirectly through tagSNPs, which are 
potentially linked with risk alleles. Another advantage is that population stratification 
can be corrected for in this approach, as with the many SNPs the ancestry of the 
individual can be determined. 
Models in complex genetics
Three models have been proposed to explain the genetic component in complex disease; 
the common disease-common variant model (CD-CV model), the rare alleles of major 
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effect (RAME) model and the infinitesimal model. 
The CD-CV model assumes that common variants contribute to risk, each explaining 
a small proportion of disease liability. Due to their high frequencies, these variants 
may explain a large part of the population risk. The genome-wide association scan 
(GWAS), based on the CD-CV model, has proven to be powerful (43). An example of 
a common disease variant consistently replicated  is APOE  in Alzheimer’s disease and 
heart disease (44). In contrast, the RAME model postulates that common diseases are in 
fact genetically heterogeneous and caused by de novo mutations. A rare variant in each 
individual (or family) with large effect may contribute to risk. Support for this model 
comes from studies of rare genetic variants in the high density lipoprotein C (HDL-C) 
gene (45;46). Rare variants were more often present in patients with low HDL-C (<fifth 
percentile) than with high HDL-C (>95th percentile). These findings were replicated in 
an independent study population (45). That the GWAS provides solid evidence for novel 
gene associations does not ultimately mean that the CD-CV model explains the genetic 
risk in complex diseases. Common SNPs identified by GWAS could be associated with 
rare mutations. Therefore, some common SNPs may be a proxy for a rare variant with 
large effect. Rare variants with large effect may provide clear information on disease 
etiology. 
The infinitesimal model assumes that liability for disease follows an asymptotic 
distribution, as shown for the continuous trait height. Hundreds of genes would be 
involved, covering a wide range of frequencies (47). This model has gained support in 
GWAS, where odds ratios of 1.2 may each account for a small fraction of the liability. 
Genetic susceptibility of diabetic nephropathy
In type 1 diabetes it has clearly been shown that some patients develop diabetic 
nephropathy within the first fifteen years and after that the incidence decreases (4). 
This suggests that some patients seem to be more susceptible to develop diabetic 
nephropathy. This is less clearly shown in type 2 diabetes as probably many die of 
cardiovascular disease before reaching the age to develop diabetic nephropathy. Several 
studies indicate that a separate genetic risk factor exists for diabetic nephropathy in type 
1 or type 2 diabetes. Evidence for a genetic predisposition is that diabetic nephropathy 
seems to aggregate in certain families (48;49). Furthermore the prevalence of diabetic 
nephropathy varies significantly among ethnic groups (48). 
1
23
Genetics in diabetic nephropathy
The first studies performed in the search for genes in diabetic nephropathy were linkage 
analyses in family studies. Several genome-wide linkage scans have been published in 
diabetic nephropathy in type 1 and type 2 diabetes. Although most of these analyses 
evaluated small numbers of families from different ethnic groups, several consistent 
regions of linkage have been detected (50-56). These regions can be helpful in choosing 
candidate genes, but these linkage studies were underpowered for directing to one 
specific gene.
In genetic association studies several candidate genes for diabetic nephropathy 
have been investigated. The frequently investigated genes were the genes involved 
in the renin-angiotensin-system. The most studied variant, the insertion/deletion 
polymorphism in intron 16 of the gene coding for angiotensin-converting enzyme 
(ACE), has shown to have a small effect in a meta-analysis of 53 studies (57). 
Furthermore, genetic variants in genes coding for aldose reductase (58), endothelial 
nitric oxide (59-61), manganese superoxide dismutase (62), vascular endothelial growth 
factor (63), TGF-β (64), apolipoprotein E (65-67), inflammatory cytokines (68) among 
several other candidates were studied in relation to diabetic nephropathy. A broad 
definition of diabetic nephropathy was used in these studies, from hyperfiltration and 
microalbuminuria to biopsy proven diabetic nephropathy. 
Combining the two approaches, also referred to as large scale mapping, has led 
to some success. A good example is the CNDP1 gene. A region on chromosome 
18q22-22.3 was found to be associated with diabetic nephropathy in large Turkish 
families who were not treated for this disease, making this an ideal population to study 
for this purpose (50). Genes of this relatively small region were searched for up- or 
downregulation in diabetic nephropathy. A few genes were differentially expressed in 
diabetic nephropathy and one of these genes was the CNDP1 gene. Genetic variations 
were sought in this gene and tested in a genetic association study. A polymorphism in 
exon 2 was found to be associated with diabetic nephropathy (26). This is an example 
of a successful finding, however, most found regions in diabetic nephropathy are 
larger. Furthermore, microarray analyses are known for the high false-positivity rate and 
finding the right variant is also a challenge considering multiple testing. Therefore, only 
few successful examples of this approach are known. 
A few GWAS have been performed in diabetic nephropathy (69;70), leading to 
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several variants in or near genes which were not hypothesized before. Examples are 
genetic variants in the engulfment and cell motility 1 gene (ELMO1) (71) and cysteinyl-
tRNA synthetase gene (CARS) (70). Most of the found variants will not prove to be 
causal and the relevance of these findings still needs to be assessed. 
Part iii - CNDP1, carnosinase and carnosine in diabetic nePhroPathy
Carnosine
In 1900 carnosine (β-alanine-L-histidine), as the name implies, was first isolated 
from meat by Gulewitsch and Amiradzibi (72). Related compounds to carnosine are 
anserine, homocarnosine, ophidine, carcinine and N-acetyl carnosine. In the human 
body, carnosine and related compounds are found in high concentrations in muscle 
and nervous tissue, but are also present in several organs such as the kidney, liver and 
small intestine. In the muscle, carnosine makes up a significant fraction of the water 
soluble nitrogen-containing compounds. The most convincing role of carnosine in the 
muscle was considered to be the control of intracellular hydrogen ion concentration. 
It was presumed that this property explains its predominant association with white, 
fast glycolytic type IIb muscles which possess relatively few mitochondria. Therefore 
these fibers will more often need anaerobic activity, which generates lactic acid. 
The importance of carnosine as a physicochemical buffer within human muscle was 
examined by calculating its buffering ability over the physiological pH range. From the 
range of carnosine concentrations observed (7.2-30.7 mmol/kg dry muscle mass), it 
was estimated that the dipeptide could buffer between 2.4 and 10.1 mmol H+/kg dry 
mass over the physiological pH range 7.1-6.5, contributing on average, approximately 
7% to the total muscle buffering. This suggests that in humans, in contrast to many 
other species, carnosine is of only limited importance in preventing the reduction 
in pH observed during exercise (73). Further evidence that carnosine is more than a 
physiological buffer, comes from Severin and co-workers (74;75). They showed that 
after addition of carnosine in medium surrounding a fatigued skeletal muscle, the 
muscle working was restored and because of special precautions in their study, it was 
shown that it did not depend on the pH-buffering capacity of carnosine.   
The protective effect of carnosine can also be explained by its antioxidant properties. 
1
25
Carnosine is capable of preventing the accumulation of oxidized products derived from 
the lipid components of biological membranes (73;76;77). This is rather surprising 
considering that carnosine is water soluble and remote from the site at which the 
peroxidation of membrane lipids takes place. However, both carnosine and anserine 
potentiate the effect of lipid soluble antioxidants such as vitamin E (78). Detailed studies 
of the time course of lipid peroxidation in the sarcoplasmic reticulum suggest that the 
ability of carnosine to inhibit the accumulation of thiobarbituric acid-reactive products 
is mediated by the result of direct interaction of the dipeptide not only with free radicals 
generated within the system, but also with primary molecular products of the lipid 
peroxidation (76). The antioxidant effect of carnosine has been demonstrated at both 
cell and tissue level as well as in suspensions of lipids derived from cell membranes. 
Carnosine is able to suppress peroxidation induced both enzymatically and non-
enzymatically and eliminates the products of free radical reactions. These effects are 
not confined to the muscle and are accomplished by membrane stabilizing action as 
shown by preservation and recovery of intact cell membrane structures. 
Kohen et al. (79) have demonstrated that these compounds can act as antioxidants 
as a result of their ability to scavenge single oxygen, peroxyl radicals and hydroxyl 
radicals. Carnosine and its analogues have been shown to be efficient chelating agents 
for copper and other transition metals. Since human skeletal muscle contains one-third 
of the total copper in the body (20-47 mmol/kg) and the concentration of carnosine 
is relatively high, the complex of carnosine:copper was thought to be of biological 
importance. Kohen et al. results indicated the complex of copper:carnosine can dismute 
superoxide radicals released by neutrophils (79). Furthermore, carnosine has shown to 
attenuate oxidative damage to DNA molecules (80) in the presence of iron and copper 
ions. 
Carnosine has also been shown to have AGE inhibitory actions; protein crosslinks 
induced by methylglyoxal (a precursor of AGE) were found to be eliminated in the 
presence of carnosine (81;82). Although the mechanism by which carnosine inhibits 
the formation of AGE is unknown, it is likely that the free amino group derived from 
β-alanine competes with the amino groups of proteins in their reaction with precursors 
of AGEs (75). Apart from the abovementioned protective capacities, carnosine has also 
shown to inhibit formation of foam cells in vitro (83) and is an natural ACE inhibitor 
(84). 
While carnosine is mainly found in skeletal muscle, homocarnosine concentration 
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is higher in the brain. It has been postulated that carnosine is a neurotransmitter. 
However, no receptors for carnosine have been found in nervous tissues (85). The role 
of carnosine in the brain is still under debate (86). 
Investigating this dipeptide gained popularity for its anti-aging potential; it 
suppresses cultured human fibroblasts senescence and delays aging in senescence-
accelerated mice (87). The exact reason why carnosine has this effect is not known, but 
it is probably due to the combination of abovementioned protective effects. In humans, 
so far no relation with carnosine and longevity have been found (88). Carnosine has 
also been investigated in age-related diseases such as Alzheimer (89) and Parkinson 
disease (90), but also in a wide variety of disorders and diseases, such as autism (91), 
cataract (92) and, cancer (93). The exact role of carnosine in these diseases still needs 
to be established.
Figure 2. Carnosine metabolism
Carnosine metabolism
Carnosine and related compounds are produced by carnosine synthase of which the 
genetic sequence has recently been identified (94) as ATP-grasp domain containing protein 
1, ATPGD1. Carnosine is synthesized by muscle cells, glial cells and oligodendrocytes 
(85). The kidney brush border also possesses a carnosine transport system (95;96). The 
majority of circulating carnosine is internalized by proximal tubular epithelial cells of 
the kidney via oligopeptide transporters Pept1 and Pept2 (97;98). Dibutyryl cyclic AMP 
























kinases strongly lower the rate of carnosine synthesis (99). 
Carnosinase degrades carnosine into L-histidine and β-alanine (figure 2). Classical 
carnosinase was first described by Hanson and Smith (100), who found hog kidney 
carnosinase in 1949. Later, a distinction was made in two isoforms of carnosinase; 
serum carnosinase (also known as carnosinase-1) and tissue carnosinase (also known 
as carnosinase 2) (101). Teufel et al. showed that in fact there were two different genes 
coding for each of the enzymes (102). Tissue carnosinase is not capable of degrading 
carnosine under physiological condition in humans and has been shown to have 
rather a broad specificity (102). Therefore, this enzyme should be renamed into ‘non-
specific dipeptidase’ and serum carnosinase into the genuine carnosinase (94;102). 
The following part will only describe data on genuine carnosinase. The physiological 
function of this carnosinase seems to be the hydrolysis of homocarnosine in the brain 
and the splitting of carnosine and anserine in the blood stream. Carnosinase is present 
in plasma and the brain and is specific to carnosine and related compounds. 
Carnosinase activity is nearly absent in neonates (103), low in children (although 
protein level are similar in children and adults) and seems to increase with age (104). 
Women have slightly higher carnosinase levels than men (105). In the literature, 
some cases have been described with serum carnosinase deficiency, leading to severe 
neurological symptoms such as epilepsy, myoclonic seizures, microcephaly, blindness 
and mental retardation (103;106-108). On the other hand, subjects with carnosinase 
deficiency without any symptoms (103) have been described and the degree of serum 
carnosinase deficiency does not seem to correlate with the severity of the disease 
(106). However, it seems evident that even without a clear dose-response relationship, 
carnosinase deficiency is often associated with mental retardation (106). 
Carnosinase-carnosine metabolism in diabetes and diabetic nephropathy
The most important clue that carnosine metabolism plays a role in diabetic nephropathy 
comes from genetic studies (26;50). A region on chromosome 18q22-22.3 was found to 
be associated with diabetic nephropathy in large Turkish families (50). A polymorphism in 
the CNDP1 gene, which encodes serum carnosinase and is located in the chromosomal 
region 18q22-22.3, was found to be associated with diabetic nephropathy (26). 
Freedman et al. (25) confirmed this finding in European Americans with end stage 
diabetic nephropathy due to type 2 diabetes, but the association between diabetic 
nephropathy and the CNDP1 gene could not be confirmed in patients with diabetic 
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nephropathy due to type 1 diabetes (27;28). The polymorphism is a microsatellite of CTG 
repeats (coding for the amino acid leucine) in exon 2 of the CNDP1 gene, which varies 
between 0, 4, 5, 6, 7 and 8 repeats. Alleles with null, four and eight repeats are rare 
(25;26;88). Patients with homozygosity for 5 leucine repeats demonstrated a reduced 
susceptibility (2.0-fold reduced risk) for developing diabetic nephropathy due to type 
2 diabetes compared with individuals with 6–8 repeats (25;26). Increasing numbers of 
leucine repeats in the leader peptide, have shown to increase the secretion of serum 
carnosinase (109) and to lead to higher serum carnosinase activity (26). Carnosines and 
related dipeptides are generally known for their protective effects. In the pathogenesis 
of diabetic nephropathy oxidative stress plays a central role. Therefore, of particular 
interest in relation to diabetic nephropathy is the scavenging of reactive oxygen species 
effect of carnosine (110). Formation of AGE is increased in a diabetic environment and 
has a major role in the development of diabetic nephropathy (111). Carnosine is able to 
scavenge precursors of AGE, such as methylglyoxal, and facilitates the degradation of 
AGEs (81). Furthermore, carnosine has shown to inhibit angiotensin converting enzyme 
(84), potentially lowering blood pressure. Elevated blood pressure could accelerate the 
development of diabetic nephropathy. Finally, TGF-β induced synthesis of extracellular 
matrix components (26) is thought to induce fibrosis and can be reduced by carnosine. 
This might explain why lower carnosinase levels (because of the 5-5 CNDP1 homozygous 
genotype) leading to high circulating carnosine concentrations, are protective in diabetic 
nephropathy (figure 3).  
Carnosine is mainly present in meat and fish and therefore it is interesting to see that 
vegetarians have higher levels of a precursor of AGE, which carnosine can scavenge, 
than carnivores. Furthermore, carnosine content increases with exercise (112;113), 
which has been shown to be body beneficial in diabetes, apart from the fact that it 
decreases mass content (114). 
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Figure 3. Hypothesis of CNDP1 genotype in relation to diabetic nephropathy
Carnosine in animal models
With exception of the Goldhamster, carnosinase is not present in serum of rodents. 
However, rodents have a functional carnosinase coded by CNDP1, but it is not excreted 
from the cell into the serum. Several studies have been performed with carnosine 
treatment in rodents with diabetic nephropathy (115-117). Ob/ob mice, a leptin-
deficient mouse used as a model for type 2 diabetes and diabetic nephropathy, were 
made transgenic for human carnosinase under a liver-specific promoter (117). Human 
carnosinase was present in serum of these transgenic mice and in this unique model, 
carnosinase could be overexpressed. When the animals were treated with carnosine, the 
hyperglycemia was reduced. The histological features of the kidney, serum creatinine 
levels and albumin creatinine levels in the carnosine-treated mice versus the untreated 
mice did not differ. These data suggest that the protective effect of the 5-5 homozygous 
genotype in diabetic nephropathy is primarily regulated by improved glycemic control 
(117). The obese Zucker rat, used as a model for metabolic syndrome (which includes 
type 2 diabetes) associated with kidney damage, was also treated with carnosine. 
Carnosine led to a reduced albumin excretion and improved kidney function in these 
rats. Furthermore, carnosine reduced the plasma triglycerides and insulin resistance 
but not plasma glucose (115). The characteristic pattern of lipid abnormalities in 
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patients with diabetes consists of moderate elevation in triglycerides, low high-density 
cholesterol values, and an increase in small dense low-density lipoprotein particles. 
Possibly in this rat model the improvement of the kidney is primarily due to improvement 
in the lipid abnormalities. In male streptozocin-treated Sprague-Dawley rats, used as a 
model for type 1 diabetes with diabetic nephropathy, the treatment with carnosine was 
also investigated. In these rats carnosine treatment reduced the amount of albumin 
excretion, but not plasma glucose (116). This is in contrast to streptozocin-treated Balb/
cA mice, which did show improved glycemic control, lower triglyceride concentrations 
after carnosine treatment. In the latter study, the effect of carnosine on the kidney was 
not investigated (118). Clearly, more studies have to be done in mice to establish the 
role of carnosine in diabetic nephropathy.
Outline of this thesis
This thesis, with as a central theme diabetic nephropathy, comprises 7 chapters. In 
chapter 2 a histological classification of diabetic nephropathy is proposed, classifying 
diabetic nephropathy according to severity of the disease. The idea is that this will 
induce clinical and pathological uniformity, leading to better patient care and scientific 
communication. As diabetic nephropathy has a strong genetic component, chapter 
3 covers the genetic variants reproducibly associated with diabetic nephropathy in a 
meta-analysis study. Chapters 4, 5 and 6 focus on one genetic variant known to be 
involved in diabetic nephropathy, the leucine repeat in exon 2 of the CNDP1 gene. 
In chapter 4, a population of South Asians Surinamese immigrants, who have an 
increased risk of developing diabetic nephropathy, was investigated for the frequency 
of the protective 5-5 homozygous genotype of the CNDP1 gene. Chapter 5 describes 
the relation between the CNDP1 genetic variant and gender in diabetic nephropathy 
in three independent diabetic nephropathy groups. In chapter 6 the relation between 
the CNDP1 genotype with glomerular kidney diseases other than diabetic nephropathy 
was investigated. Chapter 7 relates more to the physiological aspect of carnosine, 
investigating determinants such as gender, age, diet, CNDP1 genotype, carnosinase and 




 (1)  The world health report 2006; working together with health.  2006.  World Health Organisation. 
 (2)  Adler AI, Stevens RJ, Manley SE, Bilous RW, Cull CA, Holman RR. Development and progression 
of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). 
Kidney Int 2003;63(1):225-232.
 (3)  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional 
treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective 
Diabetes Study (UKPDS) Group. Lancet 1998;352(9131):837-853.
 (4)  Krolewski AS, Warram JH, Rand LI, Kahn CR. Epidemiologic approach to the etiology of type I 
diabetes mellitus and its complications. N Engl J Med 1987;317(22):1390-1398.
 (5)  Diabetes Control and Complications Trial (DCCT). Update. DCCT Research Group. Diabetes Care 
1990;13(4):427-433.
 (6)  Pompella A, Visvikis A, Paolicchi A, De T, V, Casini AF. The changing faces of glutathione, a cellular 
protagonist. Biochem Pharmacol 2003;66(8):1499-1503.
 (7)  Lee AY, Chung SS. Contributions of polyol pathway to oxidative stress in diabetic cataract. FASEB J 
1999;13(1):23-30.
 (8)  Goldin A, Beckman JA, Schmidt AM, Creager MA. Advanced glycation end products: sparking the 
development of diabetic vascular injury. Circulation 2006;114(6):597-605.
 (9)  Koya D, King GL. Protein kinase C activation and the development of diabetic complications. 
Diabetes 1998;47(6):859-866.
 (10)  Way KJ, Katai N, King GL. Protein kinase C and the development of diabetic vascular complications. 
Diabet Med 2001;18(12):945-959.
 (11)  Koya D, Jirousek MR, Lin YW, Ishii H, Kuboki K, King GL. Characterization of protein kinase C beta 
isoform activation on the gene expression of transforming growth factor-beta, extracellular matrix 
components, and prostanoids in the glomeruli of diabetic rats. J Clin Invest 1997;100(1):115-126.
 (12)  Kolm-Litty V, Sauer U, Nerlich A, Lehmann R, Schleicher ED. High glucose-induced transforming 
growth factor beta1 production is mediated by the hexosamine pathway in porcine glomerular 
mesangial cells. J Clin Invest 1998;101(1):160-169.
 (13)  Wells L, Hart GW. O-GlcNAc turns twenty: functional implications for post-translational modification 
of nuclear and cytosolic proteins with a sugar. FEBS Lett 2003;546(1):154-158.
 (14)  Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 
2001;414(6865):813-820.
 (15)  Mogensen CE, Christensen CK, Vittinghus E. The stages in diabetic renal disease. With emphasis 
on the stage of incipient diabetic nephropathy. Diabetes 1983;32 Suppl 2:64-78.:64-78.
1
32
 (16)  Magee GM, Bilous RW, Cardwell CR, Hunter SJ, Kee F, Fogarty DG. Is hyperfiltration associated with 
the future risk of developing diabetic nephropathy? A meta-analysis. Diabetologia 2009;52(4):691-
697.
 (17)  Hasslacher C. Diabetic nephropathy: structural-functional relationships. Contrib Nephrol 
1989;73:24-8; discussion 28-9.:24-28.
 (18)  Biesenbach G, Janko O, Zazgornik J. Similar rate of progression in the predialysis phase in type I and 
type II diabetes mellitus. Nephrol Dial Transplant 1994;9(8):1097-1102.
 (19)  Parving HH, Hommel E, Mathiesen E, Skott P, Edsberg B, Bahnsen M et al. Prevalence of 
microalbuminuria, arterial hypertension, retinopathy and neuropathy in patients with insulin 
dependent diabetes. Br Med J (Clin Res Ed) 1988;296(6616):156-160.
 (20)  Romero-Aroca P, Mendez-Marin I, Baget-Bernaldiz M, Fernendez-Ballart J, Santos-Blanco E. Review 
of the relationship between renal and retinal microangiopathy in diabetes mellitus patients. Curr 
Diabetes Rev 2010;6(2):88-101.
 (21)  Schmechel H, Heinrich U. Retinopathy and nephropathy in 772 insulin-treated diabetic patients in 
relation to the type of diabetes. Diabete Metab 1993;19(1 Pt 2):138-142.
 (22)  Nelson RG, Knowler WC, McCance DR, Sievers ML, Pettitt DJ, Charles MA et al. Determinants of 
end-stage renal disease in Pima Indians with type 2 (non-insulin-dependent) diabetes mellitus and 
proteinuria. Diabetologia 1993;36(10):1087-1093.
 (23)  Alsaad KO, Herzenberg AM. Distinguishing diabetic nephropathy from other causes of 
glomerulosclerosis: an update. J Clin Pathol 2007;60(1):18-26.
 (24)  White KE, Bilous RW. Type 2 diabetic patients with nephropathy show structural-functional 
relationships that are similar to type 1 disease. J Am Soc Nephrol 2000;11(9):1667-1673.
 (25)  Freedman BI, Hicks PJ, Sale MM, Pierson ED, Langefeld CD, Rich SS et al. A leucine repeat in 
the carnosinase gene CNDP1 is associated with diabetic end-stage renal disease in European 
Americans. Nephrol Dial Transplant 2007;22(4):1131-1135.
 (26)  Janssen B, Hohenadel D, Brinkkoetter P, Peters V, Rind N, Fischer C et al. Carnosine as a Protective 
Factor in Diabetic Nephropathy: Association With a Leucine Repeat of the Carnosinase Gene 
CNDP1. Diabetes 2005;54(8):2320-2327.
 (27)  Tregouet DA, Groop PH, McGinn S, Forsblom C, Hadjadj S, Marre M et al. G/T substitution in intron 
1 of the UNC13B gene is associated with increased risk of nephropathy in patients with type 1 
diabetes. Diabetes 2008;57(10):2843-2850.
 (28)  Wanic K, Placha G, Dunn J, Smiles A, Warram JH, Krolewski AS. Exclusion of polymorphisms in 
carnosinase genes (CNDP1 and CNDP2) as a cause of diabetic nephropathy in type 1 diabetes: 
results of large case-control and follow-up studies. Diabetes 2008;57(9):2547-2551.
1
33
 (29)  Xu M, Chen X, Yan L, Cheng H, Chen W. Association between (AC)n dinucleotide repeat 
polymorphism at the 5’-end of the aldose reductase gene and diabetic nephropathy: a meta-
analysis. J Mol Endocrinol 2008;40(5):243-251.
 (30)  Drummond K, Mauer M. The early natural history of nephropathy in type 1 diabetes: II. Early renal 
structural changes in type 1 diabetes. Diabetes 2002;51(5):1580-1587.
 (31)  Schwartz MM, Lewis EJ, Leonard-Martin T, Lewis JB, Batlle D. Renal pathology patterns in type 
II diabetes mellitus: relationship with retinopathy. The Collaborative Study Group. Nephrol Dial 
Transplant 1998;13(10):2547-2552.
 (32)  Hong D, Zheng T, Jia-qing S, Jian W, Zhi-hong L, Lei-shi L. Nodular glomerular lesion: a later stage 
of diabetic nephropathy? Diabetes Res Clin Pract 2007;78(2):189-195.
 (33)  Stout LC, Kumar S, Whorton EB. Insudative lesions--their pathogenesis and association with 
glomerular obsolescence in diabetes: a dynamic hypothesis based on single views of advancing 
human diabetic nephropathy. Hum Pathol 1994;25(11):1213-1227.
 (34)  Bohle A, Wehrmann M, Bogenschutz O, Batz C, Muller CA, Muller GA. The pathogenesis of chronic 
renal failure in diabetic nephropathy. Investigation of 488 cases of diabetic glomerulosclerosis. 
Pathol Res Pract 1991;187(2-3):251-259.
 (35)  Cattran DC, Coppo R, Cook HT, Feehally J, Roberts IS, Troyanov S et al. The Oxford classification 
of IgA nephropathy: rationale, clinicopathological correlations, and classification. Kidney Int 
2009;76(5):534-545.
 (36)  D’Agati VD, Fogo AB, Bruijn JA, Jennette JC. Pathologic classification of focal segmental 
glomerulosclerosis: a working proposal. Am J Kidney Dis 2004;43(2):368-382.
 (37)  Weening JJ, D’Agati VD, Schwartz MM, Seshan SV, Alpers CE, Appel GB et al. The classification of 
glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol 2004;15(2):241-
250.
 (38)  Glassock RJ. Reclassification of lupus glomerulonephritis: back to the future. J Am Soc Nephrol 
2004;15(2):501-503.
 (39)  Gellman DD, Pirani CL, Soothill JF, Muehrchke RC, KARK RM. Diabetic nephropathy: a clinical and 
pathologic study based on renal biopsies. Medicine (Baltimore) 1959;38:321-67.:321-367.
 (40)  Gambara V, Mecca G, Remuzzi G, Bertani T. Heterogeneous nature of renal lesions in type II 
diabetes. J Am Soc Nephrol 1993;3(8):1458-1466.
 (41)  Fioretto P, Mauer M, Brocco E, Velussi M, Frigato F, Muollo B et al. Patterns of renal injury in NIDDM 
patients with microalbuminuria. Diabetologia 1996;39(12):1569-1576.
 (42)  Mazzucco G, Bertani T, Fortunato M, Bernardi M, Leutner M, Boldorini R et al. Different patterns 




 (43)  Altshuler D, Daly MJ, Lander ES. Genetic mapping in human disease. Science 2008;322(5903):881-
888.
 (44)  Payami H, Kaye J, Heston LL, Bird TD, Schellenberg GD. Apolipoprotein E genotype and Alzheimer’s 
disease. Lancet 1993;342(8873):738.
 (45)  Cohen JC, Kiss RS, Pertsemlidis A, Marcel YL, McPherson R, Hobbs HH. Multiple rare alleles 
contribute to low plasma levels of HDL cholesterol. Science 2004;305(5685):869-872.
 (46)  Romeo S, Pennacchio LA, Fu Y, Boerwinkle E, Tybjaerg-Hansen A, Hobbs HH et al. Population-
based resequencing of ANGPTL4 uncovers variations that reduce triglycerides and increase HDL. 
Nat Genet 2007;39(4):513-516.
 (47)  Goldstein DB. Common genetic variation and human traits. N Engl J Med 2009;360(17):1696-
1698.
 (48)  Pettitt DJ, Saad MF, Bennett PH, Nelson RG, Knowler WC. Familial predisposition to renal disease 
in two generations of Pima Indians with type 2 (non-insulin-dependent) diabetes mellitus. 
Diabetologia 1990;33(7):438-443.
 (49)  Seaquist ER, Goetz FC, Rich S, Barbosa J. Familial clustering of diabetic kidney disease. Evidence for 
genetic susceptibility to diabetic nephropathy. N Engl J Med 1989;320(18):1161-1165.
 (50)  Vardarli I, Baier LJ, Hanson RL, Akkoyun I, Fischer C, Rohmeiss P et al. Gene for susceptibility to 
diabetic nephropathy in type 2 diabetes maps to 18q22.3-23. Kidney Int 2002;62(6):2176-2183.
 (51)  Placha G, Poznik GD, Dunn J, Smiles A, Krolewski B, Glew T et al. A genome-wide linkage scan 
for genes controlling variation in renal function estimated by serum cystatin C levels in extended 
families with type 2 diabetes. Diabetes 2006;55(12):3358-3365.
 (52)  Bowden DW, Colicigno CJ, Langefeld CD, Sale MM, Williams A, Anderson PJ et al. A genome scan 
for diabetic nephropathy in African Americans. Kidney Int 2004;66(4):1517-1526.
 (53)  Chen G, Adeyemo AA, Zhou J, Chen Y, Doumatey A, Lashley K et al. A genome-wide search 
for linkage to renal function phenotypes in West Africans with type 2 diabetes. Am J Kidney Dis 
2007;49(3):394-400.
 (54)  Imperatore G, Hanson RL, Pettitt DJ, Kobes S, Bennett PH, Knowler WC. Sib-pair linkage analysis 
for susceptibility genes for microvascular complications among Pima Indians with type 2 diabetes. 
Pima Diabetes Genes Group. Diabetes 1998;47(5):821-830.
 (55)  Iyengar SK, Abboud HE, Goddard KA, Saad MF, Adler SG, Arar NH et al. Genome-wide scans 
for diabetic nephropathy and albuminuria in multiethnic populations: the family investigation of 
nephropathy and diabetes (FIND). Diabetes 2007;56(6):1577-1585.
 (56)  Osterholm AM, He B, Pitkaniemi J, Albinsson L, Berg T, Sarti C et al. Genome-wide scan for type 
1 diabetic nephropathy in the Finnish population reveals suggestive linkage to a single locus on 
chromosome 3q. Kidney Int 2007;71(2):140-145.
1
35
 (57)  Ng DP, Tai BC, Lim XL. Is the presence of retinopathy of practical value in defining cases of diabetic 
nephropathy in genetic association studies? The experience with the ACE insertion/deletion 
polymorphism in 53 studies comprising 17,791 subjects. Diabetes 2008;57(9):2541-2546.
 (58)  Fanelli A, Hadjadj S, Gallois Y, Fumeron F, Betoule D, Grandchamp B et al. [Polymorphism of aldose 
reductase gene and susceptibility to retinopathy and nephropathy in Caucasians with type 1 
diabetes]. Arch Mal Coeur Vaiss 2002;95(7-8):701-708.
 (59)  Asakimori Y, Yorioka N, Taniguchi Y, Ito T, Ogata S, Kyuden Y et al. T(-786)-->C polymorphism of 
the endothelial nitric oxide synthase gene influences the progression of renal disease. Nephron 
2002;91(4):747-751.
 (60)  Bellini MH, Figueira MN, Piccoli MF, Marumo JT, Cendoroglo MS, Neto MC et al. Association 
of endothelial nitric oxide synthase gene intron 4 polymorphism with end-stage renal disease. 
Nephrology (Carlton ) 2007;12(3):289-293.
 (61)  Cai H, Wang X, Colagiuri S, Wilcken DE. A common Glu298-->Asp (894G-->T) mutation at exon 
7 of the endothelial nitric oxide synthase gene and vascular complications in type 2 diabetes. 
Diabetes Care 1998;21(12):2195-2196.
 (62)  Al-Kateb H, Boright AP, Mirea L, Xie X, Sutradhar R, Mowjoodi A et al. Multiple superoxide 
dismutase 1/splicing factor serine alanine 15 variants are associated with the development and 
progression of diabetic nephropathy: the Diabetes Control and Complications Trial/Epidemiology 
of Diabetes Interventions and Complications Genetics study. Diabetes 2008;57(1):218-228.
 (63)  McKnight A-J, Maxwell AP, Patterson CC, Brady HR, Savage DA. Association of VEGF-1499C[right 
arrow]T polymorphism with diabetic nephropathy in type 1 diabetes mellitus. Journal of Diabetes 
and its Complications 2007;21(4):242-245.
 (64)  Akai Y, Sato H, Ozaki H, Iwano M, Dohi Y, Kanauchi M. Association of transforming growth 
factor-beta1 T29C polymorphism with the progression of diabetic nephropathy. Am J Kidney Dis 
2001;38(4 Suppl 1):S182-S185.
 (65)  Araki S, Moczulski DK, Hanna L, Scott LJ, Warram JH, Krolewski AS. APOE polymorphisms and the 
development of diabetic nephropathy in type 1 diabetes: results of case-control and family-based 
studies. Diabetes 2000;49(12):2190-2195.
 (66)  Blaauwwiekel EE, Beusekamp BJ, Sluiter WJ, Hoogenberg K, Dullaart RP. Apolipoprotein E genotype 
is a determinant of low-density lipoprotein cholesterol and of its response to a low-cholesterol diet 
in Type 1 diabetic patients with elevated urinary albumin excretion. Diabet Med 1998;15(12):1031-
1035.
 (67)  Guan J, Zhao HL, Baum L, Sui Y, He L, Wong H et al. Apolipoprotein E polymorphism and 




 (68)  Ahluwalia TS, Khullar M, Ahuja M, Kohli HS, Bhansali A, Mohan V et al. Common variants of 
inflammatory cytokine genes are associated with risk of nephropathy in type 2 diabetes among 
Asian Indians. PLoS ONE 2009;4(4).
 (69)  Maeda S, Osawa N, Hayashi T, Tsukada S, Kobayashi M, Kikkawa R. Genetic variations associated 
with diabetic nephropathy and type II diabetes in a Japanese population. Kidney Int Suppl 
2007;(106):S43-S48.
 (70)  Pezzolesi MG, Poznik GD, Mychaleckyj JC, Paterson AD, Barati MT, Klein JB et al. Genome-
wide association scan for diabetic nephropathy susceptibility genes in type 1 diabetes. Diabetes 
2009;58(6):1403-1410.
 (71)  Shimazaki A, Tanaka Y, Shinosaki T, Ikeda M, Watada H, Hirose T et al. ELMO1 increases expression 
of extracellular matrix proteins and inhibits cell adhesion to ECMs. Kidney Int 2006;70(10):1769-
1776.
 (72)  Gulewitsch W, Amiradzibi S. Carnosine, a new organic base from meat extracts. Ber Dtsch Chem 
Ges 1900;33:1902-1903.
 (73)  Quinn PJ, Boldyrev AA, Formazuyk VE. Carnosine: its properties, functions and potential therapeutic 
applications. Mol Aspects Med 1992;13(5):379-444.
 (74)  Severin SE, Kirzon MV, Kaftanova TM. [Effect of carnosine and anserine on action of isolated frog 
muscles.]. Dokl Akad Nauk SSSR 1953;91(3):691-694.
 (75)  Reddy VP, Garrett MR, Perry G, Smith MA. Carnosine: a versatile antioxidant and antiglycating 
agent. Sci Aging Knowledge Environ 2005;2005(18):e12.
 (76)  Dupin AM, Boldyrev AA, Arkhipenko I, Kagan VE. [Carnosine protection of Ca2+ transport against 
damage induced by lipid peroxidation]. Biull Eksp Biol Med 1984;98(8):186-188.
 (77)  Decker EA, Faraji H. Inhibition of lipid peroxidation by carnosine. J Am Oil Chem Soc 2010;67:650-
652.
 (78)  Neifakh EA. Dokl Acad Nauk USSR 1966;170:1216-1219.
 (79)  Kohen R, Yamamoto Y, Cundy KC, Ames BN. Antioxidant activity of carnosine, homocarnosine, 
and anserine present in muscle and brain. Proc Natl Acad Sci U S A 1988;85(9):3175-3179.
 (80)  Mozdzan M, Szemraj J, Rysz J, Nowak D. Antioxidant properties of carnosine re-evaluated with 
oxidizing systems involving iron and copper ions. Basic Clin Pharmacol Toxicol 2005;96(5):352-360.
 (81)  Hobart LJ, Seibel I, Yeargans GS, Seidler NW. Anti-crosslinking properties of carnosine: significance 
of histidine. Life Sci 2004;75(11):1379-1389.
 (82)  Hipkiss AR, Chana H. Carnosine protects proteins against methylglyoxal-mediated modifications. 
Biochem Biophys Res Commun 1998;248(1):28-32.
1
37
 (83)  Rashid I, van Reyk DM, Davies MJ. Carnosine and its constituents inhibit glycation of low-density 
lipoproteins that promotes foam cell formation in vitro. FEBS Lett 2007;581(5):1067-1070.
 (84)  Hou WC, Chen HJ, Lin YH. Antioxidant peptides with Angiotensin converting enzyme inhibitory 
activities and applications for Angiotensin converting enzyme purification. J Agric Food Chem 
2003;51(6):1706-1709.
 (85)  Bauer K. Carnosine and homocarnosine, the forgotten, enigmatic peptides of the brain. Neurochem 
Res 2005;30(10):1339-1345.
 (86)  Bonfanti L, Peretto P, De MS, Fasolo A. Carnosine-related dipeptides in the mammalian brain. Prog 
Neurobiol 1999;59(4):333-353.
 (87)  McFarland GA, Holliday R. Retardation of the senescence of cultured human diploid fibroblasts by 
carnosine. Exp Cell Res 1994;212(2):167-175.
 (88)  Zschocke J, Nebel A, Wicks K, Peters V, El Mokhtari NE, Krawczak M et al. Allelic variation in the 
CNDP1 gene and its lack of association with longevity and coronary heart disease. Mech Ageing 
Dev 2006;127(11):817-820.
 (89)  Hipkiss AR. Carnosine, diabetes and Alzheimer’s disease. Expert Rev Neurother 2009;9(5):583-585.
 (90)  Boldyrev A, Fedorova T, Stepanova M, Dobrotvorskaya I, Kozlova E, Boldanova N et al. Carnosine 
[corrected] increases efficiency of DOPA therapy of Parkinson’s disease: a pilot study. Rejuvenation 
Res 2008;11(4):821-827.
 (91)  Chez MG, Buchanan CP, Aimonovitch MC, Becker M, Schaefer K, Black C et al. Double-blind, 
placebo-controlled study of L-carnosine supplementation in children with autistic spectrum 
disorders. J Child Neurol 2002;17(11):833-837.
 (92)  Babizhayev MA, Deyev AI, Yermakova VN, Semiletov YA, Davydova NG, Doroshenko VS et al. 
Efficacy of N-acetylcarnosine in the treatment of cataracts. Drugs R D 2002;3(2):87-103.
 (93)  Renner C, Zemitzsch N, Fuchs B, Geiger KD, Hermes M, Hengstler J et al. Carnosine retards tumor 
growth in vivo in an NIH3T3-HER2/neu mouse model. Mol Cancer 2010;9:2.:2.
 (94)  Drozak J, Veiga-da-Cunha M, Vertommen D, Stroobant V, Van SE. Molecular identification 
of carnosine synthase as ATP-grasp domain-containing protein 1 (ATPGD1). J Biol Chem 
2010;285(13):9346-9356.
 (95)  Ganapathy V, Leibach FH. Peptide transport in rabbit kidney. Studies with L-carnosine. Biochim 
Biophys Acta 1982;691(2):362-366.




 (97)  Tramonti G, Xie P, Wallner EI, Danesh FR, Kanwar YS. Expression and functional characteristics of 
tubular transporters: P-glycoprotein, PEPT1, and PEPT2 in renal mass reduction and diabetes. Am J 
Physiol Renal Physiol 2006;291(5):F972-F980.
 (98)  Kamal MA, Jiang H, Hu Y, Keep RF, Smith DE. Influence of genetic knockout of Pept2 on the in vivo 
disposition of endogenous and exogenous carnosine in wild-type and Pept2 null mice. Am J Physiol 
Regul Integr Comp Physiol 2009;296(4):R986-R991.
 (99)  Schulz M, Hamprecht B, Kleinkauf H, Bauer K. Regulation by dibutyryl cyclic AMP of carnosine 
synthesis in astroglia-rich primary cultures kept in serum-free medium. J Neurochem 1989;52(1):229-
234.
 (100)  Hanson HT, Smith EL. Carnosinase; an enzyme of swine kidney. J Biol Chem 1949;179(2):789-801.
 (101)  Lenney JF, George RP, Weiss AM, Kucera CM, Chan PW, Rinzler GS. Human serum carnosinase: 
characterization, distinction from cellular carnosinase, and activation by cadmium. Clin Chim Acta 
1982;123(3):221-231.
 (102)  Teufel M, Saudek V, Ledig JP, Bernhardt A, Boularand S, Carreau A et al. Sequence identification 
and characterization of human carnosinase and a closely related non-specific dipeptidase. J Biol 
Chem 2003;278(8):6521-6531.
 (103)  Murphey WH, Lindmark DG, Patchen LI, Housler ME, Harrod EK, Mosovich L. Serum carnosinase 
deficiency concomitant with mental retardation. Pediatr Res 1973;7(7):601-606.
 (104)  Peters V, Kebbewar M, Jansen EW, Jakobs C, Riedl E, Koeppel H et al. Relevance of allosteric 
conformations and homocarnosine concentration on carnosinase activity. Amino Acids 
2010;38(5):1607-1615.
 (105)  Bando K, Shimotsuji T, Toyoshima H, Hayashi C, Miyai K. Fluorometric assay of human serum 
carnosinase activity in normal children, adults and patients with myopathy. Ann Clin Biochem 
1984;21(Pt 6):510-514.
 (106)  Cohen M, Hartlage PL, Krawiecki N, Roesel RA, Carter AL, Hommes FA. Serum carnosinase 
deficiency: a non-disabling phenotype? J Ment Defic Res 1985;29(Pt 4):383-389.
 (107)  Perry TL, Hansen S, Tischler B, Bunting R, Berry K. Carnosinemia. A new metabolic disorder 
associated with neurologic disease and mental defect. N Engl J Med 1967;277(23):1219-1227.
 (108)  Willi SM, Zhang Y, Hill JB, Phelan MC, Michaelis RC, Holden KR. A deletion in the long arm of 
chromosome 18 in a child with serum carnosinase deficiency. Pediatr Res 1997;41(2):210-213.
 (109)  Riedl E, Koeppel H, Brinkkoetter P, Sternik P, Steinbeisser H, Sauerhoefer S et al. A CTG polymorphism 




 (110)  Hipkiss AR, Brownson C, Carrier MJ. Carnosine, the anti-ageing, anti-oxidant dipeptide, may react 
with protein carbonyl groups. Mech Ageing Dev 2001;122(13):1431-1445.
 (111)  Thomas MC, Forbes JM, Cooper ME. Advanced glycation end products and diabetic nephropathy. 
Am J Ther 2005;12(6):562-572.
 (112)  Artioli GG, Gualano B, Smith A, Stout J, Lancha AH, Jr. Role of beta-alanine supplementation on 
muscle carnosine and exercise performance. Med Sci Sports Exerc 2010;42(6):1162-1173.
 (113)  Baguet A, Bourgois J, Vanhee L, Achten E, Derave W. Important role of muscle carnosine in rowing 
performance. J Appl Physiol 2010.
 (114)  Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA et al. Reduction 
in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 
2002;346(6):393-403.
 (115)  Aldini G, Orioli M, Rossoni G, Savi F, Braidotti P, Vistoli G et al. The carbonyl scavenger carnosine 
ameliorates dyslipidemia and renal function in zucker obese rats. J Cell Mol Med 2010.
 (116)  Koeppel H, Jeung H, Riedl E, Braungel M, Hoeger S, Sauerhoefer S et al. Carnosine as a novel 
approach for prevention of diabetes induced complications in the rat model. J Am Soc Nephrol 
2008;19:51A.
 (117)  Sauerhofer S, Yuan G, Braun GS, Deinzer M, Neumaier M, Gretz N et al. L-carnosine, a substrate 
of carnosinase-1, influences glucose metabolism. Diabetes 2007;56(10):2425-2432.
 (118)  Lee YT, Hsu CC, Lin MH, Liu KS, Yin MC. Histidine and carnosine delay diabetic deterioration in 





PatholoGic classification of diabetic nePhroPathy
Cohen Tervaert TW1#, Mooyaart AL1#, Amann K2, Cohen AH3, Cook TH 4, 
Drachenberg CB5, Ferrario F6, Fogo AB7, Haas M3, de Heer E1, Joh K8, Noël 
LH9, Radhakrishnan J10, Seshan SV11, Bajema IM1, Bruijn JA1
# Equally contributing authors
1Department of Pathology, Leiden University Medical Center, Leiden, the 
Netherlands; 
2Department of Pathology, University of Erlangen-Nuernberg, Erlangen, Germany; 
3Department of Pathology, Cedars-Sinai Medical Center, Los Angeles, USA; 
4Department of Histopathology, Hammersmith Hospital, London, UK; 5Department 
of Pathology, University of Maryland, Baltimore, USA; 6Renal Immunopathology 
Center, San Carlo Borromeo Hospital, Italy; 7Department of Pathology, Vanderbilt 
University Medical Center, Nashville, USA; 8Division of Pathology, Sendai-Shaho 
Hospital, Sendai-city, Japan; 9Department of Pathology, Hôpital Necker, Université 
René Descartes, Paris, France; 10Department of Medicine, Columbia University, 
New York, New York, USA; 11Department of Pathology and Laboratory Medicine, 
Weill Cornell Medical College, New York,  New York, USA.




Although pathologic classifications exist for several renal diseases, including IgA 
nephropathy, focal segmental glomerulosclerosis, and lupus nephritis, a uniform 
classification for diabetic nephropathy is lacking. Our aim, commissioned by the 
Research Committee of the Renal Pathology Society, was to develop a consensus 
classification combining type 1 and type 2 diabetic nephropathies. Such a classification 
should discriminate lesions by various degrees of severity that would be easy to use 
internationally in clinical practice. We divide diabetic nephropathy into four hierarchical 
glomerular lesions with a separate evaluation for degrees of interstitial and vascular 
involvement. Biopsies diagnosed as diabetic nephropathy are classified as follows: 
Class I, glomerular basement membrane thickening: isolated glomerular basement 
membrane thickening and only mild, nonspecific changes by light microscopy that do 
not meet the criteria of classes II through IV. Class II, mesangial expansion, mild (IIa) 
or severe (IIb): glomeruli classified as mild or severe mesangial expansion but without 
nodular sclerosis (Kimmelstiel–Wilson lesions) or global glomerulosclerosis in more than 
50% of glomeruli. Class III, nodular sclerosis (Kimmelstiel–Wilson lesions): at least one 
glomerulus with nodular increase in mesangial matrix (Kimmelstiel–Wilson) without 
changes described in class IV. Class IV, advanced diabetic glomerulosclerosis: more than 
50% global glomerulosclerosis with other clinical or pathologic evidence that sclerosis 
is attributable to diabetic nephropathy. A good interobserver reproducibility for the 





Diabetic nephropathy (DN) is a major cause of ESRD, and the incidence of diabetes 
mellitus is rising rapidly.1 Pathologic classifications exist for several kidney diseases such 
as lupus nephritis,2 focal segmental glomerulosclerosis,3 and IgA nephropathy,4 yet there 
is no uniform classification for DN. Classification schemes lead to better communication 
between renal pathologists and clinicians, provide logistical structure for prognostic and 
interventional studies, and improve clinical management and efficiency.5
In 1959, Gellman et al.6 first reported an overview and clinical correlation of findings 
on renal biopsies from patients with DN. Before their study, the renal pathology in 
patients with diabetes mellitus was only described at autopsy. Gellman proposed 
an elaborate systematic evaluation examining glomeruli, tubules, arterioles, and the 
interstitium that was unsuitable for practical use. More recently, attempts were made to 
categorize patterns seen in DN after type 2 diabetes.7–10 Gambara et al.7 and Fioretto et 
al.8 made basic distinctions between typical and atypical DN as well as other glomerular 
diseases superimposed on DN.7,8
Although such schemes are useful for research biopsies, they also are not practical 
for clinical use. We decided to classify DN due to type 1 and type 2 diabetes together 
because there is substantial overlap with respect to histologic lesions and renal 
complications.11–13
Our aim was to develop a uniform classification system containing specific categories 
that discriminate lesions with various prognostic severities that would be easy to use. 
This proposal was launched by the Research Committee of the Renal Pathology Society 
in 2006 in San Diego and further discussed in Leiden in September 2008. 
Presented here is a consensus classification of DN developed by a group of 
international experts.
CLASSIFICATION OF DN
It is essential to evaluate renal tissue using appropriate standards for renal biopsy. 
These include hematoxylin and eosin, periodic acid–Schiff (PAS), Masson trichrome, and 
periodic acid methenamine silver stains for light microscopy. Biopsies should contain 
at least 10 glomeruli, 14 excluding incomplete glomeruli along the biopsy edge. 
Immunofluorescence requires the use of antibodies against IgA, IgG, IgM, C3, C1q, and
kappa and lambda light chains to rule out other renal diseases. Electron microscopy 
(EM) must be performed; specific guidelines are discussed below. All of these methods 
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are necessary for an accurate diagnosis of DN. DN should never be diagnosed without 
supportive clinical information, and a patient should carry a clinical diagnosis of diabetes 
mellitus to apply the classification. Furthermore, virtually any glomerular disease can 
accompany DN, postinfectious GN 9,15 and membranous glomerulopathy being the 
most common 11; thus, any coexisting disorders should also be described. Four classes 
of glomerular lesions in DN are presented in Table 1.
Table 1: Classification system for diabetic nephropathy into 4 classes
Class Description Inclusion Criteria
I Mild or non-specific LM changes and EM 
proven GBM thickening
Biopsy does not meet any of the criteria mentioned 
below for class II,III or IV
    GBM > 395 nm in female, and > 430 nm in male 
individuals of 9 years and older*
II a Mild Mesangial Expansion Biopsy does not meet criteria for class III and IV 
    Mild mesangial expansion in more than 25% of the 
observed mesangium
II b Severe Mesangial Expansion Biopsy does not meet criteria for class III and IV
    Severe mesangial expansion in more than 25% of the 
observed mesangium
III Nodular slerosis (Kimmelstiel-Wilson lesions) Biopsy does not meet criteria for class IV 
    At least one convincing Kimmelstiel-Wilson lesion
IV Advanced diabetic glomeruloslerosis Global glomerular sclerosis in >50% of glomeruli
    Lesions from classes I-III
LM = light microscopy, EM = electron microscopy, GBM = glomerular basement membrane, 
DN= diabetic nephropathy 
* based on direct measurement of GBM width by EM, these individual cut-off levels may be considered 
indicative when other GBM measurements are used
Classes of Glomerular Lesions
Class I: Glomerular Basement Membrane Thickening.
If the biopsy specimen shows no or only mild, nonspecific changes by light microscopy 
that do not meet the criteria of classes II through IV [in effect, in the absence of 
mesangial expansion, nodular increases in mesangial matrix (Kimmelstiel–Wilson 
lesions), and global glomerulosclerosis of more than 50% of glomeruli] the biopsy 
is assigned to class I (Table 1 and Figure 1), in which by direct measurements with 
EM the glomerular basement membrane (GBM) on average is thicker than 430 nm in 
males 9 years and older and thicker than 395 nm in females. These cutoff levels are 
based on a deviation from normal GBM thickness plus 2 standard deviations as recently 
determined by Haas.16 For children younger than 9 years old, we refer to Table 1 in the 
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paper by Haas.16 Upper limits for normal GBM thickness vary with the methods used 
to measure GBM width. For instance, using the orthogonal intercept method, upper 
limits of normal GBM thickness are 520 nm for adult men and 471 nm for women.17 
In individual laboratories, the upper limits for normal GBM thickness have usually been 
established, and if other methods than direct GBM measurement are used, it is advised 
to use these locally established cutoff points.
Light microscopic changes in the GBM and epithelial foot process effacement by EM 
have no influence on the classification. Class I incorporates cases that have been called 
“normal or near normal DN” by Fioretto et al.,8 but in our system, a certain degree of 
chronic and other reactive changes (e.g., changes of arterionephrosclerosis, ischemic 
type changes, or interstitial fibrosis) are accepted as part of this category. Diagnosing 
DN in cases without characteristic light microscopic glomerular lesions may be difficult, 
especially when a thicker GBM is also seen with aging or hypertension. The presence 
of arteriolar hyalinosis may be helpful in these cases, although it is not a prerequisite.
GBM thickening is a characteristic early change in type 1 and type 2 DN13 and increases 
with duration of disease.21 GBM thickening is a consequence of extracellular matrix 
accumulation, with increased deposition of normal extracellular matrix components 
such as collagen types IV and VI, laminin, and fibronectin.22,23 Such accumulations 
result from increased production of these proteins, their decreased degradation, or a 
combination of the two. GBM thickening may already be present in type 1 diabetes 
patients who are normoalbuminuric.20,21 GBM thickening has even been described as 
a “prediabetic” lesion: In patients with proteinuria and isolated GBM thickening but 
without overt diabetes, 20% were positive on a blood test for diabetes at the time of 
biopsy, whereas 44% were diagnosed with diabetes at 6 months, and 70% at 2 years 
after the biopsy was taken.24 Long-term glucose control and urinary albumin excretion 
(UAE) correlate strongly with basement membrane thickness.25 In 1979, Jensen et 
al.26 were among the first to measure GBM thickness using the orthogonal intercept 
method. In brief, a grid with eight evenly spaced intersecting lines (four horizontal and 
four vertical) is placed over a photomicrograph, and GBM measurements are made at 
each point that a line on the grid intercepts an endothelial-GBM interface. Currently, 
some laboratories use computer-assisted measurements by which the mean width is 
calculated from approximately 50 measurements of the GBM at five different locations. 
The GBM width is then compared with GBM width from normal subjects, as determined 
previously by Steffes et al.27 and recently updated by Haas.16 Ideally, glutaraldehyde-
fixed, plastic resin-embedded tissue should be used for EM, keeping in mind that other 
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methods, particularly the reprocessing of paraffin tissue for EM, may cause artifactual 
GBM thinning as recently reported by Nasr et al.28 If computer-assisted measurements 
are not available, we recommend doing direct GBM measurements as recently modified 
by Haas.16
Class II: Mesangial Expansion, Mild (IIa) or Severe (IIb).
Class II encompasses those patients classified with mild or severe mesangial expansion 
but not meeting inclusion criteria for class III or IV (Table 1 and Figure 1) and is analogous 
to the previously used term “diffuse diabetic glomerulosclerosis.”
Mesangial expansion is defined as an increase in extracellular material in the 
mesangium such that the width of the interspace exceeds two mesangial cell nuclei 
in at least two glomerular lobules. The difference between mild and severe mesangial 
expansion is based on whether the expanded mesangial area is smaller or larger than 
the mean area of a capillary lumen. If severe mesangial expansion is seen in more than 
25% of the total mesangium observed throughout the biopsy, the biopsy is classified 
as IIb. If this is not the case, but at least mild mesangial expansion is seen in more than 
25% of the total mesangium, the biopsy is classified as IIa.
Expansion of cellular and matrix components in the mesangium is a hallmark of 
type 1 and type 2 DN.13,18 It can be detected in some patients within a few years after 
the onset of type 1 diabetes.20 When the mesangium expands, it restricts and distorts 
glomerular capillaries and diminishes the capillary filtration surface. In our classification, 
we do not distinguish between mesangial hypercellularity, matrix expansion, or 
“mesangiosclerosis”— any expansion of the mesangium that conforms to our 
definitions given above and in Table 1 belongs to class II.
Various indices have been proposed to describe the amount of mesangial expansion 
in DN. Mauer et al.18 define mesangial expansion by mesangial fractional volume or 
volume density (VV), defined as the fraction or percentage of the cross-sectional area of 
the glomerular tuft made up by mesangium, expressed in the formula: Vv(mes/glom).18 
Using this formula, many correlations have been made between mesangial expansion 
and clinical parameters of DN, particularly showing highly inverse correlations exist 
between Vv(mes/glom) and GFR.18,29,30 There is also a relationship between Vv(mes/
glom) and UAE18,29 and blood pressure.31 Another index to express mesangial expansion 
is the so-called “index of mesangial expansion” (IME) for DN.18 The IME is determined 
by a semiquantitative estimate of the width of mesangial zones in each glomerulus18: 
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grade 0 is normal, 1 is twice normal thickness, 2 is three times normal thickness, and 
so forth; half grades can also be assigned. The mean of the grades for each glomerulus 
for IME can thus be determined from a single biopsy. The IME closely correlates with the 
Vv(mes/glom).18 Still, this is a rather elaborate method.
In other classifications, mesangial expansion is defined in more practical ways, such 
as in the new classification for IgA nephropathy in which it is defined as an increase in the 
extracellular material in the mesangium such that the width of the interspace exceeds 
two mesangial cell nuclei in at least two glomerular lobules.4 Because interobserver 
agreement was tested in this study and found to be satisfactory using this definition, we 
decided to use the same definition for mesangial expansion in our classification for DN.
Class III: Nodular Sclerosis (Kimmelstiel–Wilson lesions).
If at least one convincing Kimmelstiel–Wilson lesion is found and the biopsy specimen 
does not have more than 50% global glomerulosclerosis it is classified as class III (Table 
1 and Figure 1). Kimmelstiel–Wilson lesions appear in type 1 and type 2 diabetes as 
focal, lobular, round to oval mesangial lesions with an acellular, hyaline/matrix core, 
rounded peripherally by sparse, crescent-shaped mesangial nuclei.32
Paul Kimmelstiel and Clifford Wilson, a German and an Englishman who met at 
Harvard, first described nodular lesions in glomeruli from eight maturity-onset diabetes 
patients in 1936.33 According to Cameron,34 they barely noted the association with 
diabetes, and it was Arthur Allen who clarified the association in 105 patients with 
diabetes in 1941.35 Nodular sclerotic lesions may also occur in the absence of DN that 
are clinically related to hypertension, smoking, hypercholesterolemia, and extrarenal 
vascular disease.36 It is claimed that in the initial stage of developing nodular sclerotic 
lesions in DN, two important processes take place: lytic changes in the mesangial area 
called mesangiolysis and detachment of endothelial cells from the GBM.37 Exactly 
how these  two processes relate remains uncertain. Paueksakon et al.38 detected 
fragmented red blood cells in Kimmelstiel–Wilson lesions, which supports the theory 
that microvascular injury contributes to the pathogenesis of these lesions. 
Dissociation of endothelial cells may disrupt the connections between the mesangial 
area and the GBM. This process precedes expansion of the Kimmelstiel–Wilson lesion.37 
These lesions consist of an accumulation of mesangial matrix with collagen fibrils, small 
lipid particles, and cellular debris.39 A completely developed Kimmelstiel–Wilson lesion 
destroys the normal structure of glomerular tuft with a decrease in mesangial cells, 
2
48
especially in the central area.37 In 1992, a graphic method of analysis of the position of 
Kimmelstiel–Wilson lesions demonstrated the nodules were distributed in a horseshoe-
shaped area corresponding to the peripheral or intralobular mesangium,40 excluding the 
possibility of hyperfiltration as being their main cause of development.
The presence of at least one Kimmelstiel–Wilson lesion associates with longer 
duration of diabetes and less favorable clinical parameters.10,41 In a study of 36 patients 
with type 2 diabetes, patients with Kimmelstiel–Wilson lesions had more severe overall 
retinopathy and higher serum creatinine concentrations than those with mesangial 
lesions alone.10 In a study of 124 Chinese patients with type 2 diabetes, patients with 
at least one Kimmelstiel–Wilson lesion had relatively long duration of diabetes mellitus, 
a poor prognosis, and frequent evidence of diabetic retinopathy.41 Kimmelstiel–Wilson 
lesions are often found in combination with mesangial expansion. The occurrence of 
Kimmelstiel– Wilson lesions is widely considered transitional from an early or moderately 
advanced stage to a progressively more advanced stage of disease.41,42 Therefore, in our 
classification, the occurrence of Kimmelstiel–Wilson lesions implies a separate class. 
Class IV: Advanced Diabetic Glomerulosclerosis.
Class IV implies advanced DN and designates those biopsies with more than 50% global 
glomerulosclerosis in which there is clinical or pathologic evidence that the sclerosis is 
attributable to DN (Table 1 and Figure 1). Glomerulosclerosis in DN is the end point of 
multifactorial mechanisms that lead to excessive accumulation of extracellular matrix 
proteins such as collagen types I, III, and IV and fibronectin in the mesangial space, 
which through stages of mesangial expansion and development of Kimmelstiel–Wilson 
lesions finally result in glomerulosclerosis.43 The clustering of sclerotic lesions in columns 
perpendicular to the kidney surface suggests that vascular factors relating to the 
interlobular arteries also contribute.44
Designation of class IV lesions in our classification system is restricted to those 
cases in which there is evidence for DN. This evidence can come from other lesions 
in the biopsy as described for classes I through III. The occurrence of hyalinosis of the 
glomerular vascular pole or a capsular drop may also be taken as evidence for the 
presence of DN. Alternatively, if DN is the likely clinical diagnosis (e.g., by the presence 
of retinopathy) a biopsy with extensive glomerulosclerosis can also be classified as class 
IV. Glomerulosclerosis without evidence of DN should be mentioned as such in the 












Figure 1. Flow chart for classifying DN.
Tubulointerstitial Lesions, Vascular Lesions, and Nondiabetic Glomerular Lesions
Tubular Lesions.
Concomitant tubular basement membrane thickening of nonatrophic tubules is 
apparent from the development of class II glomerular diabetic lesions and becomes 
more conspicuous in class III and IV, which is best seen in PAS or silver stains. Interstitial 
fibrosis and tubular atrophy (IFTA) follow glomerular changes in type 1 DN that 
ultimately lead to ESRD.30 We score IFTA together as a percentage of the total involved 
area of interstitium and tubules (Table 2). A score of 0 is assigned when the biopsy 
specimen shows no IFTA, a score of 1 is assigned when less than 25% IFTA is present, 
a score of 2 is assigned when at least 25% but less than 50% of the biopsy has IFTA, 
and finally, a score of 3 is assigned when at least 50% IFTA is present, which is similar 
to the scoring in the recently published classification of IgA nephropathy.4 Presence of 
mononuclear cells in the interstitium is a widely recognized finding in DN. Inflammatory 
interstitial infiltrates comprise T lymphocytes and macrophages.45 In Table 2, we score 0 
if interstitial infiltrates are absent, 1 if they only occur around atrophic tubules, and 2 if 












Table 2. Interstitial and vascular lesions of DN 
Lesion Criteria Score
Interstitial lesions
IFTA No IFTA 0
<25% 1
25% to 50% 2
>50% 3
interstitial inflammation Absent 0
Infiltration only in relation to IFTA 1
Infiltration in areas without IFTA 2
Vascular lesions
arteriolar hyalinosis Absent 0
At least one area of arteriolar hyalinosis 1
More than one area of arteriolar hyalinosis 2
presence of large vessels – Yes/no
arteriosclerosis (score worst artery) No intimal thickening 0
Intimal thickening less than thickness of media 1
Intimal thickening greater than thickness of media 2
Vascular Lesions.
According to Stout et al.,46 hyalinosis of the efferent arteriole is relatively specific for 
DN, but hyalinosis of the afferent arteriole occurs in numerous other settings. Chronic 
cyclosporine nephropathy is a typical example in which arteriolar hyalinosis occurs 
outside DN.47 Tracy et al. also report the presence of arteriolar hyalinosis in kidneys of 
young patients with coronary heart disease.48 Efferent arteriolar hyalinosis is an important 
lesion by which DN is distinguished from hypertensive nephropathy.49 However, most 
studies relate arteriolar hyalinosis to clinical parameters, not distinguishing between 
efferent and afferent arterioles, showing clear correlations with UAE and disease 
progression.50,51 In Table 2 we score 0 if no arteriolar hyalinosis is present, 1 if one 
arteriole with hyalinosis is present, and 2 if more than one arteriole is observed in 
the entire biopsy. In addition to characteristic arteriolar hyalinosis, relatively nonspecific 
arteriosclerosis may be present in the biopsy specimen. Bohle and colleagues45 found 
increases in vascular disease associate with more severe glomerular disease. Osterby et 
al.52 use a so-called “matrix to media ratio” to investigate the role of arteriosclerosis and 
find this ratio is increased in patients with microalbuminuria, suggesting that arteriolar 
matrix accumulation occurs early in the course of DN. In Table 2 we score the most 
severely affected artery in the biopsy and assign a score of 0 if no intimal thickening is 
present, 1 if intimal thickening is less than the thickness of the media, and 2 if intimal 
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thickening is more than the thickness of the media. Isolated or significant medial 
thickness may be associated with concurrent hypertension. 
Other Glomerular Lesions 
In 1994, Stout et al.46 defined “insudative lesions” as consisting of intramural 
accumulations of presumably imbibed plasma proteins and lipids within renal arterioles, 
glomerular capillaries, Bowman’s capsule, or proximal convoluted tubules. Insudative 
lesions in Bowman’s capsule are called capsular drop lesions, and in afferent and efferent 
arterioles they are called hyalinized afferent and efferent arterioles. In glomerular 
capillaries they are called fibrin cap lesions, although this term is considered obsolete 
and moreover is a misnomer because the lesion does not contain fibrin; we prefer 
the term hyalinosis for these lesions. Capsular drops are mainly located between the 
parietal  epithelium and Bowman’s capsule of the glomerulus.11 Capsular drops are 
prevalent in advanced DN 53 and associate with disease progression.54 The common 
belief, reviewed by Alsaad et al.,49 is that capsular drops are specific but not entirely 
pathognomonic of DN. Stout et al.46 report a prevalence of capsular drops in 5.3% 
of biopsies without diabetes. However, finding a capsular drop in a biopsy can help 
distinguish DN from other causes of glomerulosclerosis. By light microscopy, glomerular 
hyalinosis describes the same staining characteristics as the capsular drop lesion but 
it occupies the capillary lumen instead of being attached to Bowman’s capsule. This 
lesion is not a specific finding in DN, because similar lesions are recognized in focal 
glomerulosclerosis, arterionephrosclerosis, and lupus nephritis.55
Finally, there is increasing recognition of abnormalities in the glomerulotubular 
junctions with focal adhesions called “tip lesions” and atrophic tubules with no observable 
glomerular opening (so-called “atubular glomeruli”). These lesions are typically found 
in more advanced stages of nephropathy associated with overt proteinuria.30
Interobserver Reproducibility
To assess the reproducibility of our consensus classification, a pilot study was performed 
in which five pathologists independently classified 25 renal biopsies with DN using PAS 
stains only into class I, II, III, or IV. Two pathologists scored all biopsies independently. 
Results of the raw data are given in Table 3. The reproducibility of the glomerular class 
score was evaluated using an intraclass correlation coefficient. Analyses were carried 
out using SPSS software (version 16, SPSS, Inc., Chicago, IL). There was disagreement in 
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seven cases: twice on a difference between class I and II, twice on a difference between 
class II and III, and three times on a difference between class IIa and IIb. Overall, the 
results seem satisfactory, resulting in an intraclass correlation coefficient of 0.84.
Flow Chart and Scoring Form
A flow chart was devised to help distinguish the four classes of DN (Figure 2). 
Supplemental Figure 1 shows the scoring form we recommend for classifying glomeruli
in DN and for scoring of extraglomerular lesions or other features. 
Table 3. Assessment of interobserver agreement for scoring of DN classes I to IV  
Biopsy Nr Observer 1 Observer 2 Observer 3 Observer 4 Observer 5 Agreement
1 IIA I N
2 III III Y
3 IIB IIA N
4 IIB IIA N
5 IIB IIA N
6 III III Y
7 IIB IIB Y
8 IIB IIB Y
9 IV IV Y
10 IIA IIA Y
11 IV IV Y
12 IIB IIB Y
13 III III Y
14 I I Y
15 IV IV Y
16 III III Y
17 III III Y
18 IIB I N
19 IIB III N
20 IIA IIA Y
21 III III Y
22 III IIA N
23 III III Y
24 III III Y
25 IIA IIA Y
Y = yes, N = no, intra-class correlation coefficient = 0.84
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Figure 3. Typical examples of histomorphological lesions in DN. 
A. glomerulus showing only mild ischaemic changes, with splitting of Bowman’s capsule. No clear mesangial 
alteration. B. EM of this glomerulus: the mean width of the GBM was 671 nm (mean taken over 55 random 
measurements). EM provides the evidence for classifying the biopsy with only mild light microscopic changes 
into class I. C and D: glomeruli with mild and moderate mesangial expansion, respectively. In C, the mesangial 
expansion does not exceed the mean area of a capillary lumen, whereas in D, it does. E and F: in F Kimmelstiel-
Wilson lesions. The lesion in E is not a convincing Kimmelstiel-Wilson lesion, therefore (on the basis of the 
findings in this glomerulus), findings are consistent with class IIb. For the purpose of the classification, at 
least one convincing Kimmelstiel-Wilson, like in F, needs to be present. G and H: global glomerulosclerosis. 
In H, signs of DN consist of hyalinosis of the glomerular vascular pole, and also a remnant of a Kimmelstiel-
Wilson lesion on the opposite site of the pole. G is an example of glomerulosclerosis which does not reveal 
its cause (glomerulus from the same biopsy as H). For the purpose of the classification, signs of DN either 
histopathologically or clinically should be present in order to classify a biopsy with global glomerulosclerosis 

































We developed a classification scheme for DN consisting of four progressive classes 
supported by international consensus. The classification is based on glomerular lesions, 
with a separate evaluation for interstitial and vascular lesions. We chose a classification 
scheme based on glomerular lesions because these are relatively easy to recognize with 
good interobserver agreement as shown by our pilot data and because glomerular 
lesions best reflect the natural course of progressive DN.49 Of course, glomerular 
and interstitial lesions contribute to the decline in renal function in DN and may be 
independent factors in the progression of DN13; however, many studies also show that 
severity of chronic interstitial and glomerular lesions closely associate.12,18,19,56
Although in some clinical practices there is a policy to only perform a renal biopsy 
to exclude causes of renal disease characterized by proteinuria other than DN, there is 
increasing demand to classify the severity of disease in those patients with pure DN. 
Our classification system for histopathologic lesions in DN can be used for patients 
with type 1 and type 2 diabetes, because it is now generally recognized that substantial 
overlap exists between these two types with respect to histologic lesions and renal 
complications.12,13 Various studies also report different proportions of nondiabetic 
nephropathies in patients with diabetes and proteinuria.7,57 The classification system 
proposed here is only for DN, but it can also serve to classify DN when it is complicated 
by another superimposed disease. Little is known about the pathogenesis of lesions 
developing in DN, but it is suggested that if we could unravel the various pathways 
ultimately leading to glomerulosclerosis in DN, this could open up new possibilities for 
intervention to prevent or forestall nephropathy.43 Most likely, intra- and extraglomerular 
cells are involved in the  progressive accumulation of extracellular matrix proteins in DN. 
We suggest that progression evolves from GBM thickening to mesangial expansion, 
Kimmelstiel–Wilson lesions, and global glomerulosclerosis, respectively, which is 
reflected in the four classes of our classification system. Using our system to evaluate 
protocol biopsies of patients with DN may further unravel the complex pathways of DN.
An important question for every histologic classification system is whether it is 
predictive of clinical outcome. As in other proposals for classifying renal disease (e.g., 
for lupus nephritis2 and focal segmental glomerulosclerosis3), we chose not to assess 
clinical outcome as part of this proposal. We feel validation should be done in separate 
prospective studies, preferably including protocol biopsies of patients with type 1 and 
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Aims/hypothesis This meta-analysis assessed the pooled effect of each genetic variant 
reproducibly associated with diabetic nephropathy.
Methods PubMed, EMBASE and Web of Science were searched for articles assessing the 
association between genes and diabetic nephropathy. All genetic variants statistically 
associated with diabetic nephropathy in an initial study, then independently reproduced 
in at least one additional study, were selected. Subsequently, all studies assessing 
these variants were included. The association between these variants and diabetic 
nephropathy (defined as macroalbuminuria/proteinuria or end-stage renal disease 
[ESRD]) was calculated at the allele level and the main measure of effect was a pooled 
odds ratio. Pre-specified subgroup analyses were performed, stratifying for type 1/type 
2 diabetes mellitus, proteinuria/ESRD and ethnic group. 
Results The literature search yielded 3455 citations, of which 671 were genetic association 
studies investigating diabetic nephropathy. We identified 34 replicated genetic variants. 
Of these, 21 remained significantly associated with diabetic nephropathy in a random-
effects meta-analysis. These variants were in or near the following genes: ACE, AKR1B1 
(two variants), APOC1, APOE, EPO, NOS3 (two variants), HSPG2, VEGFA, FRMD3 (two 
variants), CARS (two variants), UNC13B, ‘CPVL and CHN2’ and GREM1, plus four 
variants not near genes. The odds ratios of associated genetic variants ranged from 
0.48 to 1.70. Additional variants were detected in subgroup analyses: ELMO1 (Asians), 
CCR5 (Asians) and CNDP1 (type 2 diabetes).
Conclusions/interpretation This meta-analysis found 24 genetic variants associated with 
diabetic nephropathy. The relative contribution and relevance of the identified genes in 




Diabetes mellitus has rapidly increased to epidemic proportions over the past few 
decades. The number of patients with diabetes mellitus worldwide was estimated at 173 
million in 2002 and is predicted to increase to 350 million cases by 2030 (1). Diabetes 
mellitus is associated with severe complications including nephropathy, neuropathy, 
retinopathy and accelerated cardiovascular disease. 
Diabetic nephropathy is the leading cause of end-stage renal disease (ESRD) in 
developed countries (1). Although glycaemic control inversely relates to the degree of 
microvascular complications including diabetic nephropathy (2), some patients appear 
to be at increased risk. The majority of patients with type 1 diabetes mellitus will either 
develop diabetic nephropathy within the first 15 years after diagnosis or will remain 
relatively protected thereafter (3). Differential disease risk in diabetic nephropathy may 
be partly attributable to genetic susceptibility. Evidence for a genetic component to 
diabetic nephropathy comes from family studies displaying familial aggregation of 
diabetic nephropathy both in type 1 and in type 2 diabetes mellitus (4-6), as well as 
differences in the prevalence of diabetic nephropathy between ethnic groups (7,8). 
The literature involving genetic associations in complex disease has been plagued by 
inconsistencies (9). Small sample sizes and false positive results were often responsible 
for lack of reproducibility (10). In addition, the prior probabilities of genetic associations 
are low. Therefore, the number of false positive associations generated by chance 
alone is high, particularly when low prior probabilities were not accounted for in the 
statistical analyses. (11). Incorrect phenotyping may also lead to spurious results. Thus 
independent replication of association remains essential in order to avoid false positive 
associations. The aim of this meta-analysis was to assess the pooled effect of genetic 
variants that have reproducibly been associated with diabetic nephropathy.
methods
Eligibility criteria 
We searched for studies comparing genetic variants in diabetes mellitus patients with 
diabetic nephropathy, relative to diabetes mellitus patients without diabetic nephropathy. 
We limited our analyses to studies investigating established and advanced diabetic 
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nephropathy. To be included, all cases in the report had to have diabetes mellitus with 
macroalbuminuria and/or overt proteinuria, ESRD attributed to diabetic nephropathy 
or biopsy-proven diabetic nephropathy. In addition, diabetic control participants had 
to have either: (1) normoalbuminuria; (2) normoalbuminuria or microalbuminuria after 
>15 years diabetes mellitus duration (microalbuminuria developing after >15 years 
diabetes mellitus duration is a poor predictor of diabetic nephropathy (3)); (3) stable 
kidney function (serum creatinine < 106.1 μmol/L) after >15 years of diabetes mellitus, 
irrespective of albuminuria. 
Studies were excluded when the control group consisted of non-diabetic participants, 
since in that case genetic associations ascribed to diabetic nephropathy could have 
been due to diabetes mellitus. Follow-up and case–control studies were both eligible 
for inclusion in the meta-analysis.
Literature search and data collection  
A search strategy was devised in collaboration with a trained librarian. The following 
databases were searched: PubMed (1949 to April 2010), EMBASE (OVID-version, 1980 
to April 2010) and Web of Science (1945 to April 2010). The search strategy consisted 
of multiple queries combining: ‘Diabetic Nephropathy’ and ‘Genes’ or ‘Polymorphisms’. 
For these two concepts, all relevant keyword variations were used. In addition, the 
names of specific genes and polymorphisms were combined with the topic ‘Diabetic 
Nephropathy’. This search strategy was optimised for every database consulted, taking 
into account differences in the various controlled vocabularies and different database-
specific technical variations. The search was performed in April 2010. To ensure maximum 
sensitivity, limits or filters were not placed on the searches. Language restrictions were 
not included in the initial search. References of other narrative and systematic reviews 
were also checked for relevant articles. The search strategy was updated if a reference 
was missing. The process was performed three times to ensure that no references were 
omitted.
Two authors (A. L. Mooyaart and E. J. J. Valk) of this study independently reviewed 
the titles and abstracts of the citations to identify genetic association studies. Genetic 
association studies were screened for whether the study contained a positive or a 
negative association between the genetic variant and diabetic nephropathy (association 
defined as significant at p<0.05). When a genetic variant was found to be associated 
with established or advanced diabetic nephropathy (either at the allelic or genotypic 
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level, including the recessive and dominant model) in two independent studies, that 
variant was considered to be a reproduced genetic variant. For these replicated variants, 
all other genetic studies were identified to estimate the effect of the variant on diabetic 
nephropathy, irrespective of p values. 
Data extraction and analysis 
The main outcome of the meta-analysis was the pooled odds ratio for the association 
between reproduced genetic variants and diabetic nephropathy. Odds ratios were 
calculated at allele level and not at genotype level. Of the reproduced genes, allele 
frequencies were extracted from studies. For single nucleotide polymorphisms (SNPs), 
the frequency of the minor allele was compared between diabetic nephropathy cases and 
non-nephropathy diabetic controls. For other genetic variants such as microsatellites, we 
compared the allele between cases and controls, as used in the literature and other meta-
analyses (12, 13). The random-effects model was performed by default. Heterogeneity 
within the studies was estimated by the I2, which is the percentage of the total variation 
across studies that is due to heterogeneity rather than chance. An I2 of 25%, 50% and 
75% was considered low, moderate and high respectively (14). Pre-specified stratified 
analyses were performed to explain heterogeneity or investigate whether the reported 
association was present in a subgroup. Stratified analysis was performed for diabetes 
mellitus type (type 1 or type 2), diabetic nephropathy stage (macroalbuminuria and/
or overt proteinuria, established diabetic nephropathy and ESRD [advanced diabetic 
nephropathy]) (15) and ethnicity (European vs Asian origin). The subgroup analysis was 
only included in this study if the association between the genetic variant and diabetic 
nephropathy was reproduced in that subgroup. We tested for publication bias using 
the Begg and Egger test and provided funnel plots of all genetic variants which were 
reproducibly associated with diabetic nephropathy. It should, however, be noted that 
funnel plot asymmetry can have other causes than publication bias (16). Furthermore, 
the effect of ethnicity was assessed if there were sufficient data by metaregression. 
Most analyses were performed in Review Manager (RevMan) Version 5.0 (The Nordic 
Cochrane Centre, Copenhagen, Denmark; The Cochrane Collaboration, 2008), except 
for the analysis of publication bias and metaregression, which was performed in STATA 





Initial search and results 
The initial literature search yielded 3455 citations, 671 of which were genetic 
association studies investigating diabetic nephropathy in humans (Fig. 1). In these 
studies, we identified 34 reproduced genetic variants in 24 genes associated with 
diabetic nephropathy. Data on at least one of these 34 variants were found in 132 
articles, representing 153 studies. Only three follow-up studies were included. All other 
studies were case–control studies. The maximum number of studies in an article was 
five. References of all articles and details of these studies are shown in the Electronic 
supplementary material (ESM) Tables 1 and 2. The 132 articles were published between 
1994 and 2010. The number of cases included in these articles ranged from four to 
1572, and in a study from four to 656 cases. Of the 34 reproduced genetic variants, 
21 genetic variants in or near 16 genes were significantly associated with diabetic 
nephropathy after random-effects meta-analysis (Fig. 2a). An overview of the pooled 
odds ratios of all reproduced variants in relation to diabetic nephropathy is shown in 
Fig. 2a, b. The odds ratios of the significant associations with diabetic nephropathy 
ranged between 0.48 and 0.78 for protective effects, and 1.12 to 1.70 for risk effects. 
Figure 3 contains an overview of the pooled odds ratios of all reproduced variants in 
relation to diabetic nephropathy among subgroups. Three reproduced variants were not 
significantly associated with diabetic nephropathy in the whole population after meta-
analyses, but were associated in one subgroup: rs1799987 of CCR5 and rs741301 of 
ELMO1 in the Asian subgroup, and D18S880 of the CNDP1 gene in patients with type 
2 diabetes mellitus. Details of analyses of all assessed genetic variants are provided in 
Table 1. Forest plots of all individual genetic variants and funnel plots for publication 
bias, as well as results of meta-regression for ethnicity are shown in the ESM (ESM 
Figs 1–36). If the meta-analysis revealed a positive association between a given genetic 
variant and diabetic nephropathy, and more than ten studies investigating that variant 
in relation to diabetic nephropathy were available, a metaregression was performed. 
Only three genetic variants fitted the above-mentioned criteria (ACE rs179975, AKRB1 
CA repeat Z−2, APOE E2/3/4). In these variants, metaregression showed that ethnicity 
did not explain the heterogeneity (ESM Figs 1–36).  
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     
  
  
   
    
 
  




   
























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 2. Genetic variants reproducibly associated with diabetic nephropathy. a All genetic variants in or near 
a gene that were reproduced in an independent study and significantly associated with diabetic nephropathy 
after meta-analysis. b All genetic variants in or near a gene that were reproduced in an independent study, 
but were not significantly associated with diabetic nephropathy after meta-analysis. Parentheses (y-axis 
labelling) contain the allele used in the comparison 


           














































Figure 3. Genetic variants reproducibly associated with diabetic nephropathy in a subgroup. a All genetic 
variants in or near a gene that were reproduced in an independent study and significantly associated with 
diabetic nephropathy after meta-analysis in a subgroup. b All genetic variants in or near a gene that were 
reproduced in an independent study, but were not significantly associated with diabetic nephropathy after 
meta-analysis in a subgroup. Parentheses (y-axis labelling) contain the allele used in the comparison. The 
subgroup in which the genetic variant was reproducibly associated with diabetic nephropathy is shown 





               
        

         
            
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Genetic variants involved in the renin–angiotensin system  
A variant in ACE, rs179975, was the most studied polymorphism in diabetic 
nephropathy, with 42 studies resulting in a pooled odds ratio of 1.24 (95% CI 1.12-
1.37). The association between the deletion of the rs179975 polymorphism and diabetic 
nephropathy was reproduced in all subgroups. In the meta-analysis, the rs179975 
polymorphism was associated with diabetic nephropathy in type 1 diabetes mellitus 
(OR 1.13 [95% CI 1.04-1.23]), type 2 diabetes mellitus (OR 1.33 [95% CI 1.16-1.52]), 
ESRD (OR 1.39 [95% CI 1.21-1.60]), proteinuria (OR 1.20 [95% CI 1.07-1.36]) and in 
the Asian subgroup (OR 1.28 [95% CI 1.10-1.49]), but not in Europeans. Other variants 
in the renin–angiotensin system  that were also widely studied and reproduced, such as 
the rs699 variant of AGT with 21 studies and the rs5186 polymorphism of AGTR1 with 
15 studies, were not associated with diabetic nephropathy in the meta-analysis.  
Genetic variants involved in the polyol pathway 
The CA repeat and rs759853 in AKR1B1 were studied in nineteen and nine studies, 
respectively. The CA repeat has a Z−2 allele thought to lead to an increased risk of 
diabetic nephropathy and a Z+2 allele thought to have a protective effect. The Z+2 
allele and Z−2 allele were both reproducibly associated with diabetic nephropathy, but 
only the Z−2 allele remained associated in a combined meta-analysis with a pooled 
odds ratio of 1.12 (95% CI 1.02-1.24). Although reproducibly associated with diabetic 
nephropathy in ‘type 1 diabetes mellitus’ and ‘European’ subgroups, Z−2 was not 
associated with diabetic nephropathy in the meta-analysis in these subgroups. The 
Z+2 allele was associated with diabetic nephropathy in the ‘type 1 diabetes mellitus’ 
and ‘European’ subgroups (OR 0.79 [95% CI 0.68-0.92] and OR 0.81 [95% CI 0.66-
0.99], respectively). The T allele in SNP rs759853 was associated with risk of diabetic 
nephropathy in the meta-analysis (OR 1.40 [95% CI 1.13-1.74]) and in the subgroups 
‘diabetic nephropathy due to type 1 diabetes mellitus’ and ‘Europeans’ (OR 1.58 [95% 
CI 1.01-2.46] and OR 1.45 [95% CI 1.07-1.97], respectively). 
Genetic variants involved in lipid metabolism 
Two variants in genes each coding for two different apolipoproteins are reproducibly 
associated with diabetic nephropathy and remained associated with diabetic nephro-
pathy in the meta-analysis: E2, E3, E4 polymorphism of APOE and rs4420638 near 
APOC1. The E2 allele is thought to lead to an increased risk of diabetic nephropathy 
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and the E4 allele is thought to have a protective effect. Both the E2 and the E4 allele 
were associated with diabetic nephropathy in the meta-analysis (OR 1.70 [95% CI 1.12-
2.58] and OR 0.78 [95% CI 0.62-0.98] respectively). The E2 allele was also reproducibly 
associated with diabetic nephropathy in the subgroups ‘type 2 diabetes mellitus’, ‘Asians’ 
and ‘European/type 1 diabetes mellitus’ (all studies investigating Europeans had type 1 
diabetes mellitus and vice versa), but only associated with diabetic nephropathy in the 
meta-analysis in the ‘type 2 diabetes mellitus’ and ‘Asian’ subgroups (OR 2.21 [95% CI 
1.22-4.00] and OR 2.35 [95% CI 1.29-4.30], respectively). Rs4420638 near the APOC1 
gene was studied in two studies and was associated with diabetic nephropathy in the 
meta-analysis (OR 1.54 [95% CI 1.29-1.83]). Both studies contained type 1 diabetic 
nephropathy patients of European descent. 
Genetic variants involved in inflammatory cytokines and angiogenesis 
Rs1799987 of the CCR5 (an inflammatory cytokine) gene was only associated with 
diabetic nephropathy in the Asian subgroup (OR 0.58 [95% CI 0.43-0.76]) consisting of 
four studies (n=1534), but not in the total group consisting of nine studies (n=5527). 
For the total group, funnel plot asymmetry was indicated by a significant Begg test. 
Two genes involved in angiogenesis, VEGFA and EPO, each had a variant that was 
reproducibly associated with diabetic nephropathy. Rs833061 of VEGFA was associated 
with diabetic nephropathy in the meta-analysis in two studies (n=543) containing only 
type 1 diabetes mellitus patients of European origin (OR 0.48 [95% CI 0.37-0.61]). 
Rs1617640 of EPO was associated with diabetic nephropathy (OR 0.67 [95% CI 0.60-
0.76]) in three studies (n=2773), also in the subgroup with type 1 diabetes mellitus 
patients (OR 0.67 [95% CI 0.58-0.76]).  
Genetic variants involved in oxidative stress 
Five genetic variants in four genes thought to be related to oxidative stress were 
reproducibly associated with diabetic nephropathy. The 1/2 polymorphism of HP and 
rs1801282 of PPARG were not associated with diabetic nephropathy in the meta-
analysis. For PPARG, funnel plot asymmetry was observed (p=0.024) suggesting 
publication bias. The rs3138808 and the rs2070744 variants of NOS3 were associated 
with diabetic nephropathy in the meta-analysis (OR 1.31 [95% CI 1.02-1.67] and OR 
1.39 [95% CI 1.09-1.78] respectively). The 5L allele of CNDP1 was associated with 




Genetic variants in other pathways  
Rs17300539 of ADIPOQ, which is believed to mitigate vascular damage, was not 
associated with diabetic nephropathy in the meta-analysis. Rs841853 of GLUT1 (also 
known as SLC2A1), coding for a glucose transporter, did not show an association 
with diabetic nephropathy in eight studies (OR 1.10 [95% CI 0.89-1.35]). Rs1129456 
of GREM1, which is involved in cell growth and differentiation, was associated with 
diabetic nephropathy (OR 1.53 [95% CI 1.25-1.89]) in two studies (n=1799). Rs3767140 
of HSPG2, which is involved in maintenance of glomerular basement membrane 
electrostatic charge, was also associated with diabetic nephropathy in the meta-analysis 
(OR 0.72 [95% CI 0.59-0.87]), and additionally with diabetic nephropathy in Europeans 
with type 1 diabetes mellitus (OR 0.64 [95% CI 0.49-0.84]). Rs13293564 of UNC13B, 
thought to be involved in apoptosis, was associated with diabetic nephropathy in four 
studies (OR 1.23 [95% CI 1.11-1.35]). 
Genetic variants identified by genome-wide association studies 
Of the 14 genetic variants found to be reproducibly associated with diabetic nephropathy 
from genome-wide association studies (GWAS), ten remained associated in the meta-
analysis. Rs2268388 of ACACB, rs11993333 of PVT1, rs39075 near ‘CPVL and CHN2’, 
and rs6492208 (not near a gene) were not associated with diabetic nephropathy in the 
meta-analysis. Another variant near ‘CPVL and CHN2’, rs39059, was associated with 
diabetic nephropathy in two studies (n=1705) (OR 0.74 [95% CI 0.64-0.85]). Rs741301 
of ELMO1 was associated with diabetic nephropathy in Asians with type 2 diabetic 
nephropathy (OR 1.58 [95% CI 1.28-1.94]), but not in combination with a third study 
of European type 1 diabetes mellitus patients. Rs451041 and rs739401 of CARS were 
associated with diabetic nephropathy in the meta-analysis (OR 1.37 [95% CI 1.21-1.54] 
and OR 1.32 [95% CI 1.15-1.51] respectively). 
Rs1888747 and rs10868025 of FRMD3 were associated with diabetic nephropathy 
(OR 0.74 [95% CI 0.65-0.83] and OR 0.72 [95% CI 0.64-0.81] respectively). Another 
four variants, rs1041466, rs1411766, rs7989848 and rs9521445, which do not lie near 
a known gene, were associated with diabetic nephropathy in the meta-analysis (OR 
1.38 [95% CI 1.21-1.58], OR 1.36 [95% CI 1.20-1.54], OR 1.32 [95% CI 1.16-1.51] 
and OR 1.35 [95% CI 1.18-1.55] respectively). The variants in CARS, FRMD3, ‘CPVL 
and CHN2’ and the five variants not near genes were only investigated in European 




In this meta-analysis, 21 genetic variants were associated with advanced diabetic 
nephropathy and three additional variants were associated within specific subgroups. 
Meta-analysis of several individual genetic variants in relation to diabetic nephropathy 
has been performed previously, but this is the first complete overview assessing for 
all genetic variants that are reproducibly associated with the presence of diabetic 
nephropathy. This information could lead to improved insight into underlying 
pathogenetic mechanisms. Variants in or near ACE, AKR1B1 (two variants), APOC1, 
APOE, EPO, NOS3 (two variants), HSPG2, VEGFA, FRMD3 (two variants), CARS (two 
variants), ‘CPVL and CHN2’, UNC13B and GREM1, as well as four variants not near 
known genes, were associated with diabetic nephropathy. ELMO1, CCR5 and CNDP1 
were associated with diabetic nephropathy in a subgroup (‘Asian’s and ‘type 2 diabetes 
mellitus’ respectively). These results support a role for the following in the pathogenesis 
of diabetic nephropathy: renin–angiotensin system, polyol pathway, oxidative stress, 
inflammation, angiogenesis, glomerular filtration barrier defects, apoptosis, and cell 
growth and differentiation. Functional studies remain to be performed to establish the 
precise roles of these variants and pathways. Genetic variants initially identified using a 
genome-wide association approach in and near FRMD3, CARS, ELMO1 and ‘CPVL and 
CHN2’ were detected. The exact role of these genetic variants in relation to diabetic 
nephropathy requires further elucidation; many of these variants identified in GWAS 
will not prove to be causal. 
Our analysis has some limitations. Publication bias is a concern in all meta-analyses. 
For this study, only published data in journals were used, discarding data published 
in congresses only. Negative studies are less likely to be published, potentially leading 
to an overestimation of effects. Moreover, non-significant genetic associations might 
have been underreported in published articles. Therefore, the effect estimates of the 
present study should be interpreted with caution, especially in cases where associations 
were based on small numbers of studies and/or small sample numbers. For example, 
the rs833061 variant in the VEGFA gene shows the strongest protective effect, but 
was investigated in two studies of moderate size. In these cases, additional studies are 
necessary to establish true effect sizes. It should also be acknowledged that by selecting 
only genetic variants that were associated with diabetic nephropathy and for which 
independent replication was available, genetic variants with smaller effect sizes may 
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have been missed, an effect that may have proven significant using pooled analyses. By 
selecting only those genetic variants reproducibly associated with diabetic nephropathy, 
we have tried to reduce the chances of describing false positive associations.
The studies included in the present analysis showed heterogeneity with respect 
to ethnicity, study design and phenotypes. For some of the analysis, the clinical 
heterogeneity was accompanied by statistical heterogeneity with an I2 statistic of up to 
91%. However, there is no fully accepted statistical measure that precisely determines 
clinical heterogeneity (16). To account for potential heterogeneity, random effects 
models were performed by default. These models assume that different studies have 
different true effects. To explore potential heterogeneity due to differences in ethnicity, 
a meta-regression was performed.
A study worth mentioning, which appeared after our inclusion date, is a paper by 
Maeda et al. (17), in which the authors investigated the variants found in the genome-
wide association scan of the Genetics of Kidneys in Diabetes and Diabetes Control and 
Complications Trial studies (18) in four studies, of which three meet our criteria. We 
combined the data of Maeda et al. with results of the Genetics of Kidneys in Diabetes 
and Diabetes Control and Complications Trial studies. We found that only the rs451041 
of CARS, and rs1041466, rs9521455 and rs1411766, which are not near a gene, were 
associated with diabetic nephropathy. In contrast to the Genetics of Kidneys in Diabetes 
and Diabetes Control and Complications Trial studies, which investigated Europeans 
with type 1 diabetes, Maeda et al. investigated diabetic nephropathy in type 2 diabetes 
in an Asian population. Therefore, the lack of association with diabetic nephropathy of 
the other variants could be explained by this difference.
The identification of diabetic nephropathy susceptibility variants can lead to novel 
biological insights and improved measures of individual aetiological processes, as 
indicated previously (19). Individual aetiological processes (personalised medicine) could 
allow preventive and therapeutic interventions in complex disease to be tailored to 
individuals on the basis of their genetic profiles. From prediction studies with genetic 
variants for type 2 diabetes mellitus, it has been shown that 20 established genetic 
variants in type 2 diabetes mellitus have an AUC of 0.54 (0.5 means no predictive value, 
1.0 is perfect prediction), in contrast to the Framingham offspring and Cambridge risk 
scores (AUC of 0.78 and 0.72, respectively). Interestingly, addition of genetic information 
to phenotype-based risk models did not improve prediction (20). It is also possible that 
for diabetic nephropathy the genotypic risk does not exceed the risk contributed by 
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conventional risk factors (e.g. BMI, age, diabetes mellitus duration), which means that 
the predictive value of risk variants for diabetic nephropathy would be limited (21). 
Although genetic prediction and use of personalised medicine in diabetic nephropathy 
remains a new undertaking, prediction is likely to improve as additional disease variants 
are detected and replicated (22). 
Novel biological insights may lead to development of new therapeutic targets, 
biomarkers and opportunities for disease prevention. Hypothesis-free approaches, 
such as GWAS, are most promising in this respect. At present, it seems wise to focus 
on assessing the relevance of previously detected genetic variants. As common SNPs 
associated with diabetic nephropathy and detected by GWAS may represent rare genetic 
variants with large effects, sequencing the regions surrounding highly significant and 
replicated genomic regions to detect rare variants appears to be reasonable. Follow-up 
in vitro and in vivo studies could then assess the functional relevance of these variants 
in diabetic nephropathy. In summary, our meta-analysis identified 24 genetic variants 
(in or near 16 different genes) associated with advanced diabetic nephropathy. These 
genetic variants are likely to represent true associations and further investigations to 
elucidate their functional relationship in diabetic nephropathy should be pursued.
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We investigated the frequency of the 5/5 homozygous CNDP1 (carnosinase) genotype, 
which was found to be associated with a reduced risk of developing diabetic nephropathy, 
in three ethnic groups in the Netherlands. Particularly interesting were the South Asian 
Surinamese, who have a high prevalence of diabetic nephropathy. Furthermore, we 
investigated the association between this gene and carnosinase activity in South Asian 
Surinamese and whether carnosinase was expressed in the kidney. 
We genotyped 290 South Asian Surinamese, 532 African Surinamese, and 472 
white Dutch in a cross-sectional population study. Furthermore, an independent cohort 
of South Asian Surinamese was genotyped. In this population, carnosinase activity 
was measured in serum. Immunostaining and in-situ hybridization for CNDP1 were 
performed on kidney tissue.
Both South Asian populations had lower frequencies of the 5/5 homozygous 
genotype than African Surinamese and white Dutch (23.0%, 27.2%, 38.2%, and 
41.3%, respectively; chi-square, p<0.001). This genotype showed a lower carnosinase 
activity in South Asian Surinamese (Wilcoxon rank-sum, p=0.03). CNDP1 was expressed 
in the kidney. 
South Asian Surinamese have a lower frequency of the 5/5 homozygous genotype, 
which was associated with lower carnosinase activity. Our study provides an indication 




Diabetic nephropathy (DN) is the leading cause of end stage renal disease. Data from 
the UK prospective Diabetes Study group demonstrated that approximately 25% of 
patients with type 2 diabetes develop microalbuminuria or progressive DN within 10 
years [1]. 
Several studies show a higher incidence of DN in certain families and races [2-4]. For 
example, the South Asian Surinamese, an ethnic minority who migrated from Suriname 
to the Netherlands but originally descended from India and Bangladesh, show an 
8-times higher frequency of diabetes type 2 and a 3-fold higher risk of developing 
DN, a 40-fold higher risk of developing end-stage DN due to type 2 diabetes and a 
1.5-fold faster disease progression than white Dutch [5,6]. The question arises whether 
these differences may in part be due to increased susceptibility because of a genetic 
predisposition. 
As DN is a multi-genetic disease several susceptibility loci and candidate genes 
have been found (reviewed in [7]). One of the susceptibility loci for DN was identified 
by Vardarli et al. [4], who evaluated 18 Turkish families with type 2 diabetes and 
nephropathy in a family-based linkage study. A major susceptibility locus was found 
(LOD score 6.1) on chromosome 18q22.3-q23 for DN. This finding was confirmed by 
sib pair analysis on African Americans [8] and Pima Indians [4]. In a search for candidate 
genes within the quantitative trait locus (QTL) on chromosome 18q, Janssen et al. 
detected significant evidence for association between DN and CNDP1, which encodes 
for carnosine dipeptidase (also called serum carnosinase), in patients from Germany, the 
Netherlands, Qatar, and the Czech Republic [9]. Freedman et al. confirmed this finding 
in European Americans [10], but found a different polymorphism of the CNDP1 gene in 
African Americans [11]. Interestingly, the association between DN and CNDP1 could not 
be confirmed in patients with DN due to diabetes type 1 [12].Diabetes type 2 patients, 
who are homozygous for 5 copies of a trinucleotide repeat encoding for leucine in the 
leader peptide on exon 2, demonstrated a 2.56-fold reduced risk for DN compared 
to individuals with more leucine repeats (6-8 repeats) [9]. The presence of more than 
5 leucine repeats has been shown to lead to higher serum carnosinase secretion [13] 
and higher carnosinase activity [9]. Serum carnosinase, a dipeptidase belonging to the 
M20-metalloprotease family, is the rate-limiting enzyme for hydrolysis of carnosine into 
beta-alanine and L-histidine. Carnosine is a reactive oxygen scavenger [14], exhibits 
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anti-AGE (advanced glycation end products) effects [15], a natural ACE (angiotensin 
converting enzyme) inhibitor [16] and reduces the synthesis of matrix components and 
TGF-β (transforming growth factor) in renal cell lines [9]. 
Our hypothesis is that the frequency of the leucine repeat in the CNDP1 polymorphism 
differs with ethnic background and that South Asian Surinamese have an aberrant 
genotypic distribution of CNDP1, which could partly account for the reported higher risk 
for DN after the development of type 2 diabetes. Therefore, the primary objective was 
to investigate the frequency of the protective genotype, the 5/5 homozygous genotype, 
in South Asian Surinamese, African Surinamese (immigrants from Suriname who 
originally descended from Africa), and white Dutch in the Netherlands. The correlation 
between high carnosinase activity and more leucine repeats in the CNDP1 gene has 
been found in whites, and the secondary objective of this study was to investigate 
whether the carnosinase activity was also correlated with the CNDP1 genotype in South 
Asian Surinamese. Furthermore, to investigate the potential involvement in diabetic 
nephropathy we also determined whether carnosinase was expressed in the kidney. 
Subjects, Materials and Methods
For this study, we analysed data from SUNSET (SUrinamese in the Netherlands: Study 
on Ethnicity and health) [17] and Hindinef (Hindustani Diabetic Nephropathy Study) 
[5]. Both studies have been approved by the institutional medical ethics committee in 
accordance with the Declaration of Helsinki.
SUNSET - SUNSET is a population-based, cross-sectional survey designed to obtain 
insight into the cardiovascular risk profile of three ethnic groups: South Asian 
Surinamese (‘Hindustani’, of South Asian origin), African Surinamese (‘Creole’ of 
African origin) and white Dutch [17,18]. Details of the recruitment, data collection 
and definitions of ethnicity are described elsewhere [19]. In brief, between 2001 and 
2003 a random sample of non-institutionalised adults aged 35-60 years was selected 
from the Municipal Register of Amsterdam, the Netherlands. After informed consent, 
participants underwent an interview, followed by a physical examination, including 
donation of a fasting blood sample [19]. Ethnicity was subsequently determined based 
on self-identification.
Subjects who, did not participate in the interview and physical examination, who 
could not unequivocally be assigned to one of the three ethnic groups or who could not 
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be genotyped were excluded from the present study, leaving a total of 1294 persons 
for our present analysis. The 1294 that were genotyped consisted of 290 South Asian 
Surinamese, 532 African Surinamese and 472 white Dutch. 
Hindinef - The Hindinef study is conducted in the Netherlands in the city of The Hague. 
The study was initially set up to investigate whether familial clustering of DN occurred 
in the South Asian Surinamese population. No evidence for familial aggregation of DN 
was found, and more South Asian Surinamese were collected but not yet described in 
this cohort. 
The basic characteristics of the total cohort will be described in the results. The 
recruitment of the Hindinef study group were previously published [18]. 
Genotyping
DNA material from both SUNSET and Hindinef was genotyped as follows. A standard 
PCR protocol was used with primers 5-FAM-GCGGGGAGGGTGAGGAGAAC (forward) 
and GGTAACAGACCTTCTTGAGGAATTTGG (reverse). The denaturing, annealing and 
extension temperatures were 94°C, 60°C and 72°C, respectively. Fragment analysis was 
performed on the ABI3130 analyser (Perkin Elmer) to determine the fragment length 
corresponding with the different genotypes. Each peak corresponded with the number 
of leucine repeats on each allele. A 157 base pair product corresponded with 5 CTG 
codons encoding for 5 leucine repeats, and a product of 160 base pairs corresponds to 
6 CTG codons encoding 6 leucine repeats. Homozygotes demonstrated a single peak, 
and homozygosity for the 5 leucine repeats in exon 2 is referred to as the protective 
genotype, 5/5 homozygous genotype. Samples with six or more leucine repeats were 
referred to as not having 5/5 homozygous genotype.
Determination of serum-carnosinase activity
Serum samples were obtained from a random group of 391 South Asian Surinamese of 
the Hindinef cohort. Serum-carnosinase activity was determined according to the method 
described by Teufel et al. [20]. Briefly, the reaction was initiated by addition of substrate 
(L-carnosine) to a serum sample and stopped after 10 minutes of incubation at 37°C 
by adding 1% sulphate salicylic acid. The maximum increase was used for determining 
the maximum activity. Liberated histidine was derivatized with o-phtaldialdehyde (OPA). 
Fluorescence was measured by excitation at 360 nm and emission at 460 nm. 
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The intra- and interassay variations were respectively 6% and 16%. The lowest 
carnosinase activity detectable was 0.117 μmol/ml/h.
CNDP1 expression in the kidney 
Cadaveric donor kidneys were obtained from Eurotransplant. These kidneys 
were unsuitable for transplantation for technical or morphological reasons. For 
immunohistochemistry, paraffin slides were used. In brief, the slides were washed in 
PBS and incubated for 2 h at room temperature with the primary antibody (rabbit anti-
CNDP1, generated as described by Teufel et al[20], diluted in 1% bovine serum albumin 
in PBS). After washing with PBS, the slides were incubated for 30 min with horseradish 
peroxidase–conjugated anti-rabbit Envision (DAKO, Glostrup, Denmark). The slides were 
again washed with PBS, and the staining was developed with diaminobenzidine. The 
RNA in situ hybridization was performed as previously described [21]. In brief, paraffin 
sections were pre-treated and hybridized with digoxigenin (DIG) labelled RNA probes 
for 16 hours. RNA hybrids were detected using mouse anti-DIG (Sigma-Aldrich Chemie, 
Steinham, Germany), rabbit anti-mouse Ig (1:50, Dako, Glostrup, Denmark), and mouse 
alkaline phosphatase anti-alkaline phosphatase (APAAP, Dako). 
Glomeruli were isolated as described earlier [22]. Whole kidney and glomerular RNA 
was isolated using Trizol®, converted to cDNA using AMV reverse transcriptase (Roche 
Applied Science). Real-time polymerase chain reaction [23] was used in combination 
with the following CNDP1 primerset: forward: TTCAATCCGTCTAGTCCCTCACATG, 
reverse: TGCAATCCACGGGTGTAGTCC. Melting curve and sequence analysis were 
performed to confirm that we amplified the appropriate product.
Statistical Analysis
First, the characteristics of the SUNSET population and the frequency of 5/5 homozygous 
genotype and not having 5/5 homozygous genotype in both SUNSET and Hindinef 
were described per ethnic group. The difference in frequency of the 5/5 homozygous 
genotype between ethnic groups were assessed by means of the chi-squared test.
When the genotypes were divided in three groups with increasing number of 
leucine repeats, the statistical significance between the groups in carnosinase activity 
was determined by the Kruskal-Wallis test. The Wilcoxon sum-rank test was used to 
compare the carnosinase activity between the lowest number of leucine repeat group 
and the highest number of leucine repeat group and to compare the 5/5 homozygous 
genotype with the other genotypes.  
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A linear regression model was used to adjust for age and sex. The statistical analyses 
were all performed using SPSS 16.0 and Graphpad prism. A p-value < 0.05 was 
considered to be statistically significant.
results
Characteristics of the SUNSET population and Hindinef population 
The characteristics of the study populations are presented in Table 1. The white Dutch 
were slightly older than the South Asian Surinamese and African Surinamese and had 
the highest proportion of smokers. The African Surinamese had the highest proportion 
of female participants, as well as the highest median BMI (27.7 IQR 24.5-31.5) and a 
high frequency of high blood pressure (28.3%) compared to the other ethnic groups. 
South Asian Surinamese had the highest frequency of diabetes (26.2%) and highest 
waist-hip ratio (0.96 IQR 0.90-1.00) compared to African Surinamese and white Dutch.
South Asian Surinamese of the Sunset and Hindinef study have a similar age and 
percentage male, BMI and waist-hip ratio, prevalence of diabetes and high blood 
pressure. Only in the Hindinef study group there were slightly less smokers.   








SUNSET Hindinef    
N=290 N = 456 N= 532 N= 472
Age (years) 44 (39-50) 42 (35-50) 43 (39-48) 48 (42-54)
Sex (male) 130 (44.8%) 196 (42.8%) 170 (32.0%) 233 (49.4%)
Smoking (current) 103 (35.9%) 103 (27%) 214 (40.9%) 212 (45.0%)
BMI (kg/m2) 26.6 (23.9-29.3) 26.2 (23.5-29.4) 27.7 (24.5-31.5) 25.5 (23.0-28.4)
Waist-hip ratio 0.96 (0.90-1.00) 0.94 (0.88-1.0) 0.90 (0.84-0.95) 0.90 (0.83-0.96)
High blood pressure (yes) 91 (31.5%) 133 (29.0%) 150 (28.3%) 83 (17.6%)
Diabetes Mellitus (yes) 76 (26.2%) 118 (25.8%) 68 (12.8%) 33 (7.0%)
N (%) or median (IQR)
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Analysis of CNDP1 genotype frequency in South Asian Surinamese, African Surinamese 
and white Dutch 
The CNDP1 genotype distribution is demonstrated for each ethnic group in Table 2. The 
various genotypes were ranked according to the corresponding enzyme activities (Figure 
2). The different genotypes are determined by fragment analysis. An example of a 5/5 
homozygous genotype (A), a homozygous 6/6 genotype (B), a 5/6 heterozygous (C) and 
a 6/7 heterozygous (D) are seen in Figure 1. The frequency of 5/5 homozygous genotype 
in South Asian Surinamese (27.2%) was significantly lower than the frequency among 
African Surinamese (38.2%) and white Dutch (41.3%) in the SUNSET population (p < 
0.001, Table 1). No differences were observed in the frequency between men and women 
(data not shown). The frequency of 5/5 homozygous genotype among the South Asian 
Surinamese with familial susceptibility for diabetes, the Hindinef population, was 23.0 
% (105/456), which was similar to the frequency among the South Asian Surinamese in 
SUNSET, and significantly lower than the frequency among the African Surinamese and 
White Dutch in SUNSET (Table 2). 
Figure 1. Measurement of the leucine repeat in exon 2 of the CNDP1 gene
A = a fragment of 157 basepairs which corresponds to 5 leucine repeats in each allele (5/5 homozygous 
genotype), B = a fragment of 160 basepairs which corresponds to 6 leucine repeats in each allele, C = a 
fragment of 157 and 160 corresponding with 5 leucine repeats in one allele and 6 leucine repeats in the 
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Table 2. Distribution of CNDP1 leucine repeats of South Asian Surinamese, African Surinamese 







(SUNSET) (Hindinef)    
n=290 % n = 456 % n= 532 % n= 472 %
4/4, 4/5, 4/6 3 1 0 0 18 3.4 2 0.4
5/5 79 27.2* 105 23.0* 203 38.2 195 41.3
5/6, 5/7 117 40.3 204 44.7 239 44.9 222 47
6/6, 6/7 91 31.4 147 32.2 71 13.3 51 10.8
7/7 0 0 0 0 1 0.2 2 0.4
* p < 0.001 chi-squared, comparing South Asian Surinamese with white Dutch and African Surinamese
Determination of serum carnosinase activity
The carnosinase activity was measured in 391 South Asian Surinamese of the Hindinef 
study. The genotypes were divided into three groups, the 5/5 homozygous genotype, 
the 5/6 and 5/7 heterozygous genotype, the 6/6 and 6/7 genotype. A clear correlation 
was found between carnosinase enzyme levels and the number of leucine repeats in 
the CNDP1 gene (Figure 2). The carnosinase activity was significantly different between 
the three leucine repeat groups (p = 0.03). The 5/5 genotype differed significantly from 
the other genotypes (p = 0.03). The highest difference was found between the 6/6, 6/7 
leucine repeat group and the 5/5 homozygous genotype (p = 0.009). The carnosinase 
activity did not seem to significantly differ with age and sex. When adjusted for age 
and sex in a linear regression model the association remained significant (p = 0.04). The 
apparent difference of significances is not due to age and sex variation but is a result of 
the different statistical tests. 
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Figure 2. Mean serum-carnosinase activity in South Asian Surinamese categorised by amount of leucine 
repeats in both alleles.
Mean serum carnosinase activity with standard error of the mean divided in 3 genotype groups. ‘5-5’ consists 
of 5-5 homozygous genotype, ‘5-6/5-7’ consists of the genotype with 5 leucine repeats in one allele and 6 or 
7 in the other allele, ‘6-6/6/7’ consists of 6 leucine repeats in one allele and 6 or 7 in the other allele. 
* < 0.05, ** < 0.01
CNDP1 expression in human kidney
Immunohistochemical staining and mRNA expression by in situ hybridization were 
performed on kidney tissue (Figure 3). Both protein and mRNA for CNDP1 is expressed in 
glomerular cells and tubular epithelial cells. Real time PCR showed a specific expression 
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Figure 3. CNDP1 expression in human kidney
Immunohistochemical staining (A) and mRNA expression by in situ hybridization (B) of CNDP1 in normal 
kidney. Both protein and mRNA for CNDP1 is expressed in glomerular cells and tubular epithelial cells. Real 
time PCR showed expression of CNDP1 in both whole kidney (red lines) and isolated glomerular (blue lines) 
mRNA (C). Melting curve analysis showed specific amplification of CNDP1 (D).
discussion 
This study reports the CNDP1 polymorphism distribution in three ethnic groups in the 
Netherlands. Our study provides the first data on the frequency of 5/5 homozygous 
genotype among a population of South Asian origin. We found that the frequency 
of the protective genotype, the 5/5 homozygous genotype, was significantly lower in 
South Asian Surinamese compared to white Dutch and African Surinamese. The low 
frequency among South Asian Surinamese was confirmed in an independent South 
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Asian Surinamese cohort. Furthermore, we showed that, similar to Europeans, the 
carnosinase activity increases with the amount of leucine repeats among South Asian 
Surinamese and carnosinase was expressed in the kidney. This suggests a possible role 
in the development of DN in this population.
The white Dutch in our study show a frequency of the 5/5 homozygous genotype 
similar to that of healthy European control groups in previously published studies 
(41.3% in this study versus 36.8% in the study by Janssen et al. [9] and 38.6% in 
Freedman et al. [10].) 
In African Americans, no association between reduced risk of DN and 5/5 
homozygous genotype was found [10]. The frequency of 5/5 homozygous genotype 
among African Surinamese is similar to that of African Americans (38.2% and 35.9%, 
respectively). Other polymorphisms in the CNDP1 gene have been found to play a role 
in the development of DN in African Americans [11]. These other polymorphisms in the 
CNDP1 might play a role in African Surinamese as well, but were not included in this 
study.
The low frequency of the 5/5 homozygous genotype found in South Asian 
Surinamese observed in our study may be associated with the higher occurrence of DN 
in South Asian populations. 
Janssen et al. found an association between the leucine repeat in the CNDP1 gene 
and DN, and this finding was confirmed in a large study conducted by Freedman et al. 
in European American patients with DN and end-stage DN [9,10].
Functional studies provide evidence for the mechanism behind the association 
between 5/5 homozygous genotype and DN. The absence of 5/5 homozygous genotype 
has shown to lead to higher carnosinase levels and activity, thereby decreasing levels 
of carnosine [13]. Carnosine levels in blood are very low and vary during the day 
and therefore cannot be reliably ascertained (unpublished results). In our study we 
confirmed this increase in serum carnosinase activity with increasing number of leucine 
repeats in South Asian Surinamese. Carnosine has been shown to delay senescence in 
cultured human fibroblasts and temporarily reverse the senescence phenotype [24,25]. 
Moreover, several studies have demonstrated a likely anti-aging effect in vivo [26-28], 
which may also be related to the mechanism underlying vascular damage observed 
in DN. In that respect, in vitro supplementation of blood and plasma with carnosine 
has been shown to have an anti-oxidant effect is a promising finding [14]. If further 
developed, the implications of this discovery are potentially large, suggesting that 
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carnosine supplementation might be a possible therapeutic modality in the future for 
South Asian Surinamese subjects.
Before reaching a final conclusion, limitations deserve to be discussed. Selective 
recruitment or participation could have affected the reported frequency. The Hindinef 
population was originally selected for detecting familial clustering of DN. However, 
the frequency of 5/5 homozygous genotype was similar to the frequency in the South 
Asian population in SUNSET. We are therefore confident that our conclusion that the 
frequency of the 5/5 homozygous genotype is lower in South Asian Surinamese than in 
other ethnic groups living in the Netherlands is justified. 
This is a population-based study and therefore provides no direct relation between 
diabetic nephropathy and the CNDP1 gene in South Asian Surinamese but an indirect 
relation. Still, other investigators have found a clear relation between the CNDP1 
gene and diabetic nephropathy in Europeans [9] and European Americans [10]. South 
Asian Surinamese have found to have a significantly higher risk of diabetes type II and 
diabetic nephropathy [5,18]. The results of this study strongly suggest that the CNDP1 
polymorphism, given its distribution across ethnic groups, contribute to the higher risk 
of nephropathy in South Asian Surinamese.
Furthermore, DN is a multi-genetic disease and therefore it does seem unlikely 
that this gene is the only reason for the higher risk of developing DN of South Asian 
Surinamese. However, it might be one of the genes involved in the pathogenesis of DN 
in this ethnic minority in the Netherlands. 
On the other hand, a powerful feature of this paper is that it presents data from a 
population-based survey among three ethnic groups in the same city. Selection due to 
clinic location and setting therefore did not occur. Another strong feature is that the 
findings from the SUNSET study could be confirmed in a second, independent study 
that was carried out in a different location (Hindinef). The similarity of the findings in 
both studies increase the power of the conclusions drawn concerning the frequency of 
the 5/5 homozygous genotype among the South Asian Surinamese. 
In conclusion, South Asian Surinamese living in the Netherlands have a lower 
frequency of the protective genotype, 5/5 homozygous genotype, associated with a 
lower carnosinase activity. This polymorphism has proven to be protective for DN in 




The specific role of 5/5 homozygous genotype in the occurrence of DN among South 
Asian origin populations remains to be further investigated, as carnosines or carnosine 
enhancers have the potential to become a therapeutic modality with great clinical 
relevance.
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Objective, The 5-5 homozygous CNDP1 (carnosinase) genotype is associated with a 
reduced risk for diabetic nephropathy (DN). We investigated whether this association is 
sex-specific and independent of susceptibility for type 2 diabetes.
Research Design and Methods, Three separate groups of 114, 90, and 66 patients 
with type 2 diabetes and DN were included in this study, and compared with 93 
patients with type 2 diabetes for >15 years without DN, and 472 population controls. 
The diabetes control group was used to determine an association in the three patient 
groups separately, and the population control to estimate the genotype risk (odds ratio 
[confidence interval]) for the population in a pooled analysis. The population controls 
were also compared with 562 patients with type 2 diabetes without DN to determine 
whether the association was independent of type 2 diabetes. The CNDP1 genotype was 
determined by fragment analysis after PCR amplification. 
Results, The frequency of the 5-5 homozygous genotype was 28%, 36%, 41% in the 
three DN patient groups, and 43% and 42% in the diabetic and population controls, 
respectively. The 5-5 homozygous genotype occurred significantly less frequently in 
women in all three patient groups compared with diabetic controls. The genotype risk 
for the population was estimated to be 0.5 [0.30–0.68] in women and 1.2 [0.77–1.69] 
in men. The 562 patients with type 2 diabetes without DN did not differ from the 
general population (P=0.23).
Conclusion, This study shows that the association between the CNDP1 gene and diabetic 




Only 20– 40% of patients with type 1 or type 2 diabetes will develop diabetic 
nephropathy (DN), and if no signs of DN are present in the first 15 years after diagnosis 
of diabetes, the chance of ever developing DN is small (1). Furthermore, sibling studies 
show a strong familial component for development of DN (2;3), and certain ethnic 
groups seem to be at a greater risk of developing DN (2;4). These findings suggest that 
there is a genetic susceptibility component for DN.
Many genes are thought to be involved in DN (reviewed in (5)). One of the genes 
associated with DN in both patients with type 1 and type 2 diabetes is the CNDP1 gene, 
which encodes serum carnosinase (6). This was confirmed in European Americans with 
end stage DN due to type 2 diabetes (7), but the association between DN and the 
CNDP1 gene could not be confirmed in patients with DN due to type 1 diabetes (8;9) 
nor in African Americans (7). 
Patients with type 2 diabetes of Caucasian origin with homozygosity for 5 leucine 
repeats in exon 2 demonstrated a reduced susceptibility for developing DN compared 
with individuals with 6–8 repeats (6;7;10). With increasing numbers of leucine repeats, 
the secretion of serum carnosinase has been shown to increase (11) and to lead to higher 
serum carnosinase activity (4;6). Serum carnosinase degrades carnosines and other 
histidine-containing dipeptides. Carnosines and related dipeptides are known for their 
reactive oxygen scavenging effects (12), to degrade advanced glycation end products 
(13), and reduce the TGF-β-induced synthesis of extracellular matrix components (6). 
Some genes involved in DN have been shown to have sex-specific effects (14;15). 
For example, the RANTES receptor gene (CCR5) is only associated with DN in men (14), 
and two single nucleotide polymorphisms in the podocyte slit diaphragm gene (ACTN4) 
were only associated with DN in women (15). 
Therefore, we investigated whether the association between the CNDP1 gene 
and DN due to type 2 diabetes is sex-specific. Furthermore, we studied whether the 
association between DN and the CNDP1 gene is independent of the susceptibility for 
type 2 diabetes itself. 
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Study Design and Methods
The institutional Medical Ethics committees of the participating hospitals approved of 
the studies described below.
CASE GROUPS
For the first case group, female and male Caucasian diabetic patients with DN from 
the case-control study of Janssen et al. were re-assessed separately. DN was defined 
as diabetes with retinopathy with either macroalbuminuria or who were on dialysis 
(because of DN). The details of the recruitment of this cohort are described elsewhere 
(6). In the present analysis, only 114 DN patients with type 2 diabetes were included, 
and this group will be referred to as DN group 1.
For the second case group, DN patients were selected from the ZODIAC (Zwolle 
Outpatient Diabetes Project Integrating Available Care) study (16). DN was defined 
as having either an eGFR < 60 mL/min/1.73 m2 (17) in combination with an albumin 
excretion above 30 mg/L (18), or macroalbuminuria (above 300 mg/L) in combination 
with retinopathy (19). ZODIAC was a cross-sectional, single-centre study, investigating 
only patients with type 2 diabetes, selected from a population of > 95% Caucasian 
origin. Patients were recruited from 61 general practitioners from 1998–2000. In this 
study, 90 DN patients were identified and these will be referred to as DN grou
For the third group, DN patients were selected out of a total of 875 patients from 
the NECOSAD (Netherlands Cooperative Study on the Adequacy of Dialysis) study (20). 
NECOSAD is a multicenter, prospective follow-up study of patients with ESRD who were 
included at the start of dialysis, between 1997 and 2005. For the present analysis, only 
patients with type 2 diabetes of Caucasian origin and ESRD due to DN were selected; 
66 DN patients were included and are referred to as DN group 3. 
CONTROL GROUPS
The first control group is a diabetic group, consisting of Caucasian patients with type 2 
diabetes without microalbuminuria for at least 15 years, in the absence of ACE inhibitor 
treatment (6;16). This control group is referred to as diabetic non-nephropathy controls.
The second control group is a population control group selected from the SUNSET 
(Surinamese in the Netherlands, study for ethnicity and health) study, a population-
based, cross-sectional survey (21). In brief, between 2001 and 2003, a random sample 
of non-institutionalized adults aged 35–60 years was selected. In the present study, only 
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the 472 white Dutch participants, of whom the genotypic distribution was described in 
a previous report (4), are used and referred to as population controls.
To investigate whether the association between DN and the CNDP1 gene is not due 
to susceptibility for type 2 diabetes, we additionally studied 562 patients with type 2 
diabetes without DN (defined as any of the criteria above) selected from the ZODIAC 
study participants, referred to as the type 2 diabetes population, to compare with the 
general population.  
GENOTYPING
Genotyping was performed as described previously (4). In brief, after PCR amplification, 
fragment analysis was performed on the ABI-3130 analyzer to determine the number 
of leucine repeats in each allele. The success rate was, on average, 95% and no errors 
were detected. Genotyping was performed partially in Leiden and in Mannheim. Some 
of the samples were measured in both institutes and there was a 100% concordance.
STATISTICAL ANALYSIS
The baseline characteristics of the groups are presented as means and standard 
deviations or percentages. Continuous variables were tested using the student t-test 
and numeric variables using chi-square. All groups were tested for Hardy-Weinberg 
equilibrium (HWE), using a chi-square test.
First, the frequency of the 5-5 homozygous genotype in the respective DN groups 
was compared with the 93 diabetic non-nephropathy controls stratified by sex, to 
investigate the relevance of the genotype to disease etiology.
Second, the genotype risk for the population was estimated through comparison 
of the DN groups with population controls. Odds ratios with confidence intervals were 
calculated. A pooled analysis was performed to determine the total effect for females 
and males separately, combining the three case groups when compared with sex-
matched population controls. The fixed-effects model (inverse variance method) was 
used when heterogeneity was P > 0.1 (chi square) and the random-effects model when 
heterogeneity was P < 0.1.
Finally, to assess whether the susceptibility for DN is independent of susceptibility for 
type 2 diabetes, we compared the type 2 diabetes population with population controls.




The baseline characteristics of the three DN groups are described in Table 1 and 
comparisons are made with diabetic non-nephropathy controls. Baseline characteristics 
did not differ between diabetic non-nephropathy controls and the type 2 diabetes 
population, except for diabetes duration (data not shown). There was no significant 
difference in 5-5 homozygous genotype frequency between the diabetic non-
nephropathy controls and the population controls consisting of either all patients 
(P = 0.8), all women (P = 0.07), or all men (P = 0.13).
All cohorts were in HWE (online appendix). 
Table 1. Baseline characteristics
Diabetic nephropathy groups T2D* > 15 years without 
diabetic nephropathy1 2 3
Total n = 114 n = 90 n = 66 n = 93
Age (years) 64.0 ± 11.07 73.4 ± 8.40†‡ 66.2 ± 8.97 65.8 ± 11.30
Sex (n (%) male) 64 (56.1) 30 (33.3) †‡ 35 (53.0) 47 (50.5)
Diabetes duration (years) 14.3 ± 8.38† 9.7 ± 9.51†‡ 15.2 ± 10.99† 22.2 ± 6.78
HbA1c (%) 7.5 ± 1.71 7.5 ± 1.2 - 7.3 ± 1.51
Women
Age (years) 64.2 ± 11.64 72.2 ± 9.09†‡ 67.2 ± 7.57 65.1 ± 12.07
Diabetes duration (years) 14.8 ± 9.24* 9.2 ± 7.77†‡ 15.9 ± 11.83† 22.9 ± 6.50
HbA1c (%) 8.0 ± 2.08 7.4 ± 1.12 - 7.5 ± 1.65
Men
Age (years) 63.7 ± 10.68 75.9 ± 6.22†‡ 65.3 ± 10.07 66.4 ± 10.60
Diabetes duration (years) 13.9 ± 7.81† 10.7 ± 12.4† 14.7 ± 10.39† 21.6 ± 7.05
HbA1c (%) 7.2 ± 1.32 7.6 ± 1.38 - 7.6 ± 1.38
*T2D = type 2 diabetes, † P < 0.05 compared to T2D > 15 years without diabetic nephropathy, ‡ P < 0.05 
compared to either DN group 1 or 3. No significant differences were seen between group 1 and 3 or between 
women and men in each of the DN groups
Relevance of the 5-5 homozygous genotype to disease etiology
Overall, the 5-5 homozygous genotype frequency of the DN groups did not differ from 
the diabetic non-nephropathy controls or between the DN groups (P = 0.2). Women 
in all three DN groups had a significantly lower frequency of the 5-5 homozygous 
genotype compared with female diabetic non-nephropathy controls (Table 2), also after 
Bonferroni adjustment for multiple testing. In contrast, men in all three DN case groups 




Table 2. The relation between 5-5 homozygous genotype and DN
Diabetic nephropathy groups T2D*>15 years without 
DN1 2 3
Total n = 114 n = 90 n = 66 n = 93
Frequency 5-5 (%) 28.1 35.6 40.9 43.0
P † 0.03 0.30 0.80
Women n = 50 n = 60 n = 31 n = 46
Frequency 5-5 (%) 24.0 28.3 25.8 58.7
P † 0.001 0.002 0.006
Men n = 64 n = 30 n = 35 n = 47
Frequency 5-5 (%) 31.2 50.0 53.4 27.7
P † 0.62 0.05 0.02
*T2D = type 2 diabetes, † P < 0.05 compared to T2D > 15 years without diabetic nephropathy
Genotype risk for the population  
No heterogeneity was detected in women (P = 0.64), but heterogeneity was detected 
in men (P = 0.09). The three DN groups were pooled for women and men separately, 
resulting in a genotype risk of 0.5 [0.30–0.68] in women and 1.2 [0.77–1.69] in men 
(Figure 1).
Figure 1. The relationship between the 5-5 homozygous CNDP1 genotype and diabetic nephropathy in 
women (upper panel) and men (lower panel) in the three independent diabetic nephropathy groups, and a 









































































Specificity of 5-5 homozygous genotype for DN, not type 2 diabetes 
The 5-5 homozygous genotype frequency of both the 562 type 2 diabetes population 
and the 472 population controls are shown in Table 3, showing similar frequency of the 
5-5 homozygous genotype. 
Table 3. Comparison between type 2 diabetes population and population controls
Type 2 diabetes population Population controls
Total n = 562 n = 472 P
Frequency 5-5 (%) 38.1 41.7 0.23
Women n = 319 n = 239
Frequency 5-5 (%) 39.5 43.9 0.23
Men n = 243 n =233
Frequency 5-5 (%) 36.7 39.5 0.58
discussion
Our results show a sex-specific effect of the CNDP1 genotype in relation to DN, suggesting 
that the 5-5 homozygous genotype is only protective in women. The frequency of the 
5-5 homozygous genotype was determined in three independent DN groups. These 
groups were compared with two control groups; patients with type 2 diabetes and a low 
risk of ever developing DN and a sample from the general population. Compared with 
the diabetic control group, the 5-5 homozygous genotype frequency was significantly 
lower in women with DN in all three cohorts, but not in men. The population control 
group serves to estimate the genotype risk for the population, showing that women 
with the 5-5 homozygous genotype have a 2-fold reduced risk of ever developing DN. 
Furthermore, this study shows similar frequencies of the 5-5 homozygous genotype in 
a large type 2 diabetes population and the general population, underlining that the 
association with DN is independent of a genetic susceptibility for type 2 diabetes. 
The 5-5 homozygous genotype leads to lower carnosinase activity compared with the 
other genotypes (4;6), leaving more carnosine free to protect the kidney from oxidative 
stress. Since men have higher carnosine levels in their muscle tissue and women have 
slightly higher serum carnosinase levels (22), differences in carnosinase activity due to 
the different CNDP1 polymorphisms may have a stronger impact in women. Carnosine 
content in the muscles of female mice was shown to increase after testosterone 
administration, the increase was 268% (23). This might be because carnosine synthetase, 
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the enzyme that synthesizes carnosine, is upregulated by testosterone. It is possible that 
this phenomenon plays a role in DN, because both carnosine synthetase (preliminary 
results) and androgen receptors are expressed in human kidney (24). 
Another explanation for the sex-specific effect found in this study is that the 
association between the CNDP1 gene and DN is lost in men due to selective survival by 
cardiovascular disease. As carnosine has shown to be protective against oxidative stress 
and hemodynamic damage (6;12;13), this might also explain its role in cardiovascular 
death in DN patients. Men with DN due to type 2 diabetes have a higher risk for 
cardiovascular disease than women (25). Therefore this might be more prominent 
in men. Further support for this theory comes from the ZODIAC study. Men with a 
diabetes duration < 10 years and the 5-5 homozygous genotype have a significantly 
lower mortality risk due to cardiovascular disease than patients with more than 10 
leucine repeats in the CNDP1 genotype (data not shown). We found no difference in 
cardiovascular death between the different genotypes in women.
The relatively older age of DN group 2 might influence the number of subjects 
with an eGFR < 60 ml/min/1.73m2. Therefore, a sensitivity analysis was performed, 
adopting increasingly stringent definitions of DN. The results of this analysis support the 
conclusion that the 5-5 homozygous genotype is protective in women (online appendix). 
The statistical power to detect a similar association as was seen in women in men 
ranged from 97- 100% within the three DN groups. Insufficient statistical power 
therefore does not explain the sex-specific effect found in this study.
Limitations of this study are that ethnic origin is not defined by ethnic markers in 
these Caucasian populations and that sample sizes are relatively small. We performed 
a sensitivity analysis to exclude population stratification and a permutation analysis to 
rule out that our results are due to random fluctuation. These analyses support that 
population stratification or chance are unlikely to explain the sex-specific effect found 
in this study (online appendix).
Another limitation is that the three DN groups are compared to the same control 
group. 
In conclusion, this study shows a sex-specific effect of the association between 
the CNDP1 gene and diabetic nephropathy in three independent patient groups with 
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A polymorphism in the number of CTG-repeats in exon 2 of the CNDP1 (carnosinase) 
gene correlates with the development of nephropathy in diabetes patients. Carnosinase 
degrades carnosine, which protects glomeruli against oxidative and hemodynamic 
damage. This study investigated whether the CNDP1 polymorphism is associated with 
occurrence of ESRD and mortality risk in patients with vascular kidney diseases other than 
diabetic nephropathy, such as renal vascular disease and chronic glomerulonephritis.
Included were 97 Caucasian end stage chronic glomerulonephritis patients, 143 end 
stage renal vascular disease patients and 732 healthy Caucasian controls. Furthermore, 
104 end stage polycystic kidney disease patients and 95 end stage tubulointerstitial 
nephritis were included as disease controls. Prevalence of genotypes was compared by 
calculating odds-ratios, survival of patients by Kaplan-Meier techniques.
Compared to patients with genotypes resulting in lower carnosinase activity, 
genotypes with higher carnosinase activity were associated with an increased risk of 
developing ESRD in patients with renal vascular disease (OR [95% CI] 2.47 [1.02, 5.98]) 
and chronic glomerulonephritis (5.08 [2.15, 11.99]). These chronic glomerulonephritis 
patients also had an increased mortality risk (p log rank 0.01). In patients with other 
primary kidney diseases the genotype was not associated with ESRD or mortality.
In conclusion, in patients with glomerular damage the CNDP1 polymorphism 
predisposes for development of ESRD. In chronic glomerulonephritis this was also 
reflected by increased mortality. These findings support the hypothesis that there is a 




End stage renal disease (ESRD) has reached epidemic proportions and the number of 
ESRD patients is still increasing [1]. These patients require renal function replacement 
therapy by either dialysis or transplantation. This leads to loss of quality of life, high 
mortality rates and has become a great economic burden [1]. Identifying risk factors 
for progression to ESRD are therefore of great interest and might be able to prevent 
susceptible individuals from developing ESRD by earlier and more aggressive treatment. 
One of the most important risk factors for developing ESRD seems to be a positive family 
history of ESRD [2]. Lei et al. found that familial aggregation of renal disease could not 
be fully explained by familial clustering of diabetes and hypertension. Therefore it is 
likely that a separate genetic susceptibility factor exists for progression of ESRD [3]. 
A possible susceptibility locus for diabetic nephropathy on chromosome 18q has 
been identified in earlier studies [4;5]. We identified the responsible modifying gene 
within this locus as the CNDP1 gene [6]. These findings were further confirmed in 
963 American patients of European descent with type 2 diabetes-induced nephropathy 
[7], but not in patients with type 1 diabetes [8]. Type 2 diabetes patients with the 
homozygosity for the Mannheim allele (5 copies of a trinucleotide repeat encoding for 
leucine in the leader peptide on exon 2) of the CNDP1 gene demonstrated a 2.56-fold 
reduced risk for developing diabetic nephropathy (DN) compared to individuals with 
more leucine repeats (6-8 repeats) [6]. The presence of more than 5 leucine repeats 
has been shown to lead to higher serum carnosinase secretion [9] and more serum 
carnosinase activity [6;10]. Serum carnosinase is known to degrade histidine-containing 
dipeptides called carnosines, which function as scavengers of reactive oxygen species 
[11] and as inhibitors of angiotensin converting enzyme (ACE) [12]. 
Since injury to glomerular cells by oxidative stress and hemodynamic factors is 
not confined to development of diabetic nephropathy, we hypothesize that lower 
number of leucine repeats in the CNDP1 play a protective role in progression to ESRD 
in underlying renal diseases due to glomerular and microvascular injury, such as chronic 
glomerulonephritis and renal vascular disease. In line with this hypothesis, one would 
expect that within these vascular disease groups, survival would differ in patients with 




Patient and control subjects
Patients were selected from the Netherlands Cooperative Study on the Adequacy of 
Dialysis (NECOSAD), a multicenter, prospective follow-up study of ESRD patients who 
were included at the time of the initiation of dialysis [13]. Data on ethnic background, 
gender, primary kidney disease, comorbidities, and modality were collected between 
four weeks prior and two weeks after the start of dialysis. Patients were at least 18 
years of age with no previous renal replacement therapy and were followed till death 
or censoring. Reasons for censoring included transplantation, recovery of renal function 
or loss to follow-up. All local medical ethics committees approved of the study and 
patients gave informed consent before inclusion. 
For the current study, data from chronic glomerulonephritis, polycystic kidney 
disease, renal vascular disease and tubulointerstitial nephritis were selected. These 
diseases were classified according to the European Renal Association-European Dialysis 
and Transplantation Association (ERA-EDTA) codes (http://www.era-edta-reg.org/
files/annualreports/pdf/AnnRep2006.pdf.). Based on these ERA-EDTA codes, primary 
kidney disease groups were defined: chronic glomerulonephritis (cGN, codes 9 to 20), 
tubulointerstitial nephritis (TIN, codes 20 to 40), polycystic kidney disease (PKD, codes 
40 to 50) and renal vascular disease (RVD, codes 70 to 73, or code 79). Patients that 
were not of Caucasian origin were excluded, as the distribution of CNDP1 is dependent 
of ethnic origin [10]. Comorbidity was defined according to the risk criteria of Khan et al. 
[14]. The Khan index is a combination of age and co-morbidity that divides risk groups 
into three degrees of severity as low, medium, or high. Three months after beginning 
dialysis, a blood sample and 24-hour urine sample were collected on the same day. 
Serum albumin, plasma creatinine, and plasma urea levels were determined. Urea and 
creatinine levels were also analyzed in the urine sample. Genomic DNA was isolated 
from peripheral blood with the Puregene® DNA isolation kit (Gentra, Minneapolis, 
USA). The genotype frequencies in NECOSAD patients were compared to those in 
732 healthy controls above 18 years of age. To eliminate ethnic differences, we only 





CNDP1 genotyping was performed as described elsewhere [6]. In brief, a standard PCR 
protocol was used with the primers GCGGGGAGGGTGAGGAGAAC (forward) and 
GGTAACAGACCTTCTTGAGGAATTTGG (reverse). The denaturating, annealing and 
extension temperatures were 94°C, 60°C, and 72°C, respectively. Fragment analysis 
was performed on the ABI-3130 analyzer (Perkin Elmer) to determine the number of 
leucine repeats on each allele. A product length of 157, 160, and 163 bp corresponded 
to 5, 6, or 7 CTG (Leu) codons, respectively. 
Determination of serum-carnosinase activity
Serum-carnosinase activity was determined according to the method described by 
Teufel et al. [15]. Briefly, the reaction was initiated by addition of substrate (L-carnosine) 
to a serum sample and stopped after 10 minutes of incubation at 30°C by adding 1% 
trichloracetic acid. Liberated histidine was derivatized with o-phtaldialdehyde (OPA). 
Fluorescence was measured by excitation at 360 nm and emission at 460 nm. Serum 
samples were obtained from 60 healthy controls. 
Mortality
Causes of death were determined by treating physicians and classified according to 
the codes of the ERA-EDTA which can be found at: http://www.era-edta-reg.org/
files/annualreports/pdf/AnnRep2006.pdf. The following codes were classified as 
cardiovascular mortality: 0 (cause of death uncertain/not determined), 11 (myocardial 
ischemia and infarction), 14 (other causes of cardiac failure), 15 (cardiac arrest, cause 
unknown), 18 (fluid overload), 22 (cerebrovascular accident), 26 (hemorrhage from 
ruptured vascular aneurysm, not code 22 or 23), or 29 (mesenteric infarction).
Statistical analysis
In all analyses subjects carrying the CNDP1 Mannheim variant were used as reference 
group and contrasted to all other possible genotypes (5-0, 5-6, 5-7/6-6, 6-7/6-8/7-
7). Hardy-Weinberg equilibrium was calculated using the gene-counting method, and 
differences between NECOSAD patients and the control group were assessed by chi-
square test. In NECOSAD patients, differences in baseline characteristics between the 
different CNDP1 genotype groups were tested with the chi-square test for dichotomous 
and categorical variables and analysis of variance for continuous variables. The Armitage 
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Trend Test was used to test for genetic association, as the genotypes could be ranked 
according to the respective enzyme activities. 
Survival of patients with different CNDP1 genotypes was analyzed by means of 
Kaplan-Meier survival curves. Log rank tests were used to determine survival differences.
All statistical analyses were performed with SPSS statistical software (version 12; SPSS, 
Chicago, IL) and SAS (Version 9.1; SAS, Heidelberg, Germany).
results
A total of 439 dialysis patients were selected from the NECOSAD, consisting of 97 
chronic glomerulonephritis patients, 143 renal vascular disease patients, 104 polycystic 
kidney disease patients and 96 tubulointerstitial nephritis patients. 
Baseline characteristics of these 439 patients and these patients grouped by allelic 
variant of CNDP1 are seen in Table 1. 
Carnosinase activity
The carnosinase activity was measured in 60 healthy controls with genotypes 5-5, 5-6, 
6-6, 5-7. The genotype 5-0 was estimated on theoretical enzyme activity and the 5-8 
was extrapolated from a different study done by Riedl et al. [9]. A clear correlation 
was found between carnosinase enzyme levels and the number of leucine repeats in 
the CNDP1 gene. The various genotypes were ranked according to the corresponding 
enzyme activities (Figure 1).
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Table 1. Baseline characteristics of patients under study (N=439), grouped by allelic variant of CNDP1
Total
CNDP1 genotype
5-5 5-6 5-7/6-6 6-7/6-8/7-7
N=439 N=163 N=164 N=84 N=28
Age (yrs) 59.5 (14.0) 59.7 (13.8) 59.2 (13.9) 59.0 (15.0) 61.6 (14.3)
Gender (% female) 35.1 38.7 32.3 32.1 39.3
Chronic Therapy (% HD) 62.9 65.0 59.8 67.9 53.6
Primary kidney disease (%)
Glomerulonephritis 22.1 17.2 22.0 27.4 35.7
Interstitial nephritis 21.6 27.6 17.7 15.5 28.6
Polycystic kidney disease 23.7 27.0 24.4 21.4 7.1
Renal vascular disease 32.6 28.2 36.0 35.7 28.6
Khan co-morbidity score (%)
low 49.7 51.5 50.0 48.8 39.3
moderate 28.2 30.7 28.0 23.8 28.6
high 22.1 17.8 22.0 27.4 32.1
DM co-morbidity (%) 5.1 4.4 4.9 6.0 7.1
CVD co-morbidity (%) 35.3 31.0 36.5 36.8 48.1
Smoking habit (%)
never 27.1 27.6 28.7 28.6 10.7
ever, >3 mo ago 43.1 45.4 41.5 41.7 42.9
ever, <=3 mo ago 4.8 3.7 5.5 3.6 10.7
current 25.1 23.3 24.4 26.2 35.7
GFR (ml/min/1.73m2)† 5.3 (3.1) 5.3 (2.7) 5.4 (3.4) 5.3 (3.1) 5.1 (3.5)
Blood pressure (mmHg)
systolic 149.1 (24.8) 149.6 (26.2) 147.6 (24.7) 151.6 (24.1) 147.3 (19.8)
diastolic 83.6 (12.8) 84.0 (12.8) 82.5 (13.1) 84.8 (13.2) 83.2 (10.7)
Mean values ± SD are given for continuous variables. For categorical variables percentages are shown. DM, 
diabetes mellitus; GFR, glomerular filtration rate; CVD, cardiovascular disease; *Exclusive vasculitis; †GFR = 
glomerular filtration rate, measured between four weeks prior to and two weeks after start of dialysis (for 5-5 
[N=91], 5-6 [N=100], 5-7/6-6 [N=48] and 6-7/6-8/7-7 [N=19]).
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Figure 1. Estimated and measured serum-carnosinase activity in compound heterozygosity with the 
Mannheim allele (5-Leu) in normal Caucasian individuals.
Analysis of CNDP1 genotype frequencies by comparison of disease subgroups.
Patients with chronic glomerulonephritis had significantly more leucine repeats than 
controls (Table 1, p= 0.0006). ESRD patients with the highest number of leucine repeats 
in the CNDP1 gene have a 5.1 (95% CI 2.15, 11.99) higher risk of developing ESRD due 
to glomerulonephritis compared to glomerulonephritis patients with lower number of 
leucine repeats (Table 2). The renal vascular disease patient group also showed significant 
association with CNDP1 repeat length (p=0.011) (Table 1). ESRD patients with the 
highest number of leucine repeats in the CNDP1 gene have a 2.5 (95% CI 1.02, 5.98) 
higher risk of developing ESRD due to renal vascular disease compared to renal vascular 
disease patients with lower number of leucine repeats (Table 2). Patients who became 
dialysis-dependent due to polycystic kidney disease or tubulointerstitial nephritis, as 






































Table 2. Distribution of CNDP1 leucine repeats of NECOSAD patients grouped by primary kidney disease 
compared to controls.
  NECOSAD grouped by primary kidney disease
cGN RVD TIN PKD Control group
CNDP1# (n=97) (n=143) (n=95) (n=104) (n=732)
  n % n % n % n % n %
5/0, 6/0, 7/0 0 0 0 0 0 0 0 0 13 1.8
5-5 28 28.9 46 32.2 45 47.4 44 42.3 270 36.8
5-6 36 37.1 59 41.3 29 30.5 40 38.5 303 41.4
5/7, 6/6 23 23.7 30 21.0 13 13.7 18 17.3 127 17.3
6/7, 6/8, 7/7, 7/8 10 10.3 8 5.6 8 8.4 2 1.9 19 2.6
p* 0.0006 0.011 0.55 0.74    
GN indicates chronic glomerulonephritis; TIN, tubulointerstitial nephritis; PKD, polycystic kidney disease; RVD, 
renal vascular disease; DN, diabetic nephropathy; and OMD, other multisystem diseases.
*) NECOSAD patients vs. the control group as determined with Armitage Trend Test.
#) Genotypes grouped according to enzyme activity (Table 1).  
Mortality
Survival probabilities for patients with different CNDP1 genotypes were not different 
(log rank test, p=0.62). A stratified survival analysis revealed that the survival probability 
in patients with glomerulonephritis (log rank test, p<0.01) as primary renal disease were 
significantly different between the leucine repeat groups (5-5, 5-6, 5-7/6-6, 6-7/6-8/7-7) 
(Figure 2). Patients with glomerulonephritis and a high number of leucine repeats had 
higher mortality rate compared to glomerulonephritis patients with lower number of 
leucine repeats. Survival probabilities in ESRD patients due to polycystic kidney disease, 
tubulointerstitial nephritis and renal vascular disease did not differ between the leucine 
repeat groups. 
 
Table 3. Genotypic odds ratios (OR) comparing genotype-related risks to the 5Leu / 5Leu reference and 





5/5 (ref.) 1.00 1.00
5/6 1.14 (0.68, 1.92) 1.14 (0.75, 1.73)
5/7, 6/6 1.70 (0.95, 3.08) 1.35 (0.82, 2.25)
6/7, 6/8, 7/7, 7/8 5.08 (2.15, 11.99) 2.47 (1.02, 5.98)
cGN: chronic glomerulonephritis; RVD: renal vascular disease.
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Figure 2. Survival within the first four years of follow-up of patients with chronic glomerulonephrits, 
tubulointerstitial nephritis, cystic kidney disease and renal vascular disease. 
discussion
Our results demonstrate that the higher number of leucine repeats in the CNDP1 genotype 
is related to a faster progression to ESRD in patients with compromised kidney function 
due to chronic glomerular inflammatory renal diseases and the group of patients with 
renal vascular disease. In line with these results, the mortality risk is increased in chronic 
glomerulonephritis patients with higher number of leucine repeats in the CNDP1 gene, 
which is associated with higher serum carnosinase levels. Our data show a correlation 
between the leucine repeat distribution of the CNDP1 gene and renal vascular disease, 
however there was no relation with survival. As predicted, patients who developed 
ESRD due to either polycystic kidney disease or tubulointerstitial had a CNDP1 genotype 
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distribution similar to that of healthy controls. These findings support the hypothesis 
that the leucine repeat in CNDP1 may contribute to microvascular damage. 
In chronic glomerulonephritis the higher number of leucine repeats in the CNDP1 gene 
seems to be involved in progression to ESRD and mortality on dialysis. There are two 
pathways by which this association can be explained. Common to the development 
of ESRD in these patients is that the development of progressive glomerulosclerosis is 
accompanied by oxidative injury to glomerular cells from reactive oxygen species (ROS) 
and hemodynamic factors [16]. Histidine-containing dipeptides such as carnosines 
reportedly function as ROS scavengers [17], natural inhibitors of transforming growth 
factor beta (TGF-beta) production [6], anti-apoptotic compounds [18], and natural 
inhibitors of ACE [12]. The rapid degradation of these dipeptides by locally produced 
serum-carnosinase may impair a protective mechanism required for recovery after renal 
disease. Indeed, transfection experiments have shown that multiple leucine repeats in 
carnosinase results in increased secretion of the enzyme [9] and our results show an 
increased carnosinase activity with increasing number of leucine repeats. This current 
result is a replication, as this was found in both Caucasians [6] and South Asians [10]. 
Furthermore, carnosinase was expressed in the kidney, making a specific role in the 
kidney likely [10]. Carnosines are released from skeletal muscle after physical exercise 
[19], and the beneficial effects of exercise on diabetic nephropathy [20], hypertension-
induced nephrosclerosis [21;22], and progressive renal disease in general [23] have 
been well documented. Thus, the protective effects of carnosine seem to be essential 
for natural recovery of the kidney after microvascular injury.
The second possibility regards the connection between the autonomic nervous 
system and the kidney. Homocarnosine, a particular substrate of serum carnosinase, 
is composed of gamma-amino-butyric acid-L-histidine (GABA-his) [24]. Cleavage of 
homocarnosine by serum-carnosinase releases the neurotransmitter GABA, resulting 
in GABA-receptor-mediated activation of the sympathetic innervations of the kidney 
[24;25]. In addition, carnosine has been shown to inhibit sympathetic nerve activity 
directly, resulting in reduction of systemic blood pressure [26]. The same research group 
also demonstrated the involvement of carnosine in the regulation of blood glucose 
levels via autonomic nerves [27]. Indeed, hyperactivity of the sympathetic nerves in both 
hypertension-induced renal insufficiency and progressive renal disease in general has 
been reported in both experimental settings and clinical studies [28-31]. 
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Recently, we found that the relation between the CNDP1 gene and DN is sex-specific, 
including patients with DN from the NECOSAD study [32]. We also stratified the data 
of this study for men and women. The frequency of the 5-5 homozygous genotype was 
lower in women than in men in chronic glomerulonephritis patients (23.1% vs. 31.0%) 
and renal vascular disease patients (29.7% vs. 33.0%). Although this is in line with 
the data in DN, no definite conclusion should be drawn as due to the stratification the 
sample size became too small. 
Ideally, one would have preferred to compare the ESRD group with the diseased patients 
not progressing to ESRD to exclude the possible correlation between susceptibility for 
the disease. However we feel that such correlation is unlikely because of the aetiological 
heterogeneity within the disease groups. Furthermore, the different diseases can be 
seen to serve as disease control groups. 
Our data have clinical implications. Carnosine and related compounds have already 
been used as therapies for cataracts [33] and gastric ulcers [34]. In rats induced with 
gentamicin, treatment with carnosine led to a significant improvement of the kidney 
function [35]. Furthermore, gentamicin-induced glomerular shrinkage was absent in 
those rats treated with carnosine [35]. In humans, carnosine seems to be hydrolyzed 
within 2 hours after carnosine is absorbed by the intestine and enters the bloodstream 
[36]. However, when Parkinson patients were treated with carnosine in addition to 
dopamine (L-dopa), they had a decreased level of protein carbonyls in their blood 
plasma and increased levels of red cell superoxide dismutase compared with patients 
treated with only dopamine (L-dopa) [37]. This suggests that supplementation with 
carnosine has a biochemical effect after oral intake and could, therefore, be of potential 
therapeutic value. Our study indicates that carnosine supplementation can also be 
considered in patients with chronic glomerulonephritis and renal vascular disease.
In summary, here we have provided evidence for a genetic predisposition for 
progression to ESRD due to chronic glomerulonephritis and renal vascular disease. In 
glomerulonephritis this was reflected in both genotype distribution and in mortality risk. 
Hereby we identified a genetic polymorphism that seems to be involved in the clinical 
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Carnosine is found in high concentrations in skeletal muscles, where it is involved 
in several physiological functions. The muscle carnosine content measured within a 
population can vary by a factor 4. The aim of this study was to further characterize 
suggested determinants of the muscle carnosine content (diet, gender and age) and to 
identify new determinants (plasma carnosinase activity and testosterone). 
We investigated a group of 149 healthy subjects, which consisted of 94 men 
(12 vegetarians) and 55 women. Muscle carnosine was quantified in M. soleus, 
gastrocnemius and tibialis anterior using magnetic resonance proton spectroscopy 
and blood samples were collected to determine CNDP1 genotype, plasma carnosinase 
activity and testosterone concentrations. 
Compared to women, men have 36%, 28% and 82% higher carnosine 
concentrations in M. soleus, gastrocnemius and tibialis anterior muscle respectively, 
whereas circulating testosterone concentrations were unrelated to muscle carnosine 
levels in healthy men. The carnosine content of the M. soleus is negatively related to 
the subjects’ age. Vegetarians have a lower carnosine content of 26% in gastrocnemius 
compared to omnivores. In contrast, there is no difference in muscle carnosine content 
between subjects with a high or low ingestion of beta-alanine within an omnivore diet. 
Muscle carnosine levels are not related to the polymorphism of the CNDP1 gene nor to 
the enzymatic activity of the plasma carnosinase. 
In conclusion, neither CNDP1 genotype, nor the normal variation in circulating 
testosterone levels affect the muscular carnosine content, whereas vegetarianism, 





Carnosine (β-alanyl-L-histidine) is a dipeptide found in high concentrations in skeletal 
muscles. Several of carnosine’s physiological actions are relevant to muscular function 
and homeostasis, such as pH buffering (1; 2; 5; 6), antioxidant effects (6; 24), increasing 
the Ca2+ sensitivity of the contractile apparatus (12; 25) and inhibiting protein glycation 
(19), as recently reviewed (6; 8; 37). Interestingly, recent studies have shown that elevated 
muscle carnosine content is associated with attenuated fatigue and improved exercise 
performance in humans (10; 18; 35; 40; 41; 44; 48). The carnosine content in human 
muscles usually amounts to 20-30 mmol.kg-1 in dry weight (5-8 mM in wet weight), 
but can easily vary by a factor 3-4 between the highest and the lowest concentrations 
measured within a population. Yet, the muscle carnosine content is rather constant, as 
we showed that intra-individual variation in muscle carnosine content is only 9-15% 
over a 3-month period (3). The MRS-based technique (10) gives us the opportunity to 
explore, without the need for muscle biopsy, existing and new determinants of the 
variation in muscle carnosine content within a large population. 
The most established determinant of the muscle carnosine content is muscle fiber 
type. HPLC-based single fiber analysis in humans showed a 30-100% higher carnosine 
content in fast-twitch muscle fibers in comparison with slow-twitch (15; 18; 23). 
Indeed, Mannion et al. (27) and Suzuki et al. (43) showed a positive correlation between 
muscle fiber type and muscle carnosine content. Furthermore, elite sprinters who are 
characterized by a high proportion of fast-twitch muscle fibers have a higher muscle 
carnosine content in comparison with marathon runners (32).
The amount of food from animal sources is a likely determinant of muscle carnosine 
levels since beta-alanine, the rate-limiting precursor in carnosine synthesis, is exclusively 
found in meat and fish. The ingestion of very high doses of beta-alanine in pure form 
(4-6.4 g.day-1 as a food supplement) for several weeks (4-10 wks) results in 40-80% 
increases in muscle carnosine content (3; 10; 17; 18; 23). Whether variations in daily 
meat intake within a normal omnivorous diet also affect muscular carnosine content, 
remains to be established. The chronic and complete withdrawal of dietary beta-alanine, 
such as in vegetarianism, supposedly results in decreased carnosine content, although 
the current evidence is scarce (16). 
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Men have been shown to have higher (21%) carnosine content in the quadriceps 
femoris when compared to women (26). This sexual dimorphism is more pronounced 
in mice with a male/female ratio of approximately 3.5/1 (33), but absent in horses (28). 
Concerning the effect of age, several studies on rodents demonstrated a decreasing 
muscle carnosine content of 35-50% with senescence (9; 21; 42). To our knowledge, 
no longitudinal studies on humans are available, but there is cross-sectional evidence 
for a decreased muscle carnosine content of 33-60% in elderly people with specific 
pathologies (42; 45). 
A possible explanation for a lower muscle carnosine content amongst elderly people 
and women is their lower plasma (free) testosterone content. Both cross-sectional and 
longitudinal studies have confirmed an age-associated decline of plasma testosterone 
in aging men (reviewed in (22). Penafiel et al. (33) hypothesized that androgens might 
up regulate carnosine synthase, based upon the findings that the muscle carnosine 
content was reduced by 40% in castrated mice and that testosterone injections 
increased muscle carnosine content by 268% in female mice. To our knowledge, no 
study has investigated a possible connection between circulating testosterone and 
muscle carnosine content in eugonadal men. 
Polymorphism in the enzymes involved in the synthesis (carnosine synthase) and 
hydrolysis (carnosinase) of the dipeptide could also contribute to the muscle carnosine 
content. Since the highest activity of carnosine synthase is found in skeletal muscles (6), 
polymorphisms of the gene encoding carnosine synthase are likely to clarify variations in 
carnosine. As the gene has only recently been identified (11), there are no studies that 
have examined the effects. A leucine repeat in exon 2 of the CNDP1 gene, coding for 
the serum carnosinase enzyme, has been shown to affect carnosinase activity (20; 29) 
and likely the duration of the presence of carnosine in plasma. The enzyme carnosinase 
is supposedly not present and/or not active in skeletal muscles (3), but it is reasonable to 
assume that the plasma carnosinase activity could indirectly affect the muscle carnosine 
content. 
The aim of this study was to further characterize previously reported determinants 
(diet, gender and age) and to identify new potential determinants (plasma carnosinase 
activity, CNDP1 genotype and testosterone) of the human muscle carnosine content. 
Carnosine was quantified using proton magnetic resonance spectroscopy (1H-MRS), as 
previously described (3; 10; 31), in the slow-twitch soleus and tibialis anterior and the 
fast-twitch gastrocnemius muscle, in order to explore the possible interaction of these 




Subjects. As depicted in figure 1, a total of 149 healthy subjects volunteered to 
participate in this study. The muscle carnosine content of 12 male vegetarians was 
determined. Vegetarian subjects were either lacto-ovo, or vegan and were required to 
be vegetarian for a minimum of 8 years (mean ± SD: 15 ± 9.5 yr; range 8-36 yr) prior to 
the study. Blood samples were obtained from all omnivores (82 males, 55 females) for 
determination of plasma carnosinase activity and CNDP1 genotype (Age: mean ± SD: 
23.9 ± 7.0, range: 18 - 69 yrs). The muscle carnosine content (38 males, 20 females) 
and plasma concentration of androgens (38 males) were measured in a subgroup of 
omnivores, of which 29 male individuals registered their meat and fish consumption 
during 2 weeks. The mean (± SD) age of the male population (23.9 ± 7.2 yrs, range: 19 
- 47 yrs) is lower than the age of the vegetarians (31.3 ± 4.2 yrs, range: 22 - 38 yrs) but 
not different from the female group (23.8 ± 6.7 yrs, range: 19 - 46 yrs). The data of 19 
male omnivore subjects are originating from a previous study (3). The study protocols 
were approved by the local Ethical Committee (Ghent University Hospital, Belgium) and 
written informed consent was obtained from all participants prior to the study. 
1H-MRS. The carnosine content of 3 skeletal muscles of the lower leg (soleus, 
gastrocnemius and tibialis anterior) of a subgroup of 70 subjects was measured using 
1H-MRS, as previously described (3). The subjects lay in supine position on their back and 
the lower leg was fixed in a holder with the angle of the ankle at 20° plantar flexion. All 
the MRS measurements were performed on a 3 Tesla whole body MRI scanner (Siemens 
Trio, Erlangen) equipped with a knee-coil. Single voxel point-resolved spectroscopy with 
the following parameters was used: repetition time (TR)= 2000 ms, echo time (TE) = 30 
ms, number of excitations = 128, 1024 data points, spectral bandwidth of 1200Hz, and 
a total acquisition time of 4.24min. The average voxel size of the soleus, gastrocnemius 
lateralis and tibialis anterior was respectively 40 mm x 12 mm x 29 mm, 40 mm x 
12 mm x 29 mm, 40 mm x 14 mm x 27 mm. Following shimming procedures, the 
linewidth of the water signal was on average 24.4 Hz, 25.5 Hz and 27.6 Hz for soleus, 
gastrocnemius and tibialis anterior, respectively. A 500-ml spherical container filled 
with an aqueous solution of 20 mM carnosine (Sigma-Aldrich) was used as an external 
reference for absolute quantification. The following equation was used to determine 
the concentration of C2-H ( at ~8 ppm) carnosine in vivo: 
[Cm] = [Cr] . (Sm . Vr . CT1r . CT2r . Tm ) / (Sr . Vm . CT1m . CT2m . Tr)
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Where [Cm] is the carnosine concentration in vivo; [Cr] is the concentration of the 
external reference phantom (20 mM); Sm and Sr are the estimated signal peak areas of 
the muscle and reference phantom, respectively, obtained by curve fitting performed in 
the frequency domain and were also corrected for differences in coil loading between 
phantom and the muscle; corrected for  Vm  and Vr, the volumes of the voxels in vivo 
and in the phantom, respectively; CT1m, CT2m, CT1r and CT2r are correction factors for the 
T1 and T2 relaxation times in vivo and in the phantom, respectively; Tm and Tr are the 
temperatures in vivo and in the phantom, respectively. The T1 and T2 relaxation times 
of in vitro carnosine were measured and were found to be 2616 ± 20 ms and 250 ± 29 
ms, respectively. The formulae used to calculate the correction factors are:
CT1 = (1-e^(-TR/T1))
CT2 = e^(-TE/T2)
For the determination of T1 and T2 relaxation times in vivo 5 healthy subjects (2 
males and 3 females; age: 21 to 26 yr) were scanned for the soleus, 5 (3 males and 2 
females; age: 21 to 25 yr) for the gastrocnemius and 5 for the tibialis anterior muscle 
(5 females; 22 to 26 yr). T1 was measured using a TE of 30 ms and TR was set to 1500, 
2000, 2500, 3000, 3500, 4000, 5000 and 6000 ms. T2 was measured using a TR of 
4000 ms and TE was set to 30, 60, 90, 120, 150 and 200 ms for soleus, 30, 45, 60, 
75, 90 and 105 ms for gastrocnemius and 30, 45, 50, 60, 70 and 75 for tibialis anterior 
muscle. For each measurement 128 averages were acquired. The T1 relaxation times 
were shown to be 1488 ± 377 ms, 1771 ± 225 ms and 1692 ± 432 ms and T2 relaxation 




Figure 1. Overview of subject population. Subjects with only plasma are for comparison of CNDP1 activity 
between sexes and for relation between CNDP1 genotype and plasma carnosinase activity
Venous blood sampling. For measurement of circulating androgens, plasma carnosinase 
activity and for CNDP1 genotyping, blood of the antecubital vein was withdrawn in 
heparin tubes. Blood samples were centrifuged and the plasma and blood cells were 
stored separately at -80°C until further analyses. 
Genotyping. A more detailed description of the CNDP1 genotype determination 
is explained in the study of Mooyaart et al. (29). In brief, a standard PCR protocol 
was used with primers 5-FAM-GCGGGGAGGGTGAGGAGAAC (forward) and 
GGTAACAGACCTTCTTGAGGAATT-TGG (reverse). The denaturing, annealing 
and extension temperatures were 94°C, 60°C and 72°C, respectively. After PCR 
amplification, fragment analysis was performed on the ABI3130 analyzer (Perkin Elmer) 
to determine the fragment length corresponding with the different genotypes. Each 
peak corresponded with the number of leucine repeats on each allele. A 157, 160 and 
163 base pair product corresponded with 5, 6 and 7 CTG codons encoding for 5, 6 and 
7 leucine repeats, respectively. The 5-5 and the 5-6 CNDP1 genotypes are widespread 
and each represent approximately 40% of the population. The 6-6 genotype is present 
in ± 12% of the population while the 5-7 (± 4%) and 6-7 (± 4%) CNDP1 genotypes are 
less common (14; 20; 29).
Plasma carnosinase activity. Heparin plasma samples of 82 men and 55 women 
were used to quantify the plasma carnosinase activity. Plasma carnosinase activity was 
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determined according to the method described by Teufel et al. (47). Briefly, the reaction 
was initiated by addition of substrate (L-carnosine) to a plasma sample and stopped 
after 10 min of incubation at 37°C by adding 1% sulphate salicylic acid. The maximum 
increase was used for determining the maximum activity. Liberated histidine was 
derivatized with o-phtaldialdehyde (OPA). Fluorescence was measured by excitation at 
360 nm and emission at 460 nm. The intra- and inter-assay variations were respectively 
7% and 25%. The lowest carnosinase activity detectable was 0.117 µmol/ml/h.
Androgens. Heparin plasma samples of 38 men were analyzed using a commercial 
immunoassay kit to determine the plasma concentrations of testosterone (Orion 
Diagnostica, Espoo, Finland) and LH (ECLIA, Roche Diagnostics). The free fraction 
of testosterone was calculated from plasma testosterone, SHBG, and albumin 
concentrations using a previously validated equation (49). 
Dietary beta-alanine intake. A subgroup of 29 male omnivore subjects completed a 
questionnaire about their meat and fish consumption during 2 weeks to quantify daily 
dietary beta-alanine intake, as described in the study of Baguet et al. (3).
Statistics. The CNDP1 genotypes of exon 2 were categorized based on the leucine 
repeat length (5-5, 5-6, 5-7, 6-6, 6-7). Independent sample T-tests were used to evaluated 
the effect of gender, age and CNDP1 genotype on the muscle carnosine content. An 
univariate analysis of variance with age as covariate was used to verify the effect of 
vegetarianism on muscle carnosine content. The correlation between genotype and 
carnosinase activity was assessed by an univariate analysis of variance with carnosinase 
activity as dependent and both gender and CNDP1 genotype as independent variables 
(post hoc: pairwise comparisons). The other possible determinants were analyzed by 
bivariate correlations. All statistical analyses were performed using SPSS 16.0 software 
(SPSS, Chicago, IL, USA) and a p-value < 0.05 was considered to be statistically 
significant. 
results
Gender. As illustrated in figure 2A, men had a higher muscle carnosine content in 
comparison to women (p ≤ 0.004), but the magnitude of this sex-related difference 
depends on the type of muscle. The soleus and gastrocnemius showed a 36% and 28% 
larger carnosine content in men, whereas the difference was 82% in tibialis anterior. 
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The plasma carnosinase activity was significantly higher (p < 0.001) in women (7.20 ± 
1.62 µmol/ml/h) in comparison with men (5.79 ± 1.58 µmol/ml/h; figure 2B). 
Figure 2. a/ The carnosine content of men (n = 38) versus women (n = 20) in soleus, gastrocnemius and tibialis 
anterior, measured by proton spectroscopy, * different from men (p ≤ 0.004). b/ The plasma carnosinase 
activity of the female (n = 55) is 24,3% higher in comparison with the carnosinase activity of the male 
population (n = 82) (p < 0.001)
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Age. The carnosine concentration in the M. soleus (n = 58, p = 0.049; r = -0.260, figure 
3) declines with age in the adult range of 19-47 years (M. gastrocnemius: p = 0.112; 
r = -0.211, M. tibialis anterior: p = 0.482; r = -0.096). In the same group, age did not 
significantly correlate with plasma carnosinase activity (p = 0.355; r = 0.124).
Figure 3. Effect of age on muscle carnosine content in both male and female omnivores. There is a negative 
correlation of age and carnosine concentration in soleus (p <0.05 , r = -0,260, n = 58)
Androgens. In order to elucidate the mechanisms of the age and gender related 
effects on the muscle carnosine content, we measured plasma testosterone and free 
testosterone concentrations. The mean (± SD) total testosterone and free testosterone 
plasma levels in the male reference population were, respectively, 538.6 ± 140.3 ng.dl-1 
and 11.7 ± 3.5 ng.dl-1. Neither of them correlated with muscle carnosine content (soleus, 
gastrocnemius and tibialis anterior) nor with carnosinase activity (0.238 ≤ p ≥ 0.921). 
A scatter plot of plasma free testosterone content with M. soleus carnosine content is 
depicted in figure 4. The plasma total and free testosterone concentration is inversely 


















Figure 4. The lack of correlation between plasma free testosterone and soleus carnosine content (p = 0.921). 
Similar results were obtained for gastrocnemius and tibialis anterior (p = 0.851 and p = 0.794, respectively) 
and for the correlation of the muscle carnosine content with testosterone, luteinizing hormone (LH) and sex 
hormone binding globulin (SHBG) (p > 0.05)
Daily beta-alanine intake. Long-term vegetarianism ( > 8 years) is associated with 
declined muscle carnosine stores (figure 5). Vegetarians have lower carnosine levels of 
17% in M. soleus (p = 0.05) and 26% in M. gastrocnemius (p = 0.009) and a trend to a 
lower carnosine content (20%) in M. tibialis anterior (p=0.068) compared to omnivores. 
However, the significance of the effect of vegetarianism on soleus carnosine content 
disappeared, when the data were corrected for age (p = 0.304), whereas this was not 
the case in M. gastrocnemius nor in tibialis anterior. The mean (± SD) daily average beta-
alanine ingestion by meat and fish consumption in a subgroup of 29 omnivore male 
subjects was 0.332 ± 0.144g. Within a normal Western omnivore diet, beta-alanine 
intake by meat and fish consumption is not a determinant of the muscle carnosine 
content, as there is no correlation between beta-alanine ingestion and muscle carnosine 
content (0.671 ≤ p ≥ 0.885) nor a difference in muscle carnosine content between 
subjects with a low (< 0.332 g.day-1) or a high (> 0.332 g.day-1) intake of beta-alanine 


















Figure 5. Male vegetarians (n = 12) have a lower muscle carnosine content (* p < 0.05 and  $ p < 0.10)  in 
comparison with male omnivores (n = 38)
Genotype and plasma carnosinase activity. The most common CNDP1 genotypes were 
5-5 (35.8%) and 5-6 (38%). The 5-7, 6-6 and 6-7 CNDP1 genotypes were detected in 
respectively 7.3%, 15.3% and 3.6% of the subjects. Figure 6a shows that the plasma 
carnosinase activity is dependent on the CNDP1 genotype (p = 0.054). The plasma 
carnosinase activity of the 5-5 genotype is lower compared to the 5-6 (p = 0.05) and 
to the 6-6 genotype (p = 0.025). Also the 6-7 alleles show a lower plasma carnosinase 
activity than the 6-6 alleles (p = 0.035). The relation between the most frequent CNDP1 
genotypes (5-5 and 5-6) and the muscle carnosine content is depicted in figure 6b. The 
muscle carnosine content of the individuals with the 5-5 CNDP1 genotype is similar to 
the carnosine levels of the subjects with the 5-6 CNDP1 genotype, in both M. soleus, 
gastrocnemius and tibialis anterior (0.393 ≤ p ≤ 0.576). Likewise, there is no correlation 
between muscle carnosine levels and the activity of the carnosine degrading enzyme in 
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Figure 6. a/ Mean (± SD) plasma carnosinase activity (µmol/ml/h) categorized by amount of leucine repeats in 
CNDP1 gene of both 82 males and 55 females. b/ The carnosine content of individuals with the 5-5 CNDP1 
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Carnosine is synthesized in skeletal muscles from histidine and beta-alanine, with the 
latter being the rate-limiting precursor. It is demonstrated that an increased availability 
of beta-alanine, by means of oral supplementation, results in higher muscle carnosine 
levels (for review see: (8; 37). This is the first peer-reviewed study which shows that a 
complete and long-lasting restriction of beta-alanine from the diet, as is the case in 
habitual vegetarians (lacto-ovo or vegan, > 8 yrs), results in lower intramuscular carnosine 
concentrations as compared with omnivorous subjects. In a proceedings abstract by 
Harris et al. (16), it was shown that female vegetarians have a 45% lower carnosine 
content in M. vastus lateralis compared with male sports science students. We observed 
a 26% lower carnosine content in the gastrocnemius of male vegetarians compared to 
male omnivores. The lower muscle carnosine levels in vegetarians implies that it may 
be important for vegetarian athletes, involved in high-intensity exercise, to compensate 
a possible shortage of muscle carnosine by means of beta-alanine supplementation, 
as also recommended for creatine (13). However, the decreased intramuscular total 
creatine content in vegetarians versus omnivores is less pronounced, namely 11.1% (7). 
As there is no difference in muscle carnosine content between individuals with a higher 
or a lower beta-alanine intake within a normal western omnivore diet, we can conclude 
that only the supplementation with very high doses of beta-alanine and the complete 
and prolonged restriction of beta-alanine from the diet does influence the carnosine 
content.
This study confirms the higher muscle carnosine content in males versus females 
shown by Mannion et al. (26), but in the currently studied muscles of the lower leg, 
the gender-based differences are even more pronounced (28-82%), compared to the 
differences in M. quadriceps femoris of the previous study (21%). To the best of our 
knowledge, no other metabolite in the muscle shows such a large gender-dependent 
difference. In that light, it is interesting that a sex-specific effect was seen in the relation 
between diabetic nephropathy and the CNDP1 genotype (30). Additionally, this gender 
difference could contribute to the lower high-intensity exercise capacities of women 
compared to men. Besides the effect of gender on the muscle carnosine content, there 
is also a negative correlation between age and muscle carnosine content. Stuerenburg 
et al. (42) described a correlation coefficient of -0.4 in patients with neuromuscular 
diseases ranging from 20 to 80 years. This study is the first that shows this negative 
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correlation in a healthy adult population (19-47 years). Our cross-sectional data suggest 
a decline in soleus carnosine content of 1.2%/yr. However, the majority of the subjects 
are younger than 30 years and the confirmation of these data in an older healthy adult 
population is recommended. A number of possible factors exist as to why the carnosine 
levels are affected by gender and age. We hypothesize that both muscle fiber type 
and circulating androgen levels could be responsible for this gender and age based 
distinction in muscle carnosine levels. 
Despite the conflicting reports regarding the percentage muscle fiber type proportion 
amongst gender and age, it is generally acknowledged that women and elderly people 
are characterized with a smaller cross-sectional area of muscle fibers which is most 
pronounced in fast-twitch fibers (38; 39). Women have 56% smaller cross-sectional area 
(CSA) of type IIB/X muscle fibers in comparison with men, whereas this gender-induced 
difference is only 14% in slow-twitch muscle fibers (38; 39). As already mentioned 
in the introduction, fast twitch muscle fibers are characterized by 30 - 100% higher 
carnosine levels compared to slow-twitch muscle fibers (15; 18; 23). Thus, it is possible 
that women and elderly people have lower carnosine levels as a result of a smaller 
proportion of fast twitch muscle fibers compared to young men. 
The hypothesis that circulating androgen levels could affect the muscular carnosine 
levels is based on the study of Penafiel et al. (33) in which they successfully manipulated 
the carnosine content of murine skeletal muscles by means of subcutaneous testosterone 
injections in female mice and by removing the testes in male mice. However, we found no 
correlation between the plasma (free) testosterone levels and muscle carnosine content 
within a healthy male population. Nevertheless, this does not exclude the possibility 
that more extreme variations in total or free testosterone, such as overt hypogonadism 
or exogenous testosterone supplementation do influence muscle carnosine content. 
This argumentation is supported by the two-fold higher muscle carnosine content of 
the bodybuilders in the study of Tallon et al. (46), in which 5 of the 6 subjects reported 
to have taken anabolic steroids in the last 6 months. 
The observed influence of vegetarianism, gender and age on carnosine content seems 
to depend on the muscle type under investigation. The gastrocnemius muscle is most 
affected by dietary beta-alanine restriction, the tibialis anterior is the muscle that 
displays the largest sexual dimorphism and the age-related effect on muscle carnosine 
content is only observed in soleus. Muscle-specific differences in expression profiles of 
e.g. enzymes of carnosine metabolism, amino acid transporters or androgen receptors 
could be hypothesized. 
7
144
In line with previous reports, we observed that the CNDP1 polymorphism affects the 
plasma carnosinase activity. The higher activity of the carnosine degrading enzyme 
for the 5-6 and the 6-6 CNDP1 genotypes compared to the homozygosity for the 
Mannheim allele (5-5) is confirmed (20; 29). However, it has to be noted that there 
is a high variation in plasma carnosinase activity within one genotype group (e.g. a 
range of 2-10 µmol/ml/h in 5-5 genotype). Remarkably, individuals with the 6-7 CNDP1 
genotype have a significantly lower carnosinase activity than individuals with the 6-6 
variant. This is in contrast with the suggestion of Janssen et al. (20) that both the 6 
and 7 leucine alleles can be regarded as gain-of-function mutations associated with a 
higher enzyme activity and with the results of Riedl et al. (36) that the percentage of 
secreted carnosinase increases with increasing length of the leucine repetitions in the 
signal peptide. Variations of natural inhibitors of carnosinase such as homocarnosine 
may account for additional fluctuations in enzyme activity (34). Furthermore, the results 
of this study reveal that females are characterized with a higher plasma carnosinase 
activity versus males, confirming and strengthening the non-significant gender-based 
differences in plasma carnosinase levels which were previously reported (4; 34). Despite 
the combination of declined muscle carnosine levels and a higher activity of the plasma 
carnosinase enzyme in both women and elderly people (34), we shown no inverse 
relationship between both parameters in a gender - and age - mixed population. 
Similarly, also the polymorphism of the CNDP1 gene does not determine the muscle 
carnosine levels. A different compartimentation could underlie this finding, as carnosine 
is mainly present in the muscle and the enzyme carnosinase is present in the circulation 
but not (active) in the muscle. Additionally, muscle carnosine could be more sensitive 
to the carnosine synthetase activity than to the carnosinase activity. However, we are 
aware that our population is probably too small to completely exclude the possibility 
that muscle carnosine is related to CNDP1 genotype. It is therefore necessary to confirm 
these data in a larger population with a relevant number of subjects with less common 
genotypes (5-7, 6-6, 7-7).
In conclusion, the results of this study provide evidence for (I) a declined muscle 
carnosine content in vegetarians which implies that it may be important for vegetarian 
athletes, involved in high-intensity exercise, to compensate a possible shortage of muscle 
carnosine by means of beta-alanine supplementation, (II) a marked sexual dimorphism 
in muscle carnosine levels and plasma carnosinase activity and (III) an independency 
of the muscle carnosine content to the polymorphism of the CNDP1 gene and the 
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Diabetic nephropathy is a severe complication of both type 1 and type 2 diabetes. In this 
thesis, several aspects of diabetic kidney disease relating histopathology, genetics and 
carnosine metabolism, were investigated. 
In chapter 2 we developed a histopathologic classification scheme for diabetic 
nephropathy in type 1 and type 2 diabetes. The classification system is based on 
glomerular lesions, consisting of four classes and reflecting the natural course of diabetic 
nephropathy. Class I “Glomerular Basement Membrane Thickening (GBM)” consists 
of isolated glomerular basement membrane thickening and only mild, non-specific 
changes by light microscopy that do not meet the criteria of classes II through IV. Class 
II “Mesangial expansion, mild or severe” is characterized by glomeruli with mild or 
severe mesangial expansion but without nodular sclerosis (Kimmelstiel-Wilson lesions) 
or global glomerulosclerosis in more than 50% of glomeruli. A biopsy is classified in 
class III “Nodular sclerosis (Kimmelstiel-Wilson lesions)” if at least one glomerulus 
with nodular sclerotic lesion (Kimmelstiel-Wilson lesion) is present without changes as 
described in class IV. Class IV “Advanced diabetic glomerulosclerosis” is characterized by 
more than 50% global glomerulosclerosis with clinical or pathological evidence that the 
sclerosis is attributable to diabetic nephropathy. We chose a classification scheme based 
on glomerular lesions because these seem to reflect the natural cause of progressive 
diabetic nephropathy (1). Furthermore, glomerular lesions are easy to recognize, which 
is also reflected in the good interobserver agreement of this classification scheme. 
Interstitial lesions also contribute to the decline in renal function in diabetic 
nephropathy, and may be independent factors in the progression of diabetic nephropathy 
(2). Many studies have shown that the severity of chronic interstitial and glomerular 
lesions are closely associated (3-6). In our classification scheme a separate evaluation 
was developed for interstitial and vascular lesions.
A classification system for histopathological lesions in diabetic nephropathy that 
can be used in both type 1 and type 2 diabetes was proposed, as it is now generally 
recognized that there is substantial overlap between these two types with respect 
to histological lesions and renal complications (2;6). Various studies report that the 
proportion of non-diabetic nephropathies is higher in type 2 diabetic nephropathy 
(7;8). However, studies which investigated protocol biopsies, did not show such a high 
proportion of other kidney diseases. Most likely this is due to the fact that in some 
clinical practices, there is a policy only to perform a renal biopsy to exclude causes of 
renal disease characterized by proteinuria other than diabetic nephropathy, therefore 
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selecting for a high proportion of other kidney diseases. The classification system 
proposed in chapter 2 is meant for diabetic nephropathy only, but it can also serve to 
classify diabetic nephropathy when it is complicated by a superimposed other disease. 
An important question for every histological classification system is whether it is 
predictive of clinical outcome. The classification scheme proposed in chapter 2 can be 
used to evaluate protocol biopsies. It would be an interesting undertaking to set up 
a prospective study, preferably including protocol biopsies of patients with both type 
1 and type 2 diabetes, with clearly defined clinical endpoints. Archived renal biopsies 
with diabetic nephropathy performed for many different clinical indications, at many 
different time points during the course of the disease and clinical follow-up, were not 
always readily available. With the increasing demand for classifying the severity of 
diabetic nephropathy, we advocate a study with protocolized biopsies as previously 
mentioned. Furthermore, the reproducibility of the classification scheme should be 
thoroughly investigated, to clarify if it is indeed suitable for clinical practice. 
Chapter 3 is focused on the genetic component of diabetic kidney disease. Many 
genes have been investigated in diabetic nephropathy, but it is unclear which genetic 
variants are reproducibly associated with diabetic nephropathy. For this study, all 
genetic variants which were associated with diabetic nephropathy and replicated in 
an independent dataset were selected from the literature. All subsequent studies of 
these reproduced variants were sought and were combined in a random-effects meta-
analysis. In this study, we found a set of 21 genetic variants which were associated 
with advanced diabetic nephropathy. Three additional variants were associated in 
specific subgroups; type of diabetes, stage of diabetic nephropathy and ethnic group. 
Variants in or near ACE, AKR1B1 (2 variants), APOC1, APOE, EPO, NOS3 (2 variants), 
HSPG2, VEGFA, FRMD3 (2 variants), CARS (2 variants), UNC13B, ‘CPVL and CHN2’, 
and GREM1 (as well as four variants not near to known genes) were associated with 
diabetic nephropathy and CCR5 (Asians), ELMO1 (Asians) and CNDP1 (type 2 diabetes) 
in a subgroup. These results support roles for angiotensin converting enzyme, aldose 
reductase, apolipoproteins C1 and E, oxidative stress with carnosine, nitric oxide and 
engulfment and cell motility protein 1 as possible key players. Furthermore, it suggests a 
role for inflammation with a key role for chemokine receptor 5, angiogenesis with a role 
for vascular endothelial growth factor and erythropoietin, glomerular filtration barrier 
defects in heparan sulphate proteoglycans, apoptosis through unc-13 homolog B and 
cell growth and differentiation mediated by gremlin 1 in the pathogenesis of diabetic 
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nephropathy. Functional studies remain to be performed to establish the precise role of 
these variants and pathways. Genetic variants initially identified using a genome-wide 
association approach in and near the FRMD3, CARS, ELMO1 and ‘CPVL and CHN2’ 
were detected. Despite their value in locating the vicinity of genomic variants that may 
be causing diabetic nephropathy, these variants are unlikely to be causative variants 
themselves (9). A first step in narrowing a genome wide signal to potentially causative 
variants is to study all the known SNPs which are inherited with the SNP found in the 
genome wide association scan and investigate if one of these variants has a stronger 
association with diabetic nephropathy. The functional effect of this variant can then 
be studied. However, the association can also be explained by rare variants and then 
extensive sequencing is indicated.
It should also be acknowledged that by selecting only genetic variants that were 
associated with diabetic nephropathy and where independent replication was available, 
genetic variants with smaller effect sizes may have been missed. An effect that may 
have proven significant using pooled analyses. However, by selecting only those genetic 
variants reproducibly associated with diabetic nephropathy, we reduced the chances of 
describing false positive associations. 
Furthermore, diabetic nephropathy can be prevented or at least delayed by early 
treatment with angiotensin converting enzyme inhibitors and angiotensin receptor 
blockers (10). This might result in diabetes patients who are genetically susceptible to 
diabetic nephropathy but now enter the control group due to successful treatment. This 
leads to an underestimation of the estimated effect of the genetic variant in relation to 
diabetic nephropathy. 
Chapters 4, 5 and, 6 are focused on one genetic variant associated with diabetic 
nephropathy, the CNDP1 gene. Janssen et al. (11) found that the 5-5 homozygous 
genotype of the CNDP1 gene is associated with a reduced risk of developing diabetic 
nephropathy. This finding was confirmed in a large study conducted by Freedman et al. 
in European American patients and end-stage diabetic nephropathy (12). The presence 
of more than 5 leucine repeats has been shown to lead to higher serum carnosinase 
secretion (13) and more serum carnosinase activity (11). Serum carnosinase degrades 
carnosine. Carnosine has been shown to delay senescence in cultured human fibroblasts 
and temporarily reverse the senescence phenotype (14;15). Carnosine is further known 
to scavenge reactive oxygen species, degrade advanced glycation end products (AGE) 
(16), inhibit angiotensin converting enzyme (ACE) (17), and reduce the TGF-β induced 
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synthesis of extracellular matrix components (11). All these properties have protective 
effects in a diabetic environment.
Chapter 4 reports the 5-5 homozygous CNDP1 genotype frequency in three ethnic 
groups in the Netherlands; South Asian Surinamese, African Surinamese and White 
Dutch. We found that the frequency of the protective genotype for diabetic nephropathy, 
5-5 homozygous genotype, was significantly lower in South Asian Surinamese compared 
to white Dutch and African Surinamese. This finding was confirmed in an independent 
South Asian Surinamese sample. This low frequency of the 5-5 homozygous genotype 
found in South Asian Surinamese is likely to be associated with the higher occurrence 
of diabetic nephropathy in South Asian populations (18-20). This is further supported 
by the finding that carnosinase activity increases with the amount of leucine repeats 
among South Asian Surinamese, similar to Caucasians (11). Finally we showed that 
carnosinase was expressed in kidney, supporting a role for carnosine in the kidney. 
Although a direct link between the CNDP1 gene and diabetic nephropathy still needs 
to be assessed, this study suggests that the high diabetic nephropathy occurrence in 
South Asian Surinamese can be partially attributed to the lower frequency of the 5-5 
homozygous genotype in this population. 
In chapter 5, we showed a sex-specific effect of the CNDP1 genotype in relation to 
diabetic nephropathy, suggesting that the 5-5 homozygous genotype is only protective 
in women. The frequency of the 5-5 homozygous genotype was determined in three 
independent diabetic nephropathy groups. These groups were compared with two 
control groups; diabetes patients with a low risk of ever developing diabetic nephropathy 
and a sample from the general population. The former diabetic control group is generally 
used in the literature, and investigates the relevance of the gene to disease etiology. 
Compared with this diabetic control group, the 5-5 homozygous genotype frequency 
was significantly lower in women with diabetic nephropathy in all three cohorts, but 
not in men. The population control group serves to estimate the genotype risk for the 
population, showing that women with the 5-5 homozygous genotype have a 2-fold 
reduced risk of ever developing diabetic nephropathy. Furthermore, this study reports 
similar frequencies in type 2 diabetes patients and the general population, showing 
that this association is independent of a genetic susceptibility for type 2 diabetes. 
Although the mechanism behind the sex-specificity still needs to be elucidated, this 
study indicates that the association between the CNDP1 gene and diabetic nephropathy 
is gender specific. 
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Carnosine is protective against oxidative stress and hemodynamic damage and this is not 
confined to diabetic nephropathy. In chapter 6 the relation between other glomerular 
diseases and the CNDP1 gene was investigated. Our results suggest that a higher number 
of leucine repeats in the CNDP1 genotype is associated with a faster progression to 
end stage renal disease in patients with reduced kidney function arising from chronic 
glomerular inflammatory renal diseases and in patients with renal vascular disease. In 
line with these results, the mortality risk was increased in chronic glomerulonephritis 
patients with a higher repeat number, which was also associated with higher serum 
carnosinase levels. Our data show a correlation between the leucine repeat distribution 
of the CNDP1 gene and renal vascular disease; however, there was no relationship 
with survival. As predicted, patients who developed end stage renal disease because 
of either polycystic kidney disease or tubulointerstitial nephritis had a CNDP1 genotype 
distribution similar to that of healthy controls. These findings support the hypothesis 
that the high leucine repeat number in CNDP1 may contribute to microvascular damage. 
Although this finding has to be replicated in an independent cohort, this study suggests 
that there is also a role for carnosine in other glomerular diseases. 
In chapter 7 we investigated determinants of muscular carnosine levels. As high 
carnosine levels are thought to be advantageous, it is important to understand the 
underlying factors. We studied the relation between muscular carnosine levels and 
serum carnosinase activity, CNDP1 genotype, age, vegetarian diet and muscle fiber type. 
Serum carnosinase activity did reduce the carnosine content, but possibly due to the 
small number of investigated subjects no relation was shown with the CNDP1 genotype. 
Carnosine content was found to decline with age, which could not be explained by the 
age-related increase in carnosinase activity. Meat-restriction for 8 weeks had no effect 
on carnosine levels, but in (long-term) vegetarians lower muscular carnosine levels were 
observed. There was no linear relationship with muscular fiber type and carnosine levels. 
In addition, the relation with gender in the carnosine metabolism was studied. 
Women showed higher carnosinase activity than men and men had higher carnosine 
levels. This is in line with the idea that from an evolutionary point of view carnosine 
levels are more beneficial to men. This can be explained by the greater muscular activity 
needed for males to hunt for food, since carnosine is a buffer for the substances derived 
from lactic acid that are produced under anaerobic conditions. However, no relation 





The relation between diabetic nephropathy due to type 2 diabetes and the leucine 
repeat in exon 2 of the CNDP1 gene seems to be established. Interesting would be 
to speculate on what this finding can eventually mean for the diabetic nephropathy 
patient. The possible relevance of the CNDP1 genotype in diabetic nephropathy can be 
roughly divided in two groups; genotypic screening for diabetes patients to be able to 
predict the risk of developing diabetic nephropathy and novel biological insight in the 
etiology and pathogenesis of diabetic nephropathy, potentially leading to new therapies 
(21). 
For screening of individuals with an increased risk of disease, the measurement of 
area under the curve (AUC) of the receiver operating characteristic curve (ROC) is often 
used. An AUC of 1 is perfect prediction and an AUC of 0.5 is similar to tossing a coin, 
and therefore not predictive. It has been suggested that an AUC above 0.75 can be 
considered of predictive value. For pre-symptomatic diagnosis of the general population 
the AUC should be > 0.99 (22). The CNDP1 genotype could be used in a genotypic risk 
score, together with other associated variants related to diabetic nephropathy due to 
type 2 diabetes. In diabetic nephropathy no such genotypic scores have been tested 
in contrast to screening for type 2 diabetes. In type 2 diabetes, 18 genetic variants 
have been established and these genetic variants when combined have shown to reach 
an AUC of 0.6 in predicting type 2 diabetes onset. This is low when compared to 
traditional risk factors as only BMI, age and gender which have shown to have an AUC 
of 0.78 and risk scores, such as the QDS score (a scoring algorithm based on traditional 
risk factors without the need for laboratory tests) reaches an AUC of 0.85 in predicting 
type 2 diabetes onset (23). In a different study, the addition of genetic risk factors to 
clinical risk showed only a slight increase of the AUC (from 0.74 to 0.75), which seems 
to increase with duration of follow up (24). This indicates that genetic personalized 
medicine in type 2 diabetes will not easily be achievable in the near future. However, in 
diabetic nephropathy this still needs to be investigated. 
Novel biological insight can, in the most fortunate case, lead to new therapeutic 
targets. The association between diabetic nephropathy and CNDP1 (carnosinase) 
gene, would suggest a role for this enzyme and its substrate (carnosine) in diabetic 
nephropathy. It was shown that the genotype leading to the lowest carnosinase activity, 
leaving more carnosine, was associated with a reduced risk of diabetic nephropathy. 
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This suggests that a possible new therapeutic target for diabetic nephropathy would 
be increasing carnosine level in diabetes patients. This could be done by supplementing 
carnosine, reducing the degradation of carnosine by inhibiting carnosinase, or increasing 
carnosine production by carnosine synthase. 
Supplementing carnosine would be an interesting treatment for patients with 
diabetic nephropathy. Carnosine has been known for its many protective capacities in 
a diabetic environment and is well tolerated. Carnosine and related compounds have 
already been used as therapies for cataract (25;26) and gastric ulcers (27). In diabetic 
mice treated with angiotensin converting enzyme inhibitors, adding carnosine to the 
diet led to a significant reduction in proteinuria compared to diabetic mice treated with 
only angiotensin converting enzyme inhibitors (28). In humans, carnosine seems to be 
hydrolyzed within 2 hours after carnosine is absorbed by the intestine and enters the 
bloodstream (29). However, when Parkinson patients were treated with carnosine in 
addition to dopamine (L-dopa), they had a decreased level of protein carbonyls in their 
blood plasma and increased levels of red cell superoxide dismutase compared to patients 
treated with only dopamine (L-dopa) (30). This suggests that supplementation with 
carnosine has a biochemical effect after oral intake even though carnosine is hydrolyzed 
quickly in serum. This means that carnosine supplementation could theoretically also be 
of therapeutic value in diabetic nephropathy. 
An inhibitor of carnosinase activity is homocarnosine (31). In the literature, no studies 
have been performed in which patients were treated with homocarnosine. Although 
we would expect that homocarnosine treatment could reduce the serum degradation 
of carnosine, high concentrations of homocarnosine might lead to high concentrations 
of its degradation products gamma-aminobutyric acid (GABA) and histidine. Histidine 
can be easily converted into histamine and the impact on autonomic nerve activity 
would be unpredictable. It might result in further progression of renal insufficiency, 
since progressive renal disease has been shown to be associated with increased nerve 
activity (31). Future studies could also be focused on the regulation of the carnosinase 
gene, finding substances which downregulate the expression of CNDP1.  
Recently the gene coding for carnosine synthase has been identified as a ATP-
grasp domain containing protein 1 (ATPGD1) (32). The identification of this gene is an 
essential step in the understanding of carnosine production. It would for example be 
interesting to investigate in which organs this gene is expressed, and especially if it is 
expressed in the kidney; if so, in which cells of the kidney. Furthermore, the creation 
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of knockout mice or mice in which carnosine synthase is overexpressed, could help 
define the role of carnosine as a buffer, antioxidant, antiglycator and neurotransmitter, 
of which evidence now mostly comes from in vitro studies. It would be interesting 
to investigate whether overexpressing carnosine synthase in a diabetic kidney disease 
model, would lead to a milder phenotype of diabetic nephropathy. Finally, it would be 
interesting to investigate which substances upregulate carnosine synthase, leading to 
higher carnosine production and a possible therapeutic potential. 
Most simple and safe would be to investigate carnosine treatment in diabetic 
nephropathy, before considering other substances. However, before starting treatment 
with carnosine, it might be advisable to first understand more about the mechanisms 
of carnosine metabolism. In chapter 5 of this thesis, a sex-specific effect of the relation 
between diabetic nephropathy and the CNDP1 genotype was found. It would be 
interesting and important to understand the mechanism behind this sex-specific effect. 
A sex-specific effect has long been described in renal disease (33). In non diabetic 
progressive chronic kidney disease, female sex is thought to be protective. However, 
this advantage seems to be lost in diabetic nephropathy. The protective effect in non 
diabetic renal disease has been ascribed to the effect of estrogens (34). Female diabetes 
patients seem to have lower estrogens levels (35) and that may explain the loss of 
female protection in diabetic nephropathy. However, the relationship between sex and 
diabetic nephropathy seems to be more complicated. Several risk factors have been 
described to be involved in men while others are present in women (36-38). Of these 
risk factors, several genetic risk factors (37;39;40) have been documented to be either 
only involved in women or in men, but these findings have not yet been replicated. In 
this study, we detected an association in only women and could independently replicate 
this finding, providing evidence for a sex-specific component in the genetics of diabetic 
kidney disease. 
With an increasing number of leucine repeats (6 or 7 instead of 5) in exon 2 of 
the CNDP1 gene, carnosinase activity increases (11). The 5-5 homozygous genotype 
leads to lower carnosinase activity than that seen in the other genotypes (11), leaving 
more carnosine free to protect the kidney from oxidative stress. Since men have 
higher carnosine levels in their muscle tissue and women have slightly higher serum 
carnosinase levels (41), differences in carnosinase activity due to the different CNDP1 
polymorphisms may have a stronger impact in women. 
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Another explanation for the sex-specific effect found in this study is that the association 
between the CNDP1 gene and diabetic nephropathy is lost in men due to selective 
survival by cardiovascular disease. As carnosine has shown to be protective against 
oxidative stress and hemodynamic damage (11;16;42), this might also explain its role in 
cardiovascular death in diabetic nephropathy patients. Men with diabetic nephropathy 
due to type 2 diabetes have a higher risk for cardiovascular disease than female 
diabetic nephropathy patients due to type 2 diabetes (43), therefore this might be 
more prominent in men. In this thesis we found that men with a diabetes duration 
< 10 years and the 5-5 homozygous genotype have a significantly lower mortality 
risk due to cardiovascular disease than patients with more than 10 leucine repeats in 
the CNDP1 genotype. We found no difference in cardiovascular death between the 
different genotypes in women. This finding needs to be replicated, before drawing 
definite conclusions. 
The two hypotheses are clearly different. According to the first hypothesis, carnosine 
seems to be mainly beneficial in women and suggests that future research should 
only focus on investigating carnosine metabolism in female diabetic nephropathy 
patients. The second hypothesis suggests that carnosine might also be protective in 
macrovascular complications of diabetes and that the sex-specific effect is in fact due to 
different survival between the sexes. Therefore, it would be helpful to understand the 
mechanism behind this sex-specific effect for future therapeutic studies. 
In summary, the role for the CNDP1 genotype in the prediction for diabetic 
nephropathy due to type 2 diabetes is probably limited. On the other hand, the 
potential new additional treatment for type 2 diabetes patients with carnosine to either 
prevent or slow down the progression of diabetic nephropathy should be investigated. 
Furthermore, it is essential to understand the mechanism behind the sex-specific effect 
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Diabetes mellitus, ook wel suikerziekte genoemd, is een ziekte waarbij de patiënt 
een tekort of relatief tekort heeft aan het hormoon insuline. Insuline zorgt ervoor 
dat suiker vanuit het bloed wordt opgenomen in het lichaam. Het woord diabetes 
mellitus is afgeleid van zowel Grieks als Latijn, ‘dia’ (=δια) betekent ‘door’ en bainein 
(=βαινειν) betekent ‘stromen/gaan’. Het woord mellitus komt uit het Latijn en betekent 
honingzoet. Diabetes mellitus betekent dus ‘honing zoete doorstroom’, wat duidt op 
het verhoogde suikergehalte in bloed en urine. 
Er zijn verschillende vormen van diabetes mellitus, waarbij de meest voorkomende 
type 1 diabetes mellitus (ook wel jeugddiabetes of insuline afhankelijke diabetes 
genoemd) en type 2 diabetes mellitus (ook wel ouderdomsdiabetes of insuline 
onafhankelijke diabetes genoemd) zijn. Bij type 1 diabetes mellitus worden de insuline-
producerende cellen in de alvleesklier door het lichaam afgebroken en is de patiënt 
levenslang afhankelijk van insuline toediening. Bij type 2 diabetes mellitus is sprake 
van een combinatie van insuline resistentie, een fysiologische conditie waarbij insuline 
minder effectief wordt in het verlagen van het bloedsuikergehalte, en verminderde 
insuline aanmaak. Type 2 diabetes mellitus is geassocieerd met overgewicht en afvallen 
is dan ook de beste therapie. Verder zijn er middelen om de insuline resistentie of 
de suiker opname te verlagen. Mocht dit niet voldoende werken, dan worden deze 
patiënten ook met insuline behandeld.  
Alle vormen van therapie zijn er op gericht om hoge bloedsuikerspiegels te 
normaliseren. Als de suikerspiegels in het bloed langdurig te hoog zijn, leidt dit tot 
schade aan de bloedvaten. Deze schade is de oorzaak van latere complicaties die 
kunnen optreden bij diabetes mellitus. De complicaties zijn grofweg in te delen in 
aantasting van de kleine vaten (diabetische nier- en oogziekte en diabetische voet), grote 
vaten (hartziekte) en zenuwen (verminderd gevoel in handen en voeten, verminderde 
maaglediging). Dit promotieonderzoek richt zich op diabetische nierziekte. 
Diabetische nierziekte is de belangrijkste oorzaak van terminaal nierfalen, waarbij 
een transplantatie of dialyse noodzakelijk is. Diabetische nierziekte begint met een 
compensatoire hyperfiltratie van de zeeflichaampjes van de nier, de glomeruli, die het 
bloed filteren. Onder de microscoop is dan een verdikking van de basaalmembraan 
van glomeruli te zien. Later treedt eiwitverlies in de urine op. Naar mate de ziekte 
vordert zal aanzienlijk eiwitverlies optreden, ook wel proteïnurie genoemd. Als laatste 
neemt de functie van de nier af tot het punt waarop deze onvoldoende functioneert 
en dialyse of transplantatie noodzakelijk is. Histologisch treedt na verdikking van de 
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basaalmembraan toename van het mesangium op. Het mesangium is onderdeel van 
de glomerulus en zorgt voor onder andere de stevigheid en beweeglijkheid van het 
vaatbed in de glomerulus. In een later stadium treden ook de zogenaamde Kimmelstiel-
Wilson laesies op. Dit zijn nodulaire ophopingen waarvan men nog niet precies de 
ontstaanswijze weet. Als laatste treedt verbindweefseling van de hele glomerulus op, 
zogenaamde glomerulosclerose. 
In hoofdstuk 2 wordt een histopathologische classificatie van diabetische nierziekte 
voorgesteld, gebaseerd op het bovengenoemde ziektebeloop. Klasse I is gedefinieerd 
als basaalmembraan verdikking van de glomeruli en een verder normale histologie. 
Een biopt wordt in klasse IIa of b geclassificeerd bij respectievelijk milde of ernstige 
mesangiale toename. Een biopt wordt als klasse III gescoord als het minimaal één 
overtuigende Kimmelstiel-Wilson laesie bevat. Klasse IV bevat het laatste stadium met 
glomerulosclerose in meer dan 50% van de glomeruli in het biopt. Deze classificatie 
is opgesteld door een internationale groep van experts en is de eerste pathologische 
classificatie voor diabetische nierziekte die bruikbaar is voor klinische doeleinden. Deze 
classificatie geldt voor zowel diabetische nierziekte door type 1 als door type 2 diabetes 
mellitus. De classificatie zal nog moeten worden getest op reproduceerbaarheid en 
klinische relevantie.   
Als diabetische nierziekte optreedt, gebeurt dat meestal ongeveer 10 jaar na het 
ontstaan van diabetes mellitus. Sommige patiënten zijn gevoeliger voor deze complicatie 
dan anderen en het blijkt dat patiënten die 15 jaar na het ontstaan van diabetes nog 
geen diabetische nierziekte hebben ontwikkeld, een grote kans hebben om dit later 
ook niet meer te ontwikkelen. Dit, tesamen met de bevinding dat diabetische nierziekte 
clustert in families en de prevalentie van diabetische nierziekte verschilt tussen etnische 
groepen, heeft tot het idee geleid dat een genetische predispositie bestaat voor het 
ontwikkelen van diabetische nierziekte. 
In het werk beschreven in hoofdstuk 3 van dit proefschrift werd de medische 
literatuur onderzocht op zoek naar genetische varianten geassocieerd met diabetische 
nierziekte. Er zijn veel onderzoeken gepubliceerd over genetische varianten die mogelijk 
geassocieerd zijn met diabetische nierziekte. Een groot deel hiervan kon tot dusver 
niet worden gereproduceerd en berust waarschijnlijk op toeval. Zodoende werden in 
deze meta-analyse alleen de genetische varianten meegenomen waarvoor tenminste 
in twee onafhankelijke onderzoeken een associatie werd gevonden met diabetische 
nierziekte. Op het moment dat een genetische variant meermalen geassocieerd was 
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met diabetische nierziekte werden alle studies met betrekking tot deze genetische 
variant verzameld en samengenomen in de meta-analyse. Een meta-analyse is een 
statistische methode om resultaten van verschillende studies te kunnen samennemen. 
De genetische varianten die in de meta-analyse significant geassocieerd waren met 
diabetische nierziekte waren gelegen in of dichtbij de volgende genen: ACE, AKR1B1 
(2 varianten), APOC1, APOE, EPO, NOS3 (2 varianten), HSPG2, VEGFA, FRMD3 (2 
varianten), CARS (2 varianten), UNC13B, CPVL/CHN2, en GREM1. Verder waren er 
nog genetische varianten geassocieerd met diabetische nierziekte in alleen type 2 
diabeten en Aziaten. Het betreft genetische varianten in de volgende genen: CCR5 en 
ELMO1 bij Aziaten en CNDP1 in type 2 diabetes mellitus. Verder onderzoek naar het 
werkingsmechanisme van deze genen in relatie tot diabetische nierziekte kan leiden tot 
nieuwe inzichten in de ontstaanswijze en het ziektebeloop van diabetische nierziekte en 
nieuwe behandelingsmogelijkheden.
Hoofdstukken 4, 5 en 6 gaan over één van de genen die in hoofdstuk 3 beschreven 
zijn, namelijk het CNDP1 gen. CNDP1 codeert voor het enzym carnosinase. Dit is een 
enzym dat de stof carnosine afbreekt. Carnosine is een dipeptide, met verscheidene 
beschermende effecten. Het is een antioxidant, maar kan ook werken als een buffer, 
als een potentiële bloeddrukverlager. Daarnaast helpt het mesangiale matrix-eiwitten 
expansie voorkomen en het kan producten die ontstaan door te hoog suiker in het bloed 
helpen afbreken (de zogenaamde advanced glycation end products). Er is een genotype 
van dit gen, de 5-5 homozygoot, dat leidt tot een verminderde carnosinase secretie uit 
de cel, hetgeen weer leidt tot verminderde carnosinase activiteit in het bloed. Hierdoor 
wordt er minder carnosine afgebroken en blijft er meer carnosine over om met name 
de nier te beschermen tegen complicaties. Uit eerdere studies is gebleken dat type 2 
diabetes mellitus patiënten met het 5-5 homozygoot genotype een 2 maal verlaagde 
kans hebben op het ontwikkelen van diabetische nierziekte. Bij type 1 diabetes mellitus 
is deze relatie niet gevonden.
In het werk beschreven in hoofdstuk 4 werd de frequentie van het 5-5 homozygoot 
CNDP1 genotype in meerdere etnische groepen onderzocht: Creoolse Surinamers, 
Hindoestaanse Surinamers en blanke Nederlanders. De Hindoestaanse Surinamers 
hebben vaker diabetes mellitus en diabetische nierziekte. Het is dan ook met name 
deze populatie die een lagere frequentie had van het beschermende genotype, de 5-5 
homozygoot. Deze bevinding konden wij reproduceren in een onafhankelijke groep 
van Hindoestaanse Surinamers. Verder is gekeken naar de relatie tussen het CNDP1 
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genotype en de carnosinase activiteit in de Hindoestaanse Surinamers. Net als bij 
blanke Nederlanders, hebben Hindoestaanse Surinamers met het 5-5 homozygoot 
genotype een lagere carnosinase activiteit. De lagere frequentie van het beschermende 
5-5 homozygoot genotype bij Hindoestaanse Surinamers zou één van de verklaringen 
kunnen zijn waarom deze populatie een verhoogd risico heeft op het ontwikkelen van 
diabetische nierziekte. 
In het werk beschreven in hoofdstuk 5 werd onderzocht of de relatie tussen 
diabetische nierziekte en het CNDP1 gen verschilt tussen mannen en vrouwen. In deze 
studie zijn mannen en vrouwen met diabetische nierziekte afzonderlijk vergeleken met 
respectievelijk mannen en vrouwen met diabetes mellitus gedurende meer dan 15 jaar 
zonder diabetische nierziekte. Aangezien uit eerdere studies is gebleken dat er alleen een 
relatie bestaat met type 2 diabetes mellitus, beperkt deze studie zich tot type 2 diabetes 
mellitus patiënten. Het beschermende effect van het 5-5 homozygoot genotype bleek 
alleen aanwezig bij vrouwen en niet bij mannen. Dit werd in 3 onafhankelijke groepen 
gevonden. Verder werden deze 3 groepen met diabetische nierziekte vergeleken 
met een controlegroep uit de populatie, om een inschatting te kunnen maken over 
wat de kans is dat iemand met het 5-5 homozygoot genotype diabetische nierziekte 
ontwikkelt. Vrouwen met het 5-5 homozygoot genotype hebben een 2 keer kleinere 
kans op het ontwikkelen van diabetische nierziekte, terwijl bij mannen geen relatie met 
diabetische nierziekte werd gevonden. Deze studie laat zien dat alleen bij vrouwen een 
relatie tussen het CNDP1 gen en diabetische nierziekte bestaat, maar de precieze reden 
voor deze bevinding moet nog nader worden onderzocht. 
Aangezien carnosine een antioxidant is en verder veel andere beschermende 
eigenschappen heeft, zou het goed kunnen dat het 5-5 homozygoot genotype ook 
beschermend werkt bij andere nierziektes. Uit het onderzoek beschreven in hoofdstuk 
6 is gebleken, dat bij glomerulaire nierziekte (net als diabetische nierziekte) een relatie 
bestaat met het CNDP1 gen. Ook werd een relatie met mortaliteit bij dialysepatiënten 
en het CNDP1 gen in glomerulonefritis-patiënten gezien.
In het onderzoek beschreven in hoofdstuk 7 werd gekeken naar welke 
determinanten de carnosine concentratie in de spier beïnvloeden. Carnosine is in hoge 
concentraties aanwezig in de spier. Dit onderzoek is uitgevoerd in samenwerking met 
sportwetenschappers in België en heeft een tweeledig doel. Enerzijds om te kijken 
welke stoffen carnosine beïnvloeden voor eventuele verbetering van sportprestaties. 
Anderzijds is deze studie opgezet om meer inzicht te krijgen in het carnosine-metabolisme. 
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Mogelijk kan dit inzicht ook leiden tot nieuwe behandelingsmogelijkheden om carnosine 
spiegels te verhogen ter bescherming van diabetische nierziekte. Verschillende factoren 
die de carnosine-concentratie zouden kunnen beïnvloeden werden onderzocht, 
waaronder carnosinase activiteit in het bloed, CNDP1 genotype, leeftijd, vegetarisch 
dieet en spiervezel type. Er was een verwachte relatie tussen carnosinase activiteit en 
hoeveelheid carnosine, maar niet met het CNDP1 genotype. Carnosine in de spier 
nam af met de leeftijd, wat niet kon worden verklaard door de leeftijd-gerelateerde 
toename van carnosinase. Een vegetarisch dieet gedurende 8 weken had geen effect 
op de hoeveelheid carnosine in de spier. Langdurig vegetarisme heeft echter wel een 
effect op de hoeveelheid carnosine in de spier. Er werd geen relatie gevonden tussen 
het spiervezel type en carnosine spiegels. Verder is het effect van het geslacht op het 
carnosine metabolisme onderzocht. Vrouwen hebben een hogere carnosinase activiteit 
dan mannen en mannen een hogere carnosine concentratie in de spier. Deze bevinding 
zou de basis kunnen vormen voor het in hoofdstuk 5 gevonden geslachtsspecifieke 
effect. Aangezien vrouwen een hogere carnosinase activiteit hebben en relatief weinig 
carnosine, hebben vooral zij baat bij het hebben van een 5-5 homozygoot genotype. De 
mogelijke toename van carnosine spiegels onder invloed van testosteron kon in onze 
studie niet worden aangetoond. 
Samenvattend heeft de inhoud van dit proefschrift nieuw licht geworpen op de 









Chapter 2 – Figure 1. Scoring form for glomerular lesions, extraglomerular lesions and 
other features.
Chapter 3 – ESM Table 2 - Details of the articles which were included in this meta-
analysis study
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Figure 1. Scoring form for glomerular lesions, extraglomerular lesions and 
other features.
RPS DN Working Group score sheet
B. Extraglomerular Lesions Circle score
Case Number Tubular atrophy (%) < 25 % tubular atrophy 0
Pathologist 25-50 % tubular atrophy 1
Date >50 % tubular atrophy 2
Stainings evaluated
EM Avg GBM size (nm) Interstitial fibrosis (%) < 25 % interstitial f ibrosis 0
25-50 % interstitial f ibrosis 1
A. Glomerular lesions Tally mark no. >50 % interstitial f ibrosis 2
Total # of evaluated glomeruli
Normal glomeruli Interstitial inflammation
Global glomerulosclerosis absent 0
Infiltration only in relation to IF or TA 1
Nodular lesions Infiltration in areas without IF or TA 2
Mesangial expansion Large vessels present? Y  /  N
Mild
Severe Arteriosclerosis (score worst artery)
No intimal thickening 0
Classify into glomerular class:     ? intima thickened and < thickness of media 1
Name # Criteria intima thickened and > thickness of media 2
EM proven DN  I GBM > 395 nM (female), > 430 (male) Arteriolar hyalinosis absent 0
Mild Mesangial Expansion II A Mild mesangial expansion in >25% at least one case of arteriolar hyalinosis 1
Severe Mesangial Expansion II B Severe mesangial expansion in >25% >1 case of arteriolar hyalinosis 2
Nodular Sclerosis III At least one convincing nodular lesion
Glomerosclerosis with signs IV Global glomerular sclerosis in >50% of C. Other features
of DN glomeruli in proven DN Capsular drop present  /  absent
Fibrin cap present  /  absent
EM, electronmicroscopy; TA, tubular 
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Increasing stringent definition of DN: women (n) 5-5 homozygous frequency (%)
0 MDRD < 60 220 31
1 MDRD < 60 and age < 70 88 30
2 DN as in manuscript 60 28
3 MDRD < 60 + microalbuminuria 59 27
4 MDRD < 45 52 19
5 MDRD < 45 + microalbuminuria 23 22
6 MDRD < 30 6 17
With increasing stringent definition of the diagnosis diabetic nephropathy the frequency 
of the 5-5 homozygous genotype decreases in women, suggesting that the protective 
effect will only be stronger with a more stringent definition of diabetic nephropathy.
Permutation studies
We first analyzed Hardy-Weinberg Equilibrium (HWE) for the total dataset and various 
subgroups (table 1) to see if there would be indications for population stratification. 
Stratification by sex and disease status does not reveal any deviation from HWE. Hence, 
HWE analysis does not give an indication on population strata. 
Table 1. Tests for deviation from HWE in several subgroups of the data set. Subgroups are characterized by 
Sex (F=female, M=male) and disease status. P-values are given for the Chi-Square goodness of fit test. N 
denotes the sample size in the subgroups.
Sex Disease status p-value N
F no DN 0.53 44
M no DN 0.90 47
Both no DN 0.43 91
F DN 0.56 139
M DN 0.74 128
Both DN 0.95 267
F All 0.92 183
M All 0.48 175




















































As individual ethnicity is not known for all patients in this sample and the sample is in 
almost perfect HWE, it is difficult to construct a permutation scheme that incorporates 
population strata. We therefore first performed a permutation test without incorporating 
population strata by randomly permuting phenotype status across the whole data set. 
Such a procedure can primarily account for small sample size. The permuted P-values are 
lower than P-values based on the asymptotic Chi-Square distribution (table 2), indicating 
that small sample size cannot explain the P-values in our study. The asymptotic P-values 
behave conservative in this situation.
Table 2. P-values for genetic association of the 5-5 genotype in a recessive model. Column Total lists P-values 
for the combined sample (all cases are treated as a single group). 
Total DN group 1 DN group 2 DN group 3
Asymptotic P-value 0.0000358 0.000542 0.00102 0.00689
Permuted P-value 0.0000073 0.000234 0.000444 0.00281
Sensitivity analysis of population stratification
We addressed the question of population stratification by a sensitivity analysis. The 
sensitivity analysis was performed in R version 2.10.0. For all Chi-Square tests a 
continuity correction was used leading to slightly different numeric results compared 
to the paper. The sensitivity analysis is based on the so-called inflation factor used in 
genome wide association studies (Biometrics, 55. p.997-1004, 1999), which assesses 
how much the average/median test statistic of single nucleotide polymorphisms, 
based on a Chi-Square distribution with one degree of freedom, deviates from the 
expectation. If the inflation factor is greater than 1, there is an indication that there 
might be population stratification. This inflation factor can be used to correct results 
from genome wide association studies by dividing the test statistic by the inflation factor, 
thereby assuring that a re-analysis is uninflated. We used this concept to determine how 
large the inflation factor could be in our study to still get significant results at a certain 
significance level (table 3). 
For all groups an inflation of 1.1 is allowed to still achieve a significance of 0.01. An 
inflation factor of 1.1 is larger than the maximal inflation factor observed in the WTCCC 
study (Nature, 447. p.661-678, 2007). The maximal reported inflation factor for a 
genome wide association studies is 1.4 to our knowledge (BMC Proc, 3 Suppl 7. s.13, 
2009) (NARAC study). Note, that group 2 and group 3 do not reach the significance 
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level of 10-3 but the combined sample is still significant and still exceeds the inflation 
factor 1.4 from the NARAC study. We have repeated the analysis with a permutation 
test in the individual groups and present these results in table 4. 
In conclusion, there is no indication for a systematic error due to population 
stratification based on our sensitivity analysis.
Table 3. Sensitivity analysis for P-values of the study. For an assumed inflation factor the significance level 
would be precisely alpha for inflation factor > 1. For inflation factor = 1 the nominal p-value is greater than 
alpha.
P-value Alpha Inflation factor
DN group 1 0.0005 0.050 3.11
DN group 2 0.0010 0.050 2.81
DN group 3 0.0070 0.050 1.89
All <0.0001 0.050 4.45
DN group 1 0.0005 0.010 1.80
DN group 2 0.0010 0.010 1.63
DN group 3 0.0070 0.010 1.10
All <0.0001 0.010 2.57
DN group 1 0.0005 0.001 1.10
DN group 2 0.0010 0.001 1.00
DN group 3 0.0070 0.001 1.00
All <0.0001 0.001 1.58
Table 4. Sensitivity analysis for P-values using a permutation test. For an assumed inflation factor the 
significance level would be precisely alpha for inflation factor > 1. For inflation factor = 1 the nominal p-value 
is greater than alpha.
P-value Alpha Inflation factor
DN group 1 0.0004 0.050 3.31
DN group 2 0.0070 0.050 3.03
DN group 3 0.0045 0.050 2.10
All <0.0001 0.050 4.53
DN group 1 0.0004 0.010 1.92
DN group 2 0.0070 0.010 1.75
DN group 3 0.0045 0.010 1.22
All <0.0001 0.010 2.63
DN group 1 0.0004 0.001 1.17
DN group 2 0.0070 0.001 1.07
DN group 3 0.0045 0.001 1.00









ACE Angiotensin-converting enzyme 
AGE  Advanced glycation end products
CD-CV model Common disease-common variant model
DN  Diabetic nephropathy
EM Electron microscopy
ESRD End stage renal disease
GBM Glomerular basement membrane
GWAS  Genome wide association scan
Hindinef  Hindustani Diabetic Nephropathy Study
HWE  Hardy-Weinberg equilibrium
IFTA  Interstitial fibrosis and tubular atrophy
MODY Maturity onset diabetes of the young
NECOSAD  Netherlands Cooperative Study on the Adequacy of Dialysis
RAME model Rare alleles of major effect model
SNP  Single nucleotide polymorphism
SUNSET Surinamese in the Netherlands, study for ethnicity and health
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